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Abstract 
Endometriosis is a gynaecological disorder occurring when endometrial cells are shed 
through the fallopian tubes and implant on surfaces in the abdomen and pelvis. There 
they form lesions that respond to hormones of the cycle and stimulate inflammation. 
Women with endometriosis experience painful debilitating periods, pain on 
intercourse and defecation, and may have difficulties conceiving. It is a common 
disorder, affecting 5-10% of women of reproductive age. Diagnosis of endometriosis 
is difficult and is often delayed by 5-11 years. Symptoms do not correlate with disease 
severity and imaging techniques are only sensitive for diagnosing ovarian 
endometriomas. Definitive diagnosis is surgical, requiring laparoscopy under general 
anaesthetic, exposing patients to potentially serious complications. With these facts in 
mind, the aim of this project was to identify biomarkers for the non-invasive diagnosis 
of endometriosis. This was achieved by defining the protein expression profiles of 
tissue samples collected from women diagnosed with endometriosis and from control 
patients who underwent surgery for investigation of chronic pelvic pain or who 
underwent prophylactic surgery because of familial cancer history. Discovery work 
involved the use of complementary, quantitative proteomic profiling by 2D difference 
gel electrophoresis and multiplex mass tagging linked to liquid chromatography-based 
separation and tandem mass spectrometry. Selected candidate biomarkers (LUM, 
CPM, TNC, TPM2 and PAEP) were verified using ELISA in serum samples collected 
from the same women. Biomarkers reported in the literature were also tested. 
Diagnostic performance of each marker was established. The best single marker in 
discriminating endometriosis and controls was CA125 (AUC=0.724, P=0.002). 
Multi-marker models were also constructed and the best model in discriminating 
between endometriosis and healthy controls by cross-validation was CA125, ICAM 
(AUC=0.744). CA125, ICAM, FST model (AUC=0.75) gave the performance in 
discriminating between endometriosis and both controls by cross-validation.  
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CHAPTER ONE: INTRODUCTION 
1.1 Endometriosis- A history of the disease 
The origin of the disease we call endometriosis today is controversial and has been a 
subject of debate over the years. The history is also linked with the early history of 
adenomyosis which up until the mid-1920s was considered the same disease. The 
evidence of who discovered or identified the disease for the first time has been 
conflicting with issues arising from origin and early clinical descriptions of lesions 
and misinterpretation of histological information. The path that led to the 
identification of the disease is a complex one but it is important to recognize some of 
the researchers who contributed immensely to the creation of the overall picture of 
what constitutes the essential features of endometriosis. 
1.1.1 Vincent Knapp 
Vincent Knapp referred to endometriosis as ‘the forgotten disease’ and he believed 
that endometriosis existed 300 years ago (Knapp, 1999). In his publication; How old 
is endometriosis; Knapp attempts to document the existence of endometriosis as early 
as the 17th century. He examined various historical manuscripts, published theses and 
dissertations and several contemporary works describing endometriosis that were 
housed in the National Library of Medicine in Bethesda, Maryland. One document 
which he believed contained the first description of endometriosis was published in 
1690 and eleven others were published between 1739 and 1797 (Ronald E Batt 2011). 
In his publication, (Knapp, 1999) Knapp emphasized the 1690 manuscript presented 
at the University of Jena entitled Disputatio Inauguralis Medica de Ulceribus Uteri 
written by the German physician Daniel Schroen (Schroen 1690), whom he believes 
was the first person to give a detailed description of the disease.  
The manuscript describes what Schroen believed to be endometriosis as sores 
distributed throughout the peritoneum, bladder, intestines, broad ligaments and 
outside of the uterus and cervix. He also described these sores as inflammations and 
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reported that they had a tendancy to form adhesions which linked visceral areas 
together. He further goes on to report that these sores would constantly expand in size, 
are vasculated, pus filled, tumour like and susceptible to haemorrhage. He also 
categorically states that the disorder was very common among sexually maturing 
females. Knapp believed that this description may have been that of non-ovarian 
endometriosis. He also reports on the other eleven early manuscripts from around 
Europe where the investigators reported similar findings to those of Schroen. 
However, others have refuted (Brosens and Steeno, 2000, Benagiano and Brosens, 
2011) that what Schroen described to be indicative of endometriosis or adenomyosis. 
They state that what was described were actually symptoms and lesions linked to 
syphilis, abortions, abdominal surgeries and uterine manipulations. They also argue 
that without microscopic/histological evidence, there was no way of establishing the 
presence of endometriosis i.e. presence of uterine tissue outside the uterus. The 
authors however based their views on just a few of the papers that were studied by 
Knapp and unfortunately Vincent Knapp died shortly after his 1999 publication, 
therefore questions regarding his findings remain unanswered. 
1.1.2 Carl von Rokitansky 
Carl von Rokitansky is believed by some, to have given the first pathologic description 
of endometriosis and adenomyosis (Hudelist et al., 2009). In his publication of 1860 
(Rokitansky 1860), three forms of endometriosis are described: i) sarcoma adenoids 
uterinum which invades the muscular wall and cystosarcoma adenoids uterinum 
associated with myometrial hypertrophy, ii) cystosarcoma adenoids uterinum 
polyposum which invades the endometrial cavity forming a polyp and iii) ovarian 
cystosarcoma which invades the ovaries. Some authors (Benagiano and Brosens, 
1991) however, have strongly disputed these descriptions as being those of 
endometriosis and are of the opinion that what Rokitansky described were lesions of 
a more malignant nature than benign. 
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1.1.3 Thomas Cullen 
Thomas Cullen, a surgeon, is said to have described the morphological and clinical 
nature of endometriosis and adenomyosis for the first time. He referred to these 
conditions as uterine adenomyoma (Linda C Giudice, 2012). From his observation of 
90 uteri with adenomyomas, Cullen gave a description on the presentation and 
location of these lesions. He described them as ectopic endometrial-like tissue found 
in the ovaries, myometrium, recto-vaginal septum, uterine ligaments, bowel and 
umbilicus. 
1.1.3 John Sampson 
John A Sampson was a gynaecologist who conducted numerous studies on peritoneal 
endometriosis and ovarian endometriomas. He performed surgery on women at the 
time of menstruation. During these surgeries, he found peritoneal lesions that were 
bleeding in a similar manner to that of the normal endometrium (Clement, 2001). 
From this observation, he concluded that the tissue within the peritoneum was of 
endometrial origin. In 1927 (Sampson, 1927b) , he suggested that the presence of 
endometrial cells outside of the uterus was due to backflow of menstrual fluid through 
the fallopian tubes and dissemination of this within the peritoneum. He was therefore 
the first one to provide a theory to explain the pathogenesis of endometriosis, 
commonly known as Sampson’s theory of retrograde menstruation. The word 
‘endometriosis’ was also created by Sampson in 1928 after he observed growing bits 
of uterine mucosa on the fallopian tubes of women who had undergone sterilization. 
He believed that the tissue was transplanted surgically, and concluded that if such 
tissue could grow in that manner, then it was possible to observe similar behaviour in 
other areas of the body under different circumstances other than after surgery, hence 
the term endometriosis. 
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1.2 Disease characterisation 
Endometriosis is recognised as a commonly occurring disease. It is defined as the 
presence of endometrial glandular epithelial cells and stromal cells outside the uterus 
commonly within the peritoneal cavity. Common locations therefore include the 
ovaries, fallopian tubes, uterine ligaments, pouch of Douglas, recto-vaginal septum, 
bowels etc. These endometrial cells invade and proliferate forming endometrial 
implants which behave in a similar manner to the normal (eutopic) endometrium i.e. 
they proliferate, bleed and they remain hormonally responsive. These implants also 
have their own blood supply and are highly invasive (Meehan et al., 2010). The 
clinical symptoms of endometriosis range from severe menstrual and non-menstruual 
dysmenorrhoea (painful menstruation), dyspareunia (painful intercourse), dysuria 
(painful urination), dyschezia (painful bowel movement) to severe chronic pain and 
finally infertility. The introduction of laparoscopy in the sixties enabled clear 
description of the disease together with its presenting lesions e.g. red and black 
lesions, adhesions, ovarian endometriotic cysts etc. It has been reported that the 
disease exists as three different clinical entities namely peritoneal endometriosis, 
ovarian endometriosis and deep infiltrative endometriosis (Nisolle and Donnez, 
1997). 
1.2.1 Peritoneal endometriosis 
Peritoneal endometriosis can be explained by the transplantation theory which 
assumes that menstrual cells are regurgitated via the fallopian tubes into the 
peritoneum. These cells may also spread via lymphatic or haematogenous routes. The 
viable cells will then implant onto the peritoneum, have their own blood supply and 
continue to grow. These implants go through several stages and exhibit different 
characteristics at each stage. 
The early stage of peritoneal endometriosis is characterised by the 
presence/appearance of red lesions which are consistently located on the peritoneal 
surface (Donnez et al., 1996a).  They penetrate the extracellular matrix and have been 
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reported as the most active stage of endometriosis (Spuijbroek et al., 1992). A 
similarity exists between these red lesions and the eutopic endometrium (Nisolle and 
Donnez, 1997, Donnez et al., 1996c). This is based on the assumption that red lesions 
are recent cells which have implanted on to the peritoneum as a result of retrograde 
menstruation. Angiogenesis is also evident on the stroma of recently implanted cells 
which is characterised by a large vascular network on the peritoneal surface. Gland 
proliferation of red lesions has been evaluated previously by immunostaining and has 
shown similarity with eutopic endometrium  
Two laparoscopic studies provided detailed reports of these early lesions. One group 
reported that red lesions appear and disappear like mushrooms giving peritoneal 
endometriosis a changing appearance (Wiegerinck et al., 1993). Petichial and bleb like 
implants have been reported as the most common type of red lesion observed in 
adolescent girls (Hoshiai et al., 1993), while the early serous lesions are said to 
disappear by the age of 26. These changes in the red lesions suggest that the 
implantation of viable endometrial cells in endometriosis may not be an on-going 
process during the reproductive life, but is restricted to the early years after the onset 
of menarche which is a period characterised by anovulation and low progesterone in 
peritoneal fluid. This environment favours the implantation of viable endometrial cells 
that enter the peritoneal cavity (Brosens, 1994). 
Red haemorrhagic lesions continue to grow over time, eventually evoking an 
inflammatory response. A scar is formed which encloses the endometrial implant and 
this type now becomes a black lesion due to the presence of intraluminal debris 
(Nisolle and Donnez, 1997, Brosens, 1994). Scar formation causes de-vascularisaton 
of the endometric foci. White plaques of old collagen eventually become remnants of 
the ectopic tissue (Linda C Giudice, 2012). This stage represents the latent stages of 
peritoneal endometriosis. Progression or regression of endometriosis is therefore not 
reflected by the increase or decrease of these peritoneal implants. This variability is 
as a result of cycle differentiation, cellular activity and shedding of these early 
peritoneal implants that emerge on the surface and disappear either by resorption or 
23 
 
heal by fibrosis and scar formation. Despite this, the most important question still 
remains why endometriosis progresses in some women and not in others. 
1.2.2 Ovarian endometriosis 
The genesis of ovarian endometriosis remains controversial to date. In Sampson’s first 
paper  of 1921 he describes intraoperative and pathologic findings in 23 cases in which 
he described the endometrial nature of the ovarian cysts he observed (Clement, 2001). 
He reported these cysts as perforating cysts which upon haemorrhage, the cysts would 
spill their contents into the peritoneal cavity. As a result of the spillage, which he 
described as resembling chocolate syrup, there is an irritation of the peritoneal cavity 
together with formation of adhesions. Sampson also postulated that the endometrial 
tissue lining the ovarian cysts developed as a result of epithelialisation of a pre-
existent cyst by ovarian surface epithelium or by Mullerian remnants of the 
endometrial type located on the surface of the ovary. 
Several authors have disputed Sampson’s claim that adhesions develop as a result of 
spillage of the contents of perforating ovarian cysts (Brosens et al., 1994, Hoshiai et 
al., 1993, Kennedy et al., 1992). Brosens et al supported an earlier report (Hughesdon, 
1957) suggesting that adhesions are not the consequence, but the cause of 
endometriomas. Through studying ovarian endometriomas in situ, Hughesdon 
concluded that most endometriomas (90%) are formed as a result of invagination of 
the ovarian cortex after accumulation of menstrual debris from bleeding endometrial 
implants located on the ovarian surface and adherent to the peritoneum. Brosens et al 
also observed endometriomas in situ by using a double optic endoscopy. They also 
concluded that the most active implants were found at the site of inversion. Effects of 
chocolate cysts spillage has not been tested in experimentally. However other workers 
have attempted to test this effect in the peritoneal fluid of mice (Kennedy et al., 1992).  
No adhesions were reported as a result of the chocolate cyst fluid being injected into 
the peritoneum, but the authors state that their study is not conclusive evidence that 
this phenomenon does not occur. 
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Coelomic metaplasia of invaginated epithelial inclusions is also believed to contribute 
to the development of ovarian endometriosis. This assumption is based on the 
hypothesis that metaplasia of the coelomic epithelium invaginates into the ovarian 
cortex (Nisolle and Donnez, 1997). The expression of cytokeratin has been shown to  
indicate a close relationship with mesodermal Mullerian origin and the absence of 
vimentin expression in epithelial cells can reveal either an absence of glandular 
function or characteristic of metaplastic origin (Donnez et al., 1996b). 
1.2.3 Deep infiltrating endometriosis (DIE) 
This disease entity is also referred to as deep nodular endometriosis, recto-vaginal 
endometriosis or adenomyosis of the rectovaginal septum (Linda C Giudice, 2012). 
Deep infiltrating endometriosis has been defined as the presence of endometrial glands 
and stroma infiltrating more than 5 mm under the peritoneal surface (Koninckx et al., 
1994, Koninckx et al., 2012, Dai et al., 2012). The use of 5 mm was postulated because 
from a morphology point, lesions infiltrating  >5mm are reported to be the most active, 
aggressive and very painful (pain ranges from severe dysmenorrhoea, severe 
dyspareunia, chronic pelvic pain and dyschezia), forming nodules and causing pelvic 
distortion (Koninckx et al., 1994). This contrasts to peritoneal endometriosis whereby 
lesions are superficial, they may be asymptomatic or cause few symptoms, and they 
eventually become inactive and disappear. 
DIE has been described as a different disease from peritoneal endometriosis and 
endometrial ovarian cysts because deep lesions have a distinct histological appearance 
resembling adenomyosis i.e. endometrial glands and stroma in the myometrium. The 
lesions are nodular in nature and contain a large amoun of fibromuscular tissue with 
areas containing endometrial glands and stroma (Van Kaam et al., 2008). They also 
have a specific anatomic distribution i.e. they are commonly found in the recto-vaginal 
septum, cul-de-sac, pouch of Douglas and utero-sacral ligaments. Three categories of 
deep lesions have been reported. Type I lesions are conical shaped lesions that are said 
to occur as a result of infiltration. Type II are deep lesions covered by extensive 
adhesions probably formed by retraction of the bowel over the lesion and Type III  are 
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the largest and most severe lesions formed of a round nodule (>1cm in diameter) 
located under the peritoneum in the recto-vaginal septum. This type is also referred to 
as adenomyosis externae (Koninckx et al., 1994, Koninckx et al., 2012). 
Aetiology of DIE remains debatable. In situ development i.e. metaplasia of Mullerian 
remnants located in the recto-vaginal septum has been proposed by some authors as 
the reason for the development of deep endometriosis as opposed to implantation of 
regurgitated menstrual debris (Nisolle and Donnez, 1997). Other authors believe that 
this disease develops from infiltrating superficial peritoneal lesions in the pouch of 
Douglas (Chapron et al., 2003, Chapron et al., 2006). Various arguments against the 
assumption that DIE is associated with peritoneal lesions has been reported. Thomas 
Cullen, one of the early pioneers of endometriosis, described adenomyoma of the 
round ligament, recto-vaginal septum and umbilicus in his works of 1896-1908. He 
reported that these deep lesions occurred as a result of direct extension of lower uterine 
adenomyosis (Clement, 2001). Sampson (Sampson, 1927b) also described adenoma 
of endometrial type which invades the cervical and uterine tissue and unites the cervix 
and the rectum. 
1.3 Pathogenesis 
The current understanding on aetiology and pathophysiology of endometriosis 
remains elusive. However, different theories have been proposed. 
1.3.1 Transplantation theory 
This theory suggests that the endometrium is replaced from the uterus to another 
location inside the body. The routes of dissemination involved are: retrograde 
menstruation, lymphatic /haematogenous dissemination and iatrogenic dissemination. 
1.3.2 Retrograde menstruation 
Retrograde menstruation may be defined as the backflow of menstrual fluid through 
the fallopian tubes to ectopic sites most commonly within the organs of the peritoneal 
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cavity (Kyama et al., 2003, Sampson, 1927a). This theory is the most widely 
recognised theory of endometriosis. There are three essential conditions that must be 
met in order to consider retrograde menstruation as the explanation for endometriosis 
(Nisolle and Donnez, 1997); endometrial cells must enter the peritoneal cavity through 
the fallopian tubes, the endometrial cells within the menstrual debris must be viable 
and able to be transplanted onto pelvic structures and the anatomic distribution of 
endometriosis in the pelvic cavity must be correlated with the principles of 
transplantation of exfoliated cells. 
Reflux of endometrial cells into the peritoneal cavity during menstruation is a 
common physiological condition occurring in women with healthy tubes. Sampson 
observed menstrual blood escaping through the fimbrial ends of the fallopian tubes 
and endometrial tissue in the lumen of some women at the time of laparotomy 
scheduled during or soon after the menstrual period (Sampson, 1927b). Since then 
several studies have demonstrated this phenomenon. Blumenkrantz et al observed 
blood-stained peritoneal fluid during menses in women undergoing chronic peritoneal 
dialysis (Blumenkrantz et al., 1981). In these women, blood staining of the peritoneal 
fluid preceded vaginal bleeding for one to several days and the presence of blood was 
detected by observation of threads of sedimented red blood cells. Halme and 
colleagues found a red colour in 90% of peritoneal fluid samples of women with patent 
tubes at laparoscopy, suggesting the presence of blood (Halme et al., 1984) . However, 
only visual documentation of the colour of peritoneal fluid samples was carried out. 
One study demonstrated the presence of endometrial cells in peritoneal fluid using 
immunohistochemistry based on application of monoclonal antibodies against various 
epithelial markers (Van Der Linden et al., 1995b). They compared the 
immunohistochemical staining properties of these fragments with those of cells 
present in the endometrium, menstrual effluent, peritoneal fluid and endometriotic 
lesions. Their study showed that peritoneal fluid contains single epithelial cells rather 
than endometrial tissue fragments in women with patent tubes. It is possible that 
endometrial epithelial cells after having left the uterine cavity are modulated in the 
peritoneal cavity prior to developing into an endometriotic lesion. Retrograde 
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menstruation has also been demonstrated in the baboon; a potential animal model for 
the study of endometriosis (D'hooghe et al., 1991, D'hooghe et al., 1996a, D'hooghe 
et al., 1996b). Prevalence, laparoscopic appearance and histology of endometriosis in 
the baboon resembles that of the human disease (D'hooghe et al., 1991). It was 
demonstrated that the prevalence of retrograde menstruation is higher in female 
baboons with endometriosis as compared to those without (D'hooghe et al., 1996b).  
This was the first study to document the prevalence of retrograde menstruation in non-
human primates. 
Endometrial cells must be viable and retain their capacity to adhere and proliferate. A 
number of adhesive molecules have been identified e.g. laminin and fibronectin 
(Beliard et al., 1997), integrins and cadherins (Van Der Linden et al., 1995a) that 
promote cell-cell and cell-matrix attachment of the endometrial cells to the peritoneal 
lining. The anatomic distribution of endometriosis in the pelvic cavity has been 
described (Jenkins et al., 1986). The authors reported that the distribution of 
endometriotic lesions in the abdominal cavity relates to that of tubal reflux, therefore 
the most frequent sites of implantation are the dependent areas of the pelvis e.g. 
ovaries, posterior and anterior cul-de-sac. These areas are most likely to be affected 
by menstrual reflux from the fallopian tube. 
The theory of retrograde menstruation as the cause of endometriosis is challenged by 
the fact that it occurs in most women yet endometriosis only occurs in 6-10% of 
women in their reproductive years. It does not account for why these misplaced cells 
survive in women with endometriosis and not in non-diseased women. The puzzling 
enigma is why the pelvic environment becomes receptive to allow implantation and 
proliferation of endometrial cells. In this regard, it seems probable that there needs to 
be abnormalities of function either within the eutopic endometrium of women 
predisposed to endometriosis and/or defects in immune surveillance mechanisms 
normally responsible for the recognition and removal of endometrial fragments which 
find their way into the peritoneal cavity.  Endometrial cells recovered from the pelvic 
cavity at the end of menstruation are viable and capable of proliferating. They also 
express the aromatase enzyme allowing them to synthesize active local oestrogen and 
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have the capacity to secrete angiogenic and neurogenic molecules that encourage 
tissue growth and potential pain generating mechanisms within the developing lesions. 
Other factors must therefore be involved to allow retrogradely displaced endometrial 
tissue to implant and develop into endometriotic lesions.  
It has been hypothesised that the quantity of endometrial fragments desquamated 
during menstruation and deposited into the peritoneal cavity is higher in women who 
develop endometriotic lesions. In support of this, there is a positive correlation 
between the numbers of menstrual cycles and the prevalence, cumulative incidence 
and progression of spontaneous endometriosis on the surface of the ovaries in baboons 
(D'hooghe et al., 1996b). Similarly, women with short cycles and long durations of 
menstrual flow are more likely to develop endometriosis 
1.3.3 Lymphatic/haematogenous spread (Halban’s theory). 
Hablan developed his theory from Sampson’s original observations and hypothesised 
that endometrial tissue could be transferred into the myometrium or any other organ 
in the body through the lymphatic route (J, 1924). This theory therefore proposes that 
viable endometrial cells may spread from the uterus to distant sites through the 
lymphatic or haematogenous channels. This theory could explain the occurrence of 
endometriosis in unusual extra pelvic areas like the brain and lungs (Javert, 1949), but 
does not explain why ectopic tissue is able to become established and grow in these 
locations. Sampson also postulated that there may be more than one route available 
for the development and spread of this disease. He concluded that the invasion and 
dissemination of endometrial tissue employs the same channels as the invasion of 
cancer meaning that fragments of endometrial tissue reached other parts of the body 
through channels such as blood and lymph systems through metastasis (Clement, 
2001). 
In his paper entitled ‘Metastatic or embolic endometriosis, due to menstrual 
dissemination of endometrial tissue into the venous circulation’, Sampson describes 
his observations from four hysterectomy cases, three of which he performed during 
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menstruation and the other during the late secretory phase. He reports on the fragments 
of endometrium which he observed on the venous sinuses of the uterine wall, in the 
blood of the veins and some attached to the lining of the vessels by fibrin. These 
endometrial fragments were also confirmed by histology. In an earlier paper to 
investigate escape of foreign material into the venous circulation of the uterus, 
Sampson describes his observations after injecting barium into the endometrial cavity 
(Sampson, 1918). He reports that no barium is observed in the uterine veins when the 
endometrium is intact. When the endometrium is disrupted e.g. during menstruation, 
pregnancy or curettage the barium found its way into the uterine veins. 
1.3.4 Iatrogenic transplantation 
This theory assumes that endometrial cells may be transported to ectopic sites during 
surgery. This explanation accounts for the finding of localized endometriosis in old 
episiotomy sites or in caesarean section scars (Jensen and Coddington, 2010). It is 
proposed that biologically distinct tissue may directly attach to a site accompanied by 
initiation of oncogenic like cascades leading to implantation and survival (Bulun, 
2009, Kao et al., 2003). The immune system should in normal circumstances be able 
to clear these implants, but it is not known why this is not the case. This phenomenon 
has also been described as auto-transplantation (Redwine, 2002) . An auto transplant 
is a tissue transplanted from one site to another site in the same organism either due 
to a pathologic process or surgical intervention. 
1.3.5 In situ development theory 
The transplantation theory cannot explain all localisations and manifestations of 
endometriosis (Burney and Giudice, 2012, Sourial et al., 2014) In situ development 
theory is based on the assumption that endometriosis develops in situ from local 
tissues. Development occurs from remnants of the Wolffian or Mullerian ducts or 
from metaplasia of peritoneal or ovarian tissue (Linda C Giudice, 2012, Nap et al., 
2004).  
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1.3.6 Coelomic Metaplasia Theory 
Embryological studies have shown that all organs in the pelvis including the 
endometrium originate as cells of the peritoneal (coelomic) cavity lining (Fujii, 1991). 
The term metaplasia refers to any type of tissue that can transform to another type. 
The coelomic metaplasia theory of endometriosis proposes that some of the cells of 
the peritoneum (abdominal wall) develop into endometrial cells instead of normal 
peritoneal cells or instead of the usual cells that make up the organs within the 
abdomen.  Robert Meyer became one of the leading advocates for this theory. He 
believed that peritoneal inflammation stimulated the metaplastic transformation of the 
mesothelium to endometrial like tissue.  
This theory would explain presence of endometriosis in the absence of menstruation 
and in unusual sites (Suginami, 1991). A case of endometriosis in a 20 year old patient 
with uterine agenesis (complete absence of the uterus, cervix and vagina) was reported 
(Mok-Lin et al., 2010). The patient underwent laparoscopy for debilitating pelvic pain 
and was found to have stage 1 endometriosis manifesting as red and clear lesions in 
the posterior cul-de-sac. A small band of flat Mullerian tissue was also found along 
the pelvic side wall. The endometriosis was treated but later recurred at age 25 when 
the patient presented again with pelvic pain. In this case, retrograde menstruation 
cannot explain the presence of endometriosis. Coelomic metaplasia seems like a 
plausible explanation for the development and recurrence of her endometriosis. 
Endometriosis has also been reported in a 83 year old man undergoing oestrogen 
treatment for prostate cancer (Martin and Hauck, 1985). The authors hypothesised that 
this developed from the prostate utricle which is a remnant of the uterus existing in 
the male.  
The process by which cells differentiate into functional endometrium remains 
controversial. Steroid hormones and other exogenous molecules could be responsible 
for causing differentiation of normal mesothelial cells into endometriotic cells. One 
study showed that co-culture of ovarian surface epithelium and ovarian stromal cells 
together with 17β estradiol resulted in the ovarian surface epithelium cells forming a 
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lumen structure surrounded by endometrial stromal cells with an epithelial-
mesenchymal structure (Matsuura et al., 1999). Immunostaining showed epithelial 
membrane antigen and cytokeratin in the glandular cells. This study shows that 
metaplasia of ovarian surface epithelium could give rise to endometriotic lesions and 
this process requires 17β estradiol at concentrations 10 times higher than that in the 
peritoneal fluid. Such a concentration is found near the ovaries and is hence a possible 
explanation for ovarian endometriosis. 
This theory has several limitations; coelomic metaplasia should be manifested in all 
areas where the tissues are derived from the coelomic epithelium e.g. endometriosis 
should be present more often in chest wall since the the coelomic membrane 
contributes to cells of the thoracic cavity. If coelomic metaplasia resembles common 
metaplasia, the frequency of endometriosis should increase with advancing age. 
Peritoneal cells can easily undergo metaplastic transformation, the disease should 
therefore be observed more frequently in men. Additional basic and experimental data 
must be accumulated to confirm this theory. 
1.3.7 Immune abnormalities 
Endometrial lesions are frequently present in the peritoneal cavity where they are in 
direct contact with peritoneal fluid which bathes the pelvic cavity, uterus, fallopian 
tubes and ovaries. Retrograde menstruation occurs in most women, but relatively few 
develop endometriosis. As a result of apoptosis the body rids itself of these shed cells 
without eliciting a significant inflammatory reaction and it is not clear why this is not 
the case in women with endometriosis (Herington et al., 2011).  
Several studies have shown that immune surveillance is impaired and that the innate 
immune system responds inadequately to displaced endometrium within the pelvic 
cavity of women with endometriosis (Ulukus and Arici, 2005, Herington et al., 2011, 
Tariverdian et al., 2007). The immune cells that play a role in the destruction of 
displaced cells include: macrophages, natural killer cells and cytotoxic T cells 
(Kaminski et al., 1995, Oosterlynck et al., 1992). A failure of these immune cells to 
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clear misplaced endometrium may play a central role in providing an opportunity for 
viable endometrial cells to attach and grow ectopically. 
Activation of inflammatory responses within the peritoneal cavity may lead to local 
production of cytokines and chemokines that may enhance the growth of ectopic tissue 
by inhibiting normal apoptotic mechanisms and promoting localised angiogenesis. 
Inflammatory mediators are released upon onset of acute inflammation which is 
initiated by macrophages in the peritoneal fluid. These macrophages are responsible 
for extravasation of leucocytes from blood vessels into the tissue in an effort to clear 
ectopic endometrium. Despite this, these immune cells produce cytokines, growth 
factors and potent angiogenic factors which appear to support the survival and growth 
of ectopic tissue (Lebovic et al., 2001)  
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1.4 Epidemiology 
Endometriosis is one of the most common benign gynaecological conditions. It is a 
condition in which tissue with histological structure and physiological responses of 
the uterine mucosa occurs in sites other than the uterus, most commonly within the 
pelvis (Uno et al., 2010). The physical findings are non-specific therefore clinical 
findings can be confused with those of pelvic inflammatory diseases, benign or 
malignant ovarian disease, fibroids, gastrointestinal and urinary problems. 
Endometriosis is not widely and sufficiently recognised by the general public because 
it does not always provide a visible handicap despite its common crippling effects. 
Few well-conducted studies have reported data on the prevalence of endometriosis 
and no data is available on the incidence rates of the disease. However, from the few 
studies available, the disease is said to affect 6-10% of women of reproductive age in 
the general population. Its prevalence is 35-50% in women with chronic pelvic pain, 
infertility or both (Sensky and Liu, 1980, Uno et al., 2010, Giudice and Kao, 2004). It 
is also difficult to compare estimates of prevalence because the published studies 
include women with different conditions and are conducted in centres that apply 
different diagnostic criteria and exhibit different levels of clinical interest in 
endometriosis. A survey completed by 7,025 women with endometriosis reported that 
65% of women were initially misdiagnosed with another condition and 46% had to 
see five doctors or more before they were correctly diagnosed (Mihalyi et al., 2010). 
(European Endometriosis Alliance). This has led to estimates of 6-11 years delay in 
diagnosis.  
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1.5 Risk factors 
1.5.1 Genetic risk 
Genetic and environmental factors contribute to endometriosis risk and the disease is 
inherited as a complex trait (Bischoff and Simpson, 2004, Kennedy, 1999, Stefansson 
et al., 2002). Gene markers associated with endometriosis have been reported but the 
results have generally not been replicated in subsequent studies. The variability 
between studies has also led to concerns about estimates of the genetic contribution to 
disease risk.  Studies in Australian twins, Icelandic populations and rhesus macaques 
(Treloar et al., 1999, Stefansson et al., 2002, Zondervan et al., 2002) have provided 
strong evidence for disease heritability. 
Large genome wide association studies (GWAS) have provided a powerful approach 
to discover genes influencing the risk of many common diseases. This method 
involves genotyping DNA samples with representative single nucleotide 
polymorphisms from across the genome and allele frequencies compared between 
cases and controls. A study in Japanese women (1,423 cases and 1,318 controls) 
reported a significant association with SNPs in the noncoding RNA CDKN2BAS on 
chromosome 9p21.3 (Uno et al., 2010). The International ENDOGENE study 
represents collaboration between research groups in the United Kingdom, USA and 
Australia whose main aim was to identify variants that influence susceptibility to 
endometriosis. This study which recruited 2,270 cases and 1,870 controls from 
Australia and 924 cases and 5,190 controls from the United Kingdom, identified a 
significant association in an intergenic region on 7p15.2. They also replicated 
evidence for an association near the WNT4 gene on 1p36.12, previously reported in 
the Japanese study (Uno et al., 2010). Data from this study provides independent 
evidence for a genetic contribution to disease risk, supporting results from earlier 
family-based studies (Stefansson et al., 2002, Treloar et al., 1999). These results also 
demonstrated stronger genetic loading of moderate to severe (stage III and IV) 
endometriosis compared to minimal to mild (stage I and II). The number of variants 
discovered in GWAS is strongly correlated with the experimental sample size 
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(Visscher et al., 2012). For each disease, doubling the study size doubles the number 
of genes/regions identified above a given threshold. It has been recommended that 
increasing the sample size for genetic studies in endometriosis will increase the 
number of markers and gene regions associated with disease risk (Rogers et al., 2013). 
Results also need to be replicated to confirm associations and to establish differences 
in gene expression to identify the specific genes and pathways contributing to disease 
risk.  
1.5.2 Demographic risk factors 
Endometriosis affects women of reproductive age. A study in women under 50 
suggested that the frequency of endometriosis increases with age until menopause 
although other studies have not confirmed this (Houston et al., 1988). Age at diagnosis 
instead of age at onset is an assumption that due to the absence of fluctuating levels 
of oestrogen and progesterone, the condition is absent in girls before menarche. 
Endometriosis may be symptomatic after menopause if there is a resurgence of 
endogenous hormonal stimulation or if the use of exogenous hormones stimulates 
endometriosis (Ranney B, 1977). This suggests that sex steroid hormones play a role 
in the initiation and spread of endometriosis. 
A greater frequency of endometriosis among women of higher social economic class 
has been reported (Arumugam and Templeton, 1990). This has been linked to their 
reproductive history as this groups of women tend to have fewer and later pregnancies 
than those from lower socio-economic groups (Williams and Pratt, 1977). It has been 
suggested that a lower incidence is in blacks is not because of race, but because of 
endemic poverty among a large portion of the black population (Chatman, 1976). 
However, poverty could create an apparent differential in disease occurrence across 
racial groups because of differential access to specialised medical care and the 
existence of a prejudicial diagnostic aspect  based on what is ‘known’ about racial 
susceptibility to endometriosis. Differences in the incidence of endometriosis can also 
be attributed to the relative availability of laparoscopy for the diagnosis of pelvic 
conditions (Molgaard et al., 1985). This can account for the comparatively low 
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occurrence in certain racial and socio-economic groups, with the less affluent being 
constrained in their access to and utilisation of medical resources for the complete 
investigation of pain, infertility or both. 
1.5.3 Menstrual factors 
The correlation between menstrual history and risk of pelvic endometriosis is poorly 
understood. Some studies have suggested that women with early menarche, short and 
heavy menstrual cycles are at a higher risk of developing endometriosis (Cramer and 
Missmer, 2002, Parazzini et al., 1995, Cramer et al., 1986). This has been attributed 
to the fact that the potential for contamination of the pelvic cavity by refluxed 
menstrual debris is higher in these women hence a high risk of implantation of viable 
endometrial cells. It has however been noted that evidence for this is very inconsistent 
with  interpretation of some of these findings being biased (Mangtani and Booth, 
1993).  
1.5.4 Oral contraceptive use 
Oral contraceptives are used in the treatment of endometriosis. They do not cure the 
disease but instead work by down-regulating the endometrium, hence supressing 
menstruation, reducing pain and shrinking the ectopic implants or preventing the 
existing ones from growing any bigger. Information regarding the relation between 
oral contraceptive (OC) use and endometriosis risk remains controversial (Cramer and 
Missmer, 2002). A study  to establish prevalence and associated risk factors in 504 
women reported a lower risk among OC users (OR 0.5, 95% CI 0.2-0.90) (Sangi-
Haghpeykar and Poindexter, 1995). The same has been reported in another large study 
where the rate of disease was lower in current/recent users as compared to those who 
have never used (relative risk 0.4, 95% CI 0.2-0.7) (Vessey et al., 1993). It was also 
reported in the same study that women who had stopped the pill for more than 2 years 
were at a higher risk (RR 1.8, 9.5% CI 1.0-3.1). 
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1.5.5 Family History 
A familial risk for developing endometriosis has been proposed (Lamb et al., 1986, 
Moen and Magnus, 1993, Moen and Schei, 1997, Malinak et al., 1980, Simpson et al., 
1980). For example high prevalence in relatives of affected women has been reported 
(Moen and Magnus, 1993). A wealth of genetic factors have been anticipated to be 
linked to increased susceptibility to endometriosis (Guidace and Kao, 2004) but 
common genetic markers for endometriosis have not yet been identified. Further 
studies however need to be conducted in order to establish the role heredity plays as a 
risk factor for endometriosis. 
1.5.6 Environmental factors 
Exposure to some environmental toxins are thought to be associated with 
endometriosis e.g. dioxin (2, 3, 7, 8 tetrachlorodibenzo-p-dioxin) (Rier et al., 1993). 
It is thought that dioxin promotes the development of endometriosis by interfering 
with immune-mediated mechanisms, more specifically by stimulating the production 
of pro-inflammatory cytokines. 
1.5.7 Diet and other lifestyle factors 
Alcohol intake and diet high in fat have been suggested as risk factors of endometriosis 
(Houston, 1984, Vessey et al., 1993, Cramer et al., 1986). An association between 
tobacco smoking and endometriosis has been reported in some studies (Aban et al., 
2007, Chapron et al., 2010, Vidal et al., 2006). Smoke compounds lead to the 
disruption of oestradiol synthesis possibly reducing the risk (Vidal et al., 2006). 
However data is limited and further studies need to be conducted in order to establish 
whether diet, nutrition, alcohol and smoking could be risk factors for endometriosis.  
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1.6 Diagnosis 
1.6.1 Surgical diagnosis 
When endometriosis was first described, radical surgery was the treatment of choice. 
Laparotomy combined with histological examination was used to diagnose 
endometriosis (Linda C Giudice, 2012). Laparotomy is a highly invasive surgical 
procedure which involves making a large incision through the abdominal wall in order 
to gain access into the abdominal cavity. Later endoscopic techniques were developed 
which provided a less invasive way of inspecting the abdominal cavity whilst 
increasing understanding of the disease and improving treatment. The culdescope was 
the first endoscopic instrument and was used in a procedure called culdescopy. The 
procedure involved introducing the culdescope into the abdominal cavity via a 
puncture in the posterior vaginal wall. The advantage of this method is that there are 
no abdominal cuts or visible scars after healing. However the Inability to check the 
whole pelvic area and the abdominal cavity is a major disadvantage. 
1.6.2 Laparoscopy 
It is difficult to credit one individual with the introduction of laparoscopy. The first 
laparoscopic procedure is reported to have been performed in 1901 in dogs by George 
Kelling, a surgeon from Germany who dedicated himself to developing less invasive 
and non-surgical methods of diagnosis and treatment (Spaner and Warnock, 1997, 
Litynski, 1997). The first laparoscopy procedure in humans was performed by Hans 
Christian Jacobaeus on 17 patients with ascities (Litynski, 1997, Hatzinger et al., 
2006). He recognised the great diagnostic and therapeutic potential of laparoscopic 
surgery as well as its risks and limitations e.g. the risk of damaging organs during 
surgery especially the bowel.  
Laparoscopy is the gold standard method for the diagnosis and treatment of 
endometriosis (Kennedy, 2006, Kennedy et al., 2005). It is combined with the 
histological confirmation of the presence of endometrial glands and stroma in ectopic 
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sites. Laparoscopy has enabled thorough description of different types of ectopic 
lesions, disease classification and effective treatment of disease. In 1979, the 
American Fertility Society (AFS) proposed a classification of endometriosis so as to 
provide a standardised way of surgical recording and reporting of the disease (1979). 
Endometriosis was therefore classified into: stage I (minimal endometriosis), stage II 
(mild endometriosis), stage III (moderate endometriosis) and stage IV (severe 
endometriosis). Despite this it is still an invasive procedure with risks of organ damage 
and iatrogenic transfer of ectopic cells. 
This classification, mainly based on severity of and the presence or absence of 
adhesions was later revised (rAFS) to allow recording of additional pathology e.g. 
adhesions were quantified and reported as either filmy or dense.  In addition to this, it 
was now possible, with the rAFS classification, to predict pregnancy outcomes 
following treatment (1997). Some of the limitations of the rAFS classification include 
high observer error due to the disease manifesting in different ways and the weak 
relation between stage of disease and pelvic pain. There is also a weak relation 
between disease stage and infertility; pregnancy outcome rates do not vary with stage, 
therefore the classification is still not able to predict successful pregnancies following 
treatment with laparoscopy (Adamson et al., 1993, Adamson, 1990). A better 
predictive score for pregnancy outcomes after endometriosis surgery was proposed by 
(Adamson and Pasta, 2010). The endometriosis fertility index (EFI) is used to predict 
fertility after laparoscopy by providing detailed scores on ovarian and tubal functions 
combined with conception-related factors such as age, duration of fertility and parity 
history. 
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1.6.3 Imaging techniques 
Several imaging techniques have been used to diagnose endometriosis prior to 
laparoscopy although they are not sensitive enough to predict all forms of the disease. 
Trans-vaginal ultrasound (TVU) is a readily available and inexpensive procedure 
adequate to detect large ovarian endometriomas but is not capable of ruling out 
peritoneal endometriosis, related adhesions and some deep lesions (Kennedy et al., 
2005, Moore et al., 2002). Accurate staging of the disease is also not possible. It is 
vital that a highly trained sonographer conducts this procedure in order to achieve 
accurate results (Linda C Giudice, 2012, Abrao et al., 2009, Abrao et al., 2007).  
Magnetic resonance imaging (MRI) has been reported as an important tool in the pre-
operative diagnosis of patients with endometriosis, especially DIE and endometriosis 
affecting other areas away from the pelvis. This procedure has the advantage of being 
able to visualise the full spectrum of organ involvement. This compares to CT 
(computed tomography), whose resolution is not able to visualise pelvic organs well, 
hence its limited use in diagnosis of endometriosis (Hsu et al., 2010). Limitations of 
MRI include the lack of adequate resolution to identify adhesions and superficial 
peritoneal implants. The procedure is also very expensive compared to TVU, although 
it is the superior imaging method. Despite the availability of these imaging techniques, 
it is still not possible to detect early superficial peritoneal disease, which is the most 
active form of endometriosis. Early non-invasive or minimally invasive tests for the 
early diagnosis of endometriosis could help solve this problem. 
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1.7 Treatment of endometriosis 
Current treatments for endometriosis include both surgical and medical therapy. 
Medical treatments aim at either inducing a low oestrogen environment or 
antagonising oestrogen action. NSAIDs and Oral contraceptives are often used as an 
initial approach even without definitive diagnosis. Surgical therapy can be performed 
alongside diagnostic surgery involving ablation which is the destruction of 
endometriotic tissue by electro-cautery and laser, division of scar tissue (adhesions) 
and removal of endometriotic cysts. In advanced endometriosis, laparoscopic surgery 
is done to excise visible endometrial implants, divide adhesions or surgically interrupt 
neural pathways for treatment of pelvic pain and is the only option for larger (>3 cm) 
respond poorly to medical therapy and hormonal supression doesn’t influence the 
extent of the adhesions which are often associated with large lesions. In the case where 
these traditional methods of surgical treatment are ineffective or if the disease has 
progressed beyond the ability or desire to maiantain future fertility a hysterectomy 
may be performed. A review of surgical excision for endometriosis found that excision 
should be considered the gold standard treatment to endometriosis because it is better 
at controlling pain than traditional management (Garry, 2004). There is however 
limited data demonstrating the best method of treatment in patients with endometriosis 
who desire fertility.  
1.7.1 Medical therapies for endometriosis 
Endometriosis is an oestrogen-dependent disorder therefore current medical therapies 
are centered upon decreasing circulating oestrogens levels. This is usually achieved 
by down regulating ovarian production of steroid hormones mainly oestradiol (Linda 
C Giudice, 2012). Therapies for systemic hormonal supression of endometriosis 
include danazol; a synthetic testosterone hormone derivative, gonardotrophin 
releasing hormone (GnRH) analogues, progestogens, gestrinone and oral 
contraceptive pills. These therapies may be effective for relief of pain associated with 
endometriosis, but they also reduce fertility. Both danazol and GnRH analogues are 
associated with side effects related to hyperandrogenism e.g. hair growth and voice 
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deepening and hypoestrogenism e.g. hot flushes and vaginitis. The therapies are used 
for periods of up to 6 months, however recurrence of symptoms is common after 
cessation of medical therapy. 
1.7.1.1 Danazol 
Danazol is a 17α ethinyltestosterone that increases androgens and inhibits pituitary 
response by inhibiting secretion of FSH and LH .This medication induces a hyper-
androgenic state which in turn causes suppresson of ovarian function, amenorrhoea 
and a low oestrogenic environment causing atrophy of endometriotic lesions and 
reduction in pelvic pain (Selak et al., 2007). In a study reporting on the effects of a 
danazol impregnated IUD for the management of pelvic pain in 18 women diagnosed 
with endometriosis and with recurrent pelvic pain, showed that pelvic pain was 
reduced significantly after the first 1 month with subsequent reduction in following 6 
months after IUD removal (Cobellis et al., 2004). A few non-randomised trials that 
have demonstrated a significant decrease in pain from endometriosis after 6 months 
of danazol impregnated IUD therapy (Ozawa et al., 2006).  This form of treatment 
however has substantial androgenic side effects that have been repored like hirsutism, 
mood changes, non-reversible voice deepening, arterial damage and liver damage 
(Selak et al., 2007) 
1.7.1.2 Non-steroidal anti-inflammatory drugs 
NSAIDs are often the first line therapy for treatment of symptoms of suspected 
endometriosis such as dysmennorohoea and pelvic pain. They are inexpensive, have 
few side effects and are available without prescription. Their mechanism of action is 
by inhibiting prostaglandins that are released in the pelvis and are the suscpeted cause 
of pain associated with endometriosis (Yap et al., 2004). NSAIDs inhibit the 
cycloxygenase (COX2) in the arachodonic acid pathway. The inhibition of COX2 
decreases the production of prostaglandins, thus reducing (Marjoribanks et al., 2003). 
The most common side effects are gastro-intestinal upset with reflux disease, nausea, 
diarrhoea and headaches (Allen et al., 2005). A Cochrane review of NSAIDs for pain 
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in women with endometriosis included two randomised controlled studies comparing 
NSAIDs with placebo. The evidence was insufficient to show that NSAIDs are 
effective in treatment of pain caused by endometriosis (Allen et al., 2009). 
1.7.1.3 Progestins 
Progestins also act by creating a low oestrogenic environment by suppressing ovarian 
release of steroid hormones and thus preventing growth of endometriosis implants. 
The exact mechanisms by which progestins decrease endometriosis associated pain is 
not well understood however some postulately mechanisms include; suppression of 
ovulation resulting in marked endometrial decidualisation of both the eutopic and 
ectopic endometrium subsequently causing a decrease in active bleeding from the 
lesion, modulation of immune responses by suppression of interleukin 8 production 
in lymphocytes, reduction of  TNF-α induced nuclear factor κ-B (NFκB) activaton 
which prevents proliferation of endometriotic stromal cells (Horie et al., 2005). 
Evidence for progesterone resistance in the endometrium of women with 
endometriosis may explain also why progestins are effective in reducing pelvic pain 
but ineffective in improving pregnancy rates (Bulun, 2009, Aghajanova et al., 2010). 
Side effects experienced by these drugs include; irregular uterine bleeding, weight 
gain, mood changes, bloating, fatigue, depression and nausea. Further studies aimed 
at understanding the precise effects of progestins on nociceptive, inflammatory and 
neuropathic pain in endometriosis are required to further knowledge of 
pathophysiology and improve the treatment of endometriosis. The combined OCP is 
also prescribed to women with endometriosis as a first in-line therapy and work by 
inducing a pseudo-pregnancy state by suppressing ovulation and causing atrophy of 
endometrial implants.  
1.7.1.4 GnRH analogues 
GnRH agonists are analogs of the hypothalamic hormone gonadotrophin releasing 
hormone (GnRH). GnRH is responsible for the normal function of the ovaries by 
stimulating the release of follicle stimulating hormone (FSH) and luteinizing hormone 
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(LH) from the pitutary. GnRH agonists bind to pitutary receptors resulting in a 
downregulation of pituitary hormone secretion which in turn down regulates the 
ovarian production of oestrogen. Depriving the endometriotic cells of oestrogen is 
thought to result in endometriotic atrophy (Kokorine et al., 1997). However, 
endometriotic cells are known to express aromatase ensuring their survival 
independent of ovarian steroids. GnRH agonist therapy is associated with side effects 
normally presenting during menopause e.g. hot flushes, vaginal dryness, loss of bone 
density (Sagsveen et al., 2003) therefore in some cases small amounts of steroid 
hormone can be administered indefinately in what is known as ‘add back therapy’ 
which appears to stem the severity of these side effects without significantly affecting 
the relief of endometriosis-associated pain.  
1.7.1.5 Aromatase inhibitors 
Aromatase is the key enzyme in the synthesis of oestrogens and mediates the 
conversion of androstenedione and testosterone to estrone and oestradiol. Aromatase 
inhibitors were developed to act on sex steroid-dependent neoplasms e.g. breast 
cancer, by suppressing the in situ production of oestrogen. In endometriosis, poor 
response to hormonal therapy may be due to the resistant nature of endometriotic cells 
to progestin compounds due to the under-expression of progesterone receptors, but 
also the over-expression of oestrogenic receptors in endometriotic cells that renders 
them less sensitive to progestin therapies.This enzyme is therefore a good target for 
inhibition of oestradiol synthesis. 
Aromatase inhibiting compounds are currently being considered for the treatment of 
endometriosis that is unresponsive to current therapy and have shown promising 
preliminary results (Attar and Bulun, 2006, Nothnick, 2011). The side effects 
associated with this treatment are milder compared to those associated with GnRH 
treatment. However, long term use carries a potential risk of osteoporosis and 
osteoponia. Clinical trials are yet to be carried out to ascertain whether aromatase 
inhibitors could have a significant role in medical management of endometriosis. 
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1.8 Biomarkers of endometriosis 
Laparoscopy is the gold standard method used to definitively diagnose endometriosis. 
It involves visualisation of lesions in surgery followed by histological confirmation 
by a pathologist (Kennedy et al., 2005). This procedure is invasive in nature, could 
cause complications and is very expensive. (Chapron et al., 2002, Vercellini et al., 
2009). There is often a delay in diagnosis of between 7-10 years on average. The delay 
is partly attributed to the fact that laparoscopy is a surgical procedure and is not the 
primary choice for diagnosis of women presenting with suspected disease. Variability 
of signs and symptoms does not make it simple to make a definitive diagnosis and 
symptoms are often mistaken to be those of other disorders such as irritable bowel 
syndrome. (Rogers et al., 2009a, Husby et al., 2003, Hadfield et al., 1996). Symptoms 
such as dysmenorrhoea, chronic pelvic pain and dyspareunia are commonly associated 
with endometriosis (Ballard et al., 2008, Falcone and Lebovic, 2011). However, the 
predictive value of these symptoms for the diagnosis of endometriosis is limited 
(Eskenazi et al., 2001, Chapron et al., 2005). Imaging techniques also are not able to 
diagnose all forms of this disease. Thus molecular biomarkers are urgently needed for 
the more accurate diagnosis of endometriosis. Before establishment of diagnosis by 
surgery, a less invasive test would be important for initial screening of possible cases 
of endometriosis. 
A biomarker may be defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacological responses to a therapeutic intervention (Jain, 2010). There is a great 
need for biomarkers that can function as alternatives for important clinical end points 
in endometriosis and for the development of a non-invasive diagnostic test.  
To date there are no reliable markers for the diagnosis and prognosis of endometriosis. 
However, efforts continue in the search for suitable markers. Several systematic 
literature reviews have been published on potential markers that have been identified 
to date (Fassbender et al., 2013, May et al., 2010, May et al., 2011). Some reported 
markers for the non-invasive or semi-invasive diagnosis of endometriosis are 
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discussed below. In some cases, these markers have been tested as part of a panel and 
this has shown to improve diagnostic performance. However, most markers/marker 
panels require appropriate independent validation. 
1.8.1 Serum/plasma markers 
1.8.1.1 CA125 
CA125/mucin 16 is a high molecular weight mucin and antigenic determinant 
expressed on the surface of coelomic epithelium, including epithelium of the 
endocervix, endometrium, fallopian tubes, pelvic peritoneum and placental tissue. It 
is also found in biological fluids such as human milk, amniotic and peritoneal fluids. 
CA125 was initially thought to be specific for ovarian malignancies and is currently 
used to aid in the diagnosis of ovarian cancer and to monitor recurrence following 
treatment. However, CA125 has been found to be raised in various benign conditions 
endometriosis, pelvic inflammatory disease, liver cirrhosis, benign ovarian cysts, tubo 
ovarian abscesses, and fibroids. 
Many studies have been carried out to evaluate the diagnostic performance of CA125 
for detecting endometriosis. Some studies have reported high specificity (80-95%) but 
with inadequate sensitivity (rarely above 50%) (Moretuzzo et al., 1988, Barbati et al., 
1994). The diagnostic performance of CA125 in endometriosis is complicated by the 
fact that endometriosis has varying degrees of chronicity and CA125 is mostly 
elevated in advanced disease. CA125 is also not a marker specific to endometriosis 
and therefore an elevated level cannot differentiate endometriosis from other diseases 
with similar indications such as fibroids or pelvic inflammatory disease. 
Association of an increased serum CA125 and the presence of severe endometriosis 
have been known for some time with the first reports being published in the mid-1980s 
(Pittaway, 1989, Giudice et al., 1986). One early study (Barbieri et al., 1986) 
demonstrated elevated serum CA125 in patients with advanced endometriosis.  
47 
 
Several teams have evaluated CA125 levels in serum and peritoneal fluid but have 
shown conflicting results. CA125 levels in peritoneal fluid are said to be higher than 
in serum, but no significant difference was observed in either serum or peritoneal fluid 
levels between women with and without endometriosis (Moen et al., 1991, Williams 
et al., 1988). By using a two-step immunoradiometric assay, Barbati et al found that 
the levels of CA125 in peritoneal fluid are a more sensitive indicator of disease than 
the levels in serum (Barbati et al., 1994). However, serum levels may provide a useful 
indicator on the extent of disease or response to therapy (Matalliotakis et al., 1994, 
Pittaway and Fayez, 1986). 
In a meta-analysis, Mol et al evaluated the performance of CA125 in serum of patients 
with laparascopically confirmed endometriosis compared to healthy controls from 
multiple studies (Mol et al., 1998). They also evaluated its ability to differentiate 
between mild disease (stage I and II) and severe disease (stage III and IV). 74% of 
studies included in this meta-analysis used a CA125 cut-off level of 35 IU/mL, while 
others used lower and higher cut-offs. ROC curve summaries were calculated for the 
ability of a single CA125 measurement to predict any type of endometriosis. The 
diagnostic performance was low with a sensitivity of 28% at 90% specificity. 
Increasing sensitivity to 50% resulted in a corresponding specificity of 72%. CA125 
was found to be a better predictor of advanced disease (stage III and IV) with a 
sensitivity of 47% and specificity of 89%. A later study in 775 women found a 78% 
NPV (negative predictive value) using <20 IU/mL for pre-operative CA125 levels and 
92.9% PPV using >30 IU/mL (Kitawaki et al., 2005) 
CA125 could be a useful marker of disease recurrence although this aspect has not 
been extensively studied. In a longitudinal study evaluating CA125 measurements in 
post-operative women with endometriosis over 12 months, the authors found that 
women whose CA125 levels dropped to below 16 IU/ml after surgery were more 
successful at achieving pregnancy within one year (Pittaway et al., 1995). Rising 
CA125 levels however could be of great value in post-operative management of 
women with infertility associated with endometriosis who may benefit from a more 
aggressive treatment regimen and assisted reproductive procedures. However serum 
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CA125 on its own does not have adequate sensitivity and specificity to be used to 
diagnose endometriosis especially in screening for peritoneal lesions that are missed 
by current imaging techniques.  
1.8.1.2 CA19-9 
CA19-9 (Carbohydrate antigen 19-9) is a marker associated with pancreatic and 
colorectal cancer. In gynaecology, serum CA19-9 levels can be elevated in patients 
with malignant and benign ovarian tumours (Ye C et al, 1994; (Harada et al., 2002) 
and has been shown in endometriosis (Panidis et al., 1988). The investigators reported 
raised serum CA19-9 in 5 out of 8 women with endometriosis. The levels were also 
found to drop significantly during treatment with danazol.  There was no control group 
that was used in this study. A drop in CA19-9 following danazol treatment was also 
reported in a later study (Matalliotakis et al., 1998).  
Several studies have evaluated the diagnostic properties of CA19-9 in comparison to 
CA125 in women with and without endometriosis (Harada et al., 2002). The 
investigators found the mean concentrations of CA19-9 were higher in 101 women 
with endometriosis compared to 22 controls. There was also a positive correlation 
with disease stage. By using a cut-off of 37 IU/mL, 34 out of 101 (33.7%) cases had 
raised CA19-9. Concentrations greater than 37 IU/mL were observed in women with 
advanced disease (stage III and IV). Another study reported reported higher serum 
CA19-9 concentrations in 101 endometriosis cases compared to 78 controls with 
levels also higher in advanced disease (Kurdoglu et al., 2009). Using the commonly 
accepted cut off of 37 IU/ml the sensitivity was 89% and specificity was 52%, values 
similar to those of CA125. These results contradict with those from previous studies 
which have reported high specificities and low sensitivities for CA19-9. However, 
consistent with previous reports CA19-9 could only predict severe stage disease 
thereby limiting this marker for broad application. Most studies have been limited by 
small subject numbers and an inability to diagnose early stage disease. 
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1.8.2 Cytokines 
Cytokines are glycoproteins that play a role in controlling cell proliferation, immune 
cell activation, motility, cell adhesion and chemotaxis. They are secreted into the 
extra-cellular environment by leucocytes, macrophages and other inflammatory cells. 
It is widely known that retrograde menstruation occurs in most women but why some 
end up developing endometriosis is still unknown and it has been hypothesiszed that 
a change in the function of the immune cells in the peritoneal environment may be a 
major reason (Wu and Ho, 2003, Lebovic et al., 2001).  
Macrophages are major secretors of cytokines and have been shown to be increased 
in the peritoneal cavity of women with endometriosis inducing a local inflammatory 
response (Sukhikh et al., 2004, Haney et al., 1981). Changes in cytokine 
concentrations reflects the immune system’s response to initial disease. Therefore 
many studies have focused on finding alterations in markers of inflammation between 
women with and without endometriosis to define potential biomarkers but also aid in 
understanding  the pathogenesis of the disease. 
The most studied cytokines as biomarkers of endometriosis are IL-6 and TNF-α, but 
the results have been conflicting (May et al., 2011). IL-6 is a pro-inflammatory 
cytokine involved in the activation of T cells and differentiation of B cells. Alterations 
in IL-6 in endometriosis have been studied by several groups (Bedaiwy et al., 2002, 
Bedaiwy and Falcone, 2004, Somigliana et al., 2004, Martinez et al., 2007, Seeber et 
al., 2008a, Othman et al., 2008, Iwabe et al., 2002). In a multi-marker panel study, 
increased levels of IL-6 were demonstrated in women with early stage endometriosis 
(Bedaiwy et al., 2002). At a threshold of 2 pg/mL, IL-6 was able to discriminate 
between groups with a sensitivity of 90%  and specificity of 47%. The other markers 
tested (IL-1β, IL-8, IL-12, IL-13 and TNF-α) were not discriminatory. The authors 
however noted that they were unable to obtain sufficient serum to measure all the 
cytokines in all subjects and their findings were based on the comparison of only 20 
cases and 11 controls.  
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In a prospective study to compare the diagnostic performance of IL-6 and CA125, 
elevated levels of IL-6 were found in women with endometriosis, but only those with 
minimal-mild disease yielding a sensitivity and specificity of 75% and 83% 
respectively, at a threshold of 5.75 pg/mL (Martinez et al., 2007). CA125 was 
increased 3 fold in women with late stage disease. However, the combination of both 
markers did not offer any additional value. These data do suggest that IL-6 may be a 
good marker for early stage disease where ultrasound is not as helpful and because 
IL-6 levels were not affected by other pelvic pathologies e.g. myomas, benign ovarian 
cysts. A protein array system using cytokine-specific antibody coated beads was used 
to quantify cytokine concentrations in samples from 68 women with endometriosis 
and controls (Othman et al., 2008). IL-6, MCP1 and IFN-γ were found to be higher in 
women with endometriosis compared to controls. At a threshold of 1.9 pg/mL, IL-6 
gave the best results in discriminating endometriosis from controls. Combining IL-6, 
MCP1 and IFN-γ did not provide additional discriminatory power over using IL-6 
alone. Combination with CA125 was not reported. In another prospective cohort study 
of CA125 and IL-6 no significant improvements in diagnostic accuracy were reported 
for this combination. In another study (Somigliana et al., 2004) classification tree 
analysis was applied to determine the diagnostic ability of IL-6, TNF-α, MCP1, MIF, 
CA125 and leptin. Combination of some of the markers improved diagnostic 
performance; CA125, MCP1 and leptin was able to diagnose 51% of cases with 89% 
accuracy, while CA125, MCP1, leptin and MIF could diagnose 48% of cases with 
93% accuracy (Seeber et al., 2008a). The discrepancies observed in these studies can 
be attributed to various factors including the type of assay used and the different study 
sets used. Whilst the same ELISA kit was used in two of these studies, different results 
were reported (Somigliana et al., 2004, Bedaiwy et al., 2002). In addition IL-6 
evaluation methods are not properly standardised and IL-6 is likely to reflect non-
specific inflammatory responses that differ from case to case.  
TNF-α is a monocyte-derived cytokine with pro-inflammatory and pro-angiogenic 
roles. An increase in serum TNF-α concentrations in endometriosis has been reported 
by several studies (Matalliotakis et al., 1997, Pizzo et al., 2002, Darai et al., 2003, 
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Xavier et al., 2006), whilst others have failed to show any significant difference 
(Vercellini et al., 1993, Seeber et al., 2008a, Othman et al., 2008). In one of these 
studies, elevated TNF-α levels were decreased after treatment with danazol 
(Matalliotakis et al., 1997). Significantly higher levels of TNF-α were reported in 
women with endometriomas compared to those with benign cysts, but were not higher 
in those with malignant cysts (Darai et al., 2003). High levels of serum TNF-α were 
shown in endometriosis patients throughout the menstrual cycle compared to controls 
(Xavier et al., 2006). Another study evaluating TNF-α, TGF-β, IL-8 and MCP1 in 
serum and peritoneal fluid reported increased TNF-α levels in early stage disease, but 
a significant decrease as the disease progressed (Pizzo et al., 2002). This is contrary 
to another report whose findings showed no difference in TNF-α levels  between 
women with endometriosis-associated infertility to those with idiopathic infertility 
(Bedaiwy et al., 2002). In summary, the diagnostic potential of TNF-α is as yet unclear 
and more studies are required to evaluate its worth as a marker either individually or 
as part of a panel of other markers. 
1.8.3 Cell adhesion molecules 
Soluble intracellular adhesion molecule 1 (sICAM1) can be secreted from the 
endometrium and endometriotic implants (Vigano et al., 2001, Vigano et al., 2000). 
Studies of this protein as a possible biomarker of endometriosis have been conflicting. 
In a cross-sectional study, sICAM1 was found to be increased in serum of women 
with advanced stage endometriosis (Wu et al., 1998). Another study showed no 
difference in endometriosis patients compared to controls although when sICAM1 
was evaluated by stage of disease it was reported to be increased in women with early 
stage disease (De Placido et al., 1998). Similarly, sICAM1 was found to be elevated 
in early stage disease and rose further during treatment and was maintained for 3 
months after treatment (Matalliotakis et al., 2001). Decreased levels in cases with 
stage III-IV disease have also been reported (Barrier and Sharpe-Timms, 2002). They 
concluded that it could be possible that the levels are high during early stage disease, 
but decrease as the disease progresses.  
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Other studies have shown marginal increases in sICAM (Daniel et al., 2000, 
Somigliana et al., 2002), although women with deep endometriosis had significantly 
raised sICAM levels compared to those with peritoneal disease and controls. A 
sensitivity and specificity of 19% and 97% respectively, were reported. The use of 
CA125 in detecting deep lesions in the same patients yielded a sensitivity and 
specificity of 14% and 92%, respectively. When both markers were combined, there 
was an improved sensitivity of 28% at 92% specificity. Thus sICAM1 may play a role 
in the pathophysiology of the disease, but appears to be an unreliable non-invasive 
marker when used alone.  
In a relatively large study, 28 plasma biomarkers were evaluated for diagnosis in 232 
plasma samples from women with endometriosis and 121 without endometriosis at 
laparoscopy in the menstrual phase (Vodolazkaia et al., 2012). Two models of four 
biomarkers each were developed. Model 1 consisted of annexin V, VEGF, CA125 and 
glycodelin/PAEP, while in model 2, glycodelin was replaced with sICAM1. When 
evaluated, models yielded sensitivities and specificities of 81-90% and 68-81%, 
respectively. Validation in an independent set yielded a sensitivity of 82% and a 
specificity of 63-75%. This study demonstrates the value of using a panel of markers 
instead of a single biomarker to improve diagnostic performance. 
1.8.4 Angiogenic factors 
Angiogenesis is the formation of new blood vessels from existing vessels. The 
establishment of a new blood supply is essential for the survival of the endometrium 
attached to the peritoneum and the maintenance of endometriosis. Macrophage 
derived cytokines like transforming growth factor beta (TGF-β) and vascular 
endothelial growth factor (VEGF) have been suggested to contribute to the 
development of endometriosis by promoting the neovascularisation of endometrial 
cells attached to the peritoneum (Harada et al., 2001). Increased angiogenesis is 
reported to be common around peritoneal explants and increased angiogenic markers 
has been observed in serum and peritoneal fluid of women with endometriosis 
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(Mclaren et al., 1996a, Mclaren et al., 1996b, Garcia Manero et al., 2009, Taylor et 
al., 2002) 
VEGF is the most potent angiogenic factor which has been detected in high 
concentrations in serum and peritoneal fluid of women with moderate to severe 
endometriosis. It is also secreted in endometriotic lesions, possibly as a downstream 
consequence of pro-inflammatory cytokine IL-1β activity (Mclaren et al., 1996a, 
Mclaren et al., 1996b). However, the usefulness of VEGF as a biomarker of 
endometriosis remains unclear. Some studies have reported increased peripheral 
VEGF in women with endometriosis (Xavier et al., 2006, Vodolazkaia et al., 2010, 
Bourlev et al., 2010), whilst others reported no significant changes (Othman et al., 
2008, Pupo-Nogueira et al., 2007). 
Glycodelin/PAEP is a glycoprotein expressed in reproductive tissues. It has numerous 
glycosylation sites and isoforms. Glycodelin A is found in amniotic fluid (Riittinen et 
al., 1989), the glandular epithelium of the secretory endometrium (Meola et al., 2009) 
and is also secreted into serum and peritoneal fluid by endometriotic lesions 
(Koninckx et al., 1992, Kocbek et al., 2013). Glycodelin has immunosuppressive, 
angiogenic and contraceptive effects. There is therefore a likelihood that it plays a role 
in the development of endometriosis and endometriosis-associated infertility 
(Fassbender et al., 2013). Few studies have evaluated glycodelin as a possible serum 
biomarker of endometriosis. In one study, glycodelin A levels were reported to be 10-
fold higher in peritoneal fluid than serum of endometriosis patients in both the 
proliferative and secretory phase of the menstrual cycle (Kocbek et al., 2013). Pain 
frequency and intensity was directly proportional to glycodelin A concentrations. In 
assessing the diagnostic capabilities for ovarian endometriosis, serum glycodelin A 
yielded a sensitivity of 82.1% and specificity of 78.4%, compared to 79.7% sensitivity 
and 77.5% specificity in peritoneal fluid.  Glycodelin A has been evaluated as part of 
a multi-marker panel for the non-invasive diagnosis of endometriosis and has shown 
promising results (Vodolazkaia et al., 2012). It may therefore have a potential role as 
a biomarker for endometriosis and further studies need to be carried out to assess its 
possible significance. 
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1.8.5 Circulating antigens and auto-antibodies 
Reports on serum endometrial antigens and auto-antibodies are few and inconsistent. 
The inconsistency is due to different study designs, use of different cell lines as 
antigenic cell lines and different assays used. Despite this, efforts have been made to 
test the value of anti-endometrial antibodies and antigens as potential biomarkers. 
Anti-endometrial IgM was reported in 27% of endometriosis patients, while anti-
endometrial IgG was present in 33% of the patients (Gajbhiye et al., 2008). A different 
study by the same group demonstrated endometrial antigens using 1D and 2D western 
blotting using serum of patients with endometriosis compared to healthy controls 
(Gajbhiye et al., 2012). Five differentially detected spots were identified by mass 
spectrometry as tropomyosin 3 (TPM3), stomatin-like protein 2 (SLP2) and 
tropomodulin 3 (TMOD3), and their auto-antibodies were found to be elevated in 
women with endometriosis. One of the auto-antibodies (anti-TMOD3) gave a 
sensitivity of 78% and specificity of 96% in detecting early stage endometriosis. 
Larger studies need to be carried out to evaluate these auto-antibodies as biomarkers.  
1.8.6 Endometrial tissue markers 
1.8.6.1 Interleukin 1 (IL-1) 
Endometrial tissue cytokine expression has also been assessed with the aim of 
identifying candidate biomarkers. IL-1 belongs to a group of cytokines that play a role 
in the regulation of immune and inflammatory responses to a wide sectrum of 
pathophysiological processes associated with host defence and inflammation. It is also 
involved in normal immunological and reproductive activities that occur in the human 
endometrium during a normal menstrual cycle (Lawson et al., 2007, Akoum et al., 
2008, Akoum et al., 2007). Several studies point to a significant role for IL-1 in 
endometriosis. IL-1β levels have been shown to be increased in women with 
endometriosis during the secretory phase (Kyama et al., 2008). IL-1RII a decoy 
receptor known for its ability to inhibit IL-1 functions has also been shown to be 
significantly altered in women with endometriosis. A significant decrease of IL-1RII 
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mRNA was reported in the endometrium of women with early stage disease in the 
proliferative and secretory phase of the menstrual cycle (Lawson et al., 2008). Another 
study from the same group reported that increased proteolysis causes the down-
regulation of IL-1RII in the endometrium of women with endometriosis (Bellehumeur 
et al., 2005). This research group has conducted many studies on IL-1RII expression 
in endometriosis (Akoum et al., 2008, Lawson et al., 2007, Bellehumeur et al., 2005, 
Kharfi and Akoum, 2001, Lawson et al., 2008, Kharfi et al., 2002, Akoum et al., 2001). 
All their studies report on a significant decrease in IL-1RII. This decrease is proposed 
to result in an insufficient ability of the endometrium and ectopic implants to down 
regulate IL-1 function that plays a role in the abnormal inflammatory processes 
reported in ectopic sites. Independent validation of IL-1RII as a biomarker is therefore 
warranted. 
1.8.6.2 Aromatase 
In the human endometrium, it is known that androgens cannot be converted to 
oestrogen due to a of lack of the enzyme aromatase (Bulun et al., 1993). This is 
contrary to several reports that indicate an abnormally high expression of aromatase 
in eutopic and ectopic tissue of women with endometriosis (Noble et al., 1996, Maia 
et al., 2009, Hudelist et al., 2007, Bulun et al., 2004). Endometriosis is not associated 
with increased oestrogen levels in serum, therefore aromatase expression in eutopic 
and ectopic tissue suggest a local oestrogen production in the endometrium and 
endometriotic tissue of women with endometriosis. This phenomenon may promote 
growth and maintenance of ectopic lesions and may play a role in endometriosis-
related infertility by altering the programming of eutopic endometrium. 
The diagnostic usefulness of tissue aromatase has been evaluated (Kitawaki et al., 
1999b, Kitawaki et al., 1999a). This group reported 91% sensitivity and 100% 
specificity for distinguishing-disease free women from those with endometriosis and 
other diseases like adenomyosis and fibroids. Other studies have reported no 
detectable changes in expression of aromatase in the endometrium of women with 
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disease (Colette et al., 2009, Velasco et al., 2006). Additional studies need to be 
conducted to evaluate the role of aromatase and to assess its value as a biomarker. 
1.8.6.3 Nerve Fibres 
High density small unmyelinated sensory nerve fibres have been shown in the 
functional layer of the endometrium from women with endometriosis especially in the 
secretory phase of the menstrual cycle (Tokushige et al., 2006b, Tokushige et al., 
2006a). The detection of endometrial nerve fibres has been proposed as a semi-
invasive diagnostic tool for endometriosis (Al-Jefout et al., 2009, Bokor et al., 2009). 
Endometrial biopsies from 99 women presenting with pelvic pain and infertility were 
stained for the neuronal protein PGP9.5 (Al-Jefout et al., 2009). Sensitivity and 
specificity was 83% and 98%. Nerve fibre density did not differ between cycle phase 
and women with endometriosis and pain had significantly higher nerve fibre density 
compared to those who were infertile with no pain. This study was however limited 
by lack of uniform histological confirmation of endometriosis. The other study tested 
the presence of sensory nerve fibres in the secretory phase of the endometrium of 
patients with minimal to mild endometriosis compared to controls (Bokor et al., 2009). 
Tissues were stained with PGP9.5, neurofilamin (NF), vasoactive intestinal peptide 
(VIP), substance P (SP), neuropeptide Y (NY) and calcitonin gene related peptide. 
The density of nerve fibres was 14 times higher in the eutopic endometrium of 
endometriosis patients compared to controls. A predictive model with PGP9.5, VIP 
and SP was able to detect early stage endometriosis with 95% sensitivity, 100% 
specificity and 97.5% accuracy. These results are promising, but need to be evaluated 
further, especially to establish whether nerve fibres could be useful markers of 
endometriosis and are not just related to pelvic pain. 
1.8.6.4 Matrix metalloproteinase (MMPs)  
MMPs are a group of enzymes important for the control of extracellular matrix 
turnover (Brunner K.L et al, 1999). They are involved in tissue remodelling and 
angiogenesis. MMPs are upregulated by TNF-α and IL-1, which could contribute to 
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the invasiveness of endometrial fragments in women with endometriosis (Sillem M et 
al, 2001). TNF-α may also contribute to decreased expression of endogenous tissue 
inhibitors of MMPs (TIMPs) (Gottschalk et al, 2000). The expression of MMP1 by 
endometriotic cells was shown to be increased as compared to eutopic endometrium 
of patients and controls (Hudelist G et al, 2005, Di Carlo 2009). Another study 
however reported no change in MMP1 expression (Kyama et al., 2006a). Raised MMP 
3 expression has also been reported in the eutopic endometrium of patients with 
endometriosis versus controls (Ramon et al., 2005, Gilabert-Estelles et al., 2007). 
1.9 Proteomics in endometriosis research 
Proteomics is the study of the expressed proteins in a cell or tissue, also known as the 
proteome. This includes the expression of all protein isoforms, their chemical 
modifications, structures and interactions with other proteins and biomolecules (Tyers 
and Mann, 2003, Anderson and Anderson, 1998). Variation in protein expression in 
different diseases may happen by different mechanisms which often cannot be 
detected using genomic methods. Therefore one of the main objectives of proteomics 
is to determine these protein changes and to assess how these changes could affect 
function (Patterson and Aebersold, 2003). Areas of current research in biomedicine 
where proteomics is used include: study of altered protein expression at the tissue, 
cellular and sub-cellular level, discovery of novel biomarkers for the diagnosis and 
early detection of various diseases and the identification of new therapeutic targets 
(Hanash, 2003, Anderson and Anderson, 1998). The proteome is a very complex and 
dynamic entity and because of this, the impact of proteomics in medicine (as 
compared to genomics) has yet to be felt. Advances in proteomic technologies 
however are likely to improve the detail at which proteomes can be characterised and 
therefore provide important leads in the future. 
The molecular pathways by which endometriosis occurs are currently not known. 
Genome analysis has been widely applied with the hope of providing additional useful 
information about the differences between women with and without endometriosis. 
Transcriptomics (gene expression profiling) which is the study of the transcripts 
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(mRNA) in a cell or tissue population has been used to provide information regarding 
the molecular basis of endometriosis (Giudice, 2003b, Giudice, 2003a). It is important 
to note however that changes in mRNA levels do not necessarily reflect changes to 
the abundance of the corresponding translated proteins. Various mechanisms of post-
transcriptional regulation exist such as mRNA degradation, silencing and splicing, 
whilst protein translation and turnover also vary considerably. Proteomics has the 
potential to provide considerably more information about disease and can identify 
relevant targets for diagnosis and therapy (Hanash, 2003). 
The main goal of proteomic approaches to date in the study of endometriosis has been 
the search for biomarkers (Fassbender et al., 2013). However, despite numerous 
studies in this area, no single biomarker or panel of markers has been deemed fit 
enough for accurate diagnosis for clinical use, and whilst some show promise, they 
require further testing and validation (Fassbender et al., 2012b, Vodolazkaia et al., 
2011, Vodolazkaia et al., 2010, Bokor et al., 2009). From these studies however, a 
vast amount of knowledge has been acquired regarding the molecular events and 
pathways that lead to disease development and progression, hence providing a better 
understanding of this enigmatic disease. 
The reason why application of proteomic technologies has not yet provided applicable 
tools for diagnosis of endometriosis is likely because of the heterogeneous nature of 
the tissue and the fact that the endometrium is constantly remodelling itself in response 
to fluctuations in sex steroid hormones and drug treatments. Emerging technologies 
for protein detection which are more sensitive, as well as better sample preparation 
methods, pre-fractionation, protein quantitation and improved bioinformatics are 
permitting a more in-depth understanding of the proteomes of tissues and biological 
fluids. These methods can now be applied in the search for biomarkers of 
endometriosis. 
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1.10 Proteomic technologies for biomarker discovery in endometriosis 
Proteomic analysis allows comparison of proteins from any biological source and 
permits the identification and quantitation of multiple proteins within a single 
experiment (Meehan et al., 2010). Experimental reproducibility is the key to 
biomarker identification. Sample handling at all stages of the experiment is a crucial 
factor. Samples must be collected, processed and stored according to highly 
standardised and robust procedures. To date, the two most commonly applied 
technologies in the investigation of endometriosis have been two dimensional gel 
electrophoresis (2DE) and surface-enhanced laser desorption ionisation time-of-flight 
mass spectrometry (SELDI-TOF MS) (Fassbender et al., 2013, Linda C Giudice, 
2012). 
In 2DE, proteins are first separated by iso-electric focusing according to their native 
pI (iso-electric point) and then by SDS-PAGE (sodium dodecyl polyacrylamide gel 
electrophoresis) according to their molecular weight. Protein species are then detected 
in the gel by direct staining or by imaging if the proteins have first been labelled with 
fluorescent tags. In studies of endometriosis, 2DE has been applied to both tissue 
biopsies and biofluids. The first study compared protein profiles of serum and 
peritoneal fluid of women with and without endometriosis (Joshi et al., 1986) with the 
hope of establishing whether infertility in women with endometriosis was as a result 
of autoimmune mechanisms. No significant changes were observed, but an 
unidentified protein of 70 kDa was observed in 18/20 peritoneal fluid samples in the 
secretory phase that was not present in the proliferative phase.  
In another study, 2DE and mass spectrometry were used to establish the effects of 
endometriosis on the proteome of eutopic endometrium comparing tissue from women 
with and without endometriosis (Fowler et al., 2007). Proteins found to be 
differentially expressed included chaperones, redox regulators, proteins involved in 
DNA metabolism and secreted proteins.  
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Protein profiling using SELDI-TOF MS is a relatively high-throughput, but low 
coverage technique that involves capture of proteins on protein chips which have 
different chromatographic surface chemistries to enrich specific protein subsets. 
Captured proteins are directly analysed by mass spectrometry and comparisons made 
between spectra to identify changes in protein abundance between samples. Some of 
the advantages of SELDI are that small amounts of sample can be used and it is a rapid 
technique. Its main limitation however is that it does not allow for the direct 
identification of proteins (Poliness et al., 2004, Linda C Giudice, 2012). 
SELDI-TOF MS has been applied in the analysis of serum, plasma and tissue from 
women with and without endometriosis. The first SELDI-TOF MS study in 
endometriosis demonstrated several polypeptides and proteins that were expressed 
differentially in eutopic endometrial tissue from women with and without 
endometriosis (Kyama et al., 2006b). Endometrial polypeptides of 2.8-12.3 kDa were 
decreased in women with endometriosis whilst a 23 kDa protein subsequently 
identified as transgelin, was increased. A follow-up study to investigate differentially 
expressed proteins and peptides in endometrial tissue at the secretory phase revealed 
two up-regulated (90.7 kDa and 36 kDa) and two down-regulated peaks (1.9 kDa and 
2.5 kDa) that together could classify minimal-mild  endometriosis with 100% 
accuracy (Kyama et al., 2011). The up-regulated proteins were identified as T plastin 
and annexin V; proteins reported to play roles in cell mobility, proliferation, 
attachment and early invasion of endometrial cells. Five peaks (5,385 m/z, 5,425 m/z, 
5,891 m/z, 6,448 m/z and 6,898 m/z) were described in another study that could 
discriminate endometriosis from healthy controls (Wang et al., 2010). These studies 
suggested that SELDI-TOF MS analysis of endometrial tissue may be a promising 
method for biomarker identification for the diagnosis of endometriosis.  
Analysis of serum proteins using SELDI-TOF MS identified peaks that together 
achieved >90% specificity with 20% sensitivity (Seeber et al., 2010). Combining these 
with their best performing markers from a previous study (Seeber et al., 2008b), 
resulted in 73% of all subjects that would have been diagnosed with 94% accuracy. 
Another study analysed 254 plasma samples in women with and without 
61 
 
endometriosis during the menstrual phase (Fassbender et al., 2012b). A model was 
developed using five peaks: 2,058 m/z, 2,456 m/z, 14,694 m/z 3,883 m/z and 42,065 
m/z that was able to detect ultrasound-negative endometriosis with a sensitivity of 
88% and specificity of 84%. They also identified a high intensity peak (2,189 m/z) 
that was down-regulated in women with moderate to severe endometriosis compared 
to the controls. This peptide, identified by MALDI-TOF/TOF as a fragment of 
fibrinogen β chain, has been reported by the same group to be down-regulated in 
uterine fluid from baboons induced with endometriosis 
(Patentstorm.Us/Patents/7794958, Fassbender et al., 2013).  
Despite these advancements, SELDI-TOF is known for its poor reproducibility and 
poor mass accuracy, making reliable protein identification difficult. To this end, other 
quantitative proteomic tools that allow for the comparison of complex protein profiles 
have been developed. Described below are the major approaches that will be used in 
this study to search for the discovery of potential biomarkers for the non-invasive 
diagnosis of endometriosis. These approaches will be used in combination to 
quantitatively characterise and identify proteins that are differentially expressed in 
endometrial tissue of women with and without endometriosis. 
1.10.1 Two dimensional-difference gel electrophoresis (2D-DIGE) 
Separation of complex protein mixtures into simpler fractions or individual 
constituents is normally the initial step in any proteomics experiment. For many years 
2DE was the method of choice for protein separation and profiling (O'farrell, 1975, 
Garrels, 1979). As mentioned earlier, 2DE involves separation of proteins in two 
dimensions by their isoelectric points and by their molecular weight. This method 
however has several limitations with poor reproducibility being the most significant 
(Viswanathan et al., 2006, Timms and Cramer, 2008, Minden et al., 2009). It was 
reasoned that separating multiple samples on the same gel would partly overcome this 
problem, allowing a level of internal control. To facilitate this, a method of 
differentially labelling proteins within a mixture was needed. This was made possible 
in difference gel electrophoresis (DIGE) with the introduction of fluorescent dyes that 
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are used to label the proteins before running on a gel. The CyDyes (Cy3-NHS, Cy5-
NHS and Cy2-NHS), are synthetic cyanine dyes with a reactive N-
hydroxysuccinimidyl ester (NHS). The CyDyes react with primary amino groups on 
proteins, have the same molecular weight and preserve the charge of the target amino 
acid, but have specific fluorescence emission spectra . The charge and mass matching 
ensures that proteins from differenlly labelled samples will co-migrate to the same 
position during 2DE. 
The principle of DIGE was originally described by Minden and colleagues (Unlu et 
al., 1997). Since then, this method has been extensively used to analyse protein 
changes in different cells, tissues and body fluids. Experimental design and sample 
preparation are vital in any DIGE experiment. The protocols depend on the type and 
number of samples to be analysed. A typical DIGE experiment involves sample lysis 
to extract and denature the proteins with lysis carried out using urea- and zwitterionic 
detergent-containing 2DE lysis buffer. Equal amounts of proteins are then 
differentially labelled with the fluorescent dyes (Cy3, Cy5 and Cy2) which covalently 
label lysine residues -amino groups and polypeptide N-terminal amino groups in the 
different samples. The labelled proteins are then mixed together in equal amounts and 
separated by 2DE on the same gel. The Cy2 dye is typically used to label an internal 
standard that is run on all gels against pairs of test samples labelled with the other two 
dyes (Alban et al., 2003, Gharbi et al., 2002). Resolved, labelled proteins are thereafter 
detected at appropriate excitation and emission wavelengths using a fluorescence 
scanner and signals from protein spots compared. Gels are typically post-stained after 
differentially expressed proteins/spots are selected and spots of interest are then 
picked from the gel for identification by mass spectrometry (MS).  
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Figure 1.1 2D-Difference gel electrophoresis 
Samples are labelled using three dyes; Cy2, Cy3 and Cy5. Proteins are resolved by 
electrophoresis in two dimensions, the gels imaged on a fluoresecence scanner and 
iamge analysis performed. Differentially expressed proteins are picked from gels 
and identified by MS. 
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Protein profiling by fluoresence 2D-DIGE has several advantages over standard 2DE 
using protein stains: it is more reproducible, more accurate and more sensitive with a 
higher throughput and a larger dynamic range of protein abundance can be analysed. 
Samples are subjected to the same conditions during 2D separation, hence raising the 
confidence with which proteins can be matched and quantified. Post-translational 
modifications which play a role in regulating protein function can also be detected if 
they affect protein pI. Introduction of the internal standard allows for normalisation 
of each spot across all gels enabling more accurate differentiation of biological from 
experimental variation (Alban et al., 2003, Diez et al., 2010). However, several 
problems inherent to 2DE still exist; there is poor resolution of basic, hydrophobic 
and large proteins. Additionally labelled proteins migrate slower than unlabelled ones 
causing spot misalignment in the lower molecular mass region. This may interfere 
with spot picking and subsequent MS identification (Gharbi et al., 2002). Other 
problems can include high fluoresence background, detection of non-protein signals 
and protein-dye bias (Timms and Cramer, 2008). 
2D-DIGE has not been used extensively in endometriosis studies. 2D-DIGE and 
MALDI-TOF-MS were used to identify proteins with altered abundance in mid-
secretory phase eutopic endometrium from women with and without endometriosis 
(Stephens et al., 2010). A total of 72 differentially expressed proteins spots were found 
with 20 of these identified by MS. Most had not been previously reported as being 
associated with endometriosis. Five proteins were selected for validation by 
immunohistochemistry and western blotting: vimentin (VIM), peroxiredoxin 6 
(PDRX6), ribonuclease/angiogenin inhibitor 1 (RNH1), coronin 1A (CORO1A) and 
transgelin 2 (TAGLN2). RNH1, VIM and PDRX6 all showed a confirmatory decrease 
in patients with endometriosis, however an additional isoform of PDRX6 was over-
expressed in endometriosis patient samples compared to those from healthy women. 
The fold-changes were compared with previously reported micro-array data (Burney 
et al., 2007) in an attempt to compare gene expression with protein abundance data in 
endometriosis patients. Most of the proteins showed no correlation with their mRNA 
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level in line with previous reports that protein abundance chnages are  poorly 
correlated with changes in mRNA in endometrial tissue (Chen et al., 2009, Fassbender 
et al., 2012a). 
1.10.2 Mass spectrometry 
One of the most powerful modern analytical techniques available is mass spectrometry 
(MS). Over the last decade MS-based proteomics has rapidly become the analytical 
method of choice for identification and characterisation of proteins (Kicman et al., 
2007, Yates et al., 2009). MS allows molecules to be identified by the production of 
ions, their subsequent separation and detection based on their mass to charge ratio, 
conferring a high level of specificity with sensitivity.  
The development of different types of ion sources and mass analysers has had 
considerable impact in biomedical studies of large organic molecules (Aebersold and 
Mann, 2003, Mano and Goto, 2003, Kito and Ito, 2008). Ionisation techniques in the 
past limited research to volatile compounds or those that could be enhanced to make 
them volatile. Large, polar biomolecules that are involatile e.g. proteins and peptides 
presented a particular problem. In 1990, two ionisation techniques were able to enter 
fully into the biological arena. These were electrospray ionisation (ESI) and matrix-
assisted laser desorption/ionisation (MALDI). These approaches are known as soft 
ionisation techniques and they allow molecules to remain relatively intact during the 
ionisation process permitting accurate mass measurement and identification of 
polypeptides (Fenn et al., 1989, Karas and Hillenkamp, 1988, Kicman et al., 2007, 
Yates et al., 2009).. ESI works by ionizing the analytes from the liquid phase and is 
the preferred ionization method for the analysis of complex mixtures. It is often 
coupled to liquid-based separation tools such as chromatography. MALDI is used to 
analyse simpler mixtures of peptides by sublimating and ionizing the analytes from a 
dry, crystalline matrix via laser pulses (Aebersold and Mann, 2003, Kicman et al., 
2007).  
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The mass analyser is interfaced with the ionization process. Ions produced are 
subjected to separation according to their mass to charge ratio (m/z) in the mass 
analyser. There are five basic types of mass analysers: ion trap (IT), quadrupole trap 
(QT), time of flight (TOF), orbitrap and Fourier transform ion cyclotron resonance 
(FT-ICR). The type of mass analyser will dictate the type and quality of experimental 
data obtained with reference to mass accuracy, mass resolution, mass range and 
sensitivity. Each mass analyser however has inherent advantages and disadvantages 
which should be considered before the start of any MS experiment. 
The ions emitted from the mass analysers are measured by a detector. The detector is 
an electron multiplier or micro channel plates. When each ion hits the detector a wave 
of electrons is emitted resulting in amplification of the signal for improved sensitivity. 
To ensure that non-sample ions do not collide with sample ions, this process is 
performed under high vacuum. Data from the detector is then analysed to provide 
information regarding the m/z of the ions and their relative abundance. This generates 
a mass spectrum. This information is then processed through database searching to 
identify the molecule of interest based on its accurate mass and other information such 
as protease specificity and taxonomy. 
Mass analysers have been hyphenated to allow fragmentation of ions and subsequent 
analysis of daughter ions in the second analyser. In this so called tandem MS 
(MS/MS), ions of interest from the first mass spectrum (MS1) are selected based on 
their intensity and m/z. These ions (precursor ions) are then fragmented by colliding 
the ions with an inert gas such as helium. This fragmentation process is commonly 
referred to as collision induced dissociation (CID). Another round of MS is carried 
out on the fragmented ions generating a second mass spectrum (MS2). Since the 
fragmentation can be controlled, a series of fragment ions is generated, the mass 
differences of which can be used to determine amino acid sequence, greatly improving 
on the ability to identify peptides and proteins.  
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1.10.3 Separation technologies 
Mass spectrometry is highly dependent on powerful separation technologies that 
simplify complex biological samples prior to mass analysis. Multidimensional 
separation couples two or more different separation methods by which the analytes 
are first separated by one method and then by one or more independent separation 
methods. It is important to consider the orthogonality of the individual separation 
methods in which each dimension uses different (orthogonal) molecular properties of 
molecules as a basis for separation. Two major approaches for separation are gel-
based and liquid chromatography-based. 
1.10.3.1 Ion exchange chromatography (IEC) 
Ion exchange chromatography is the reversible adsorption of charged molecules to 
immobilised ion groups on a matrix of opposite charge. Separation can be selectively 
achieved by adsorption and release of analytes from the matrix by applying a gradient 
of eluting buffer of increasing ionic strength or pH (Figure 1.2.). Fractionation of 
proteins and peptides by IEC depends upon differences in the charge of different 
proteins and peptides which depends upon the number and type of ionisable amino 
acid side chains.  
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Figure 1.2 Schematic diagram showing anion exchange chromatography 
The stationery phase is a positively charged resin which binds negatively charged 
molecules. The strength of binding is affected by the pH and salt concentration of the buffer 
and by changing either of the conditions the bound molecules can be eluted off. Increasing 
the salt concentration of the buffer, the anions in the salt would displace the bound anions on 
the column. 
 
1.10.3.2 High Performance Liquid Chromatography 
HPLC is a chromatographic method used to resolve molecular species on the basis of 
their interactions with a column-bound stationery phase. Analyte molecules are passed 
through the column and are retarded by specific chemical and physical interactions 
with immobilised chromatographic supports. Bound peptides are sequentially eluted 
using a graduated mobile phase. The specific point at which a peptide elutes from the 
column is known as the retention time and is a unique property of the analyte 
molecule. Reversed-phase liquid chromatography (RPLC) separates peptides 
according to hydrophobicity using a linear gradient of organic solvent. It is usually 
the final dimension of separation and can be coupled directly to a mass spectrometer 
in so-called LC-MS/MS. For compatibility, low flow rates are required (200-500 
nL/min), so the technique is often referred to as nano-LC-MS/MS 
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1.10.4 Electrospray ionisation (ESI) 
ESI is a soft ionisation technique which allows the analysis of large intact 
biomolecules such as protein and DNA. This process involves production of ions by 
spraying a solution containing the analyte into an electrical field under atmospheric 
pressure (Fenn et al., 1989). The analyte is ionised by the source which is held at a 
positive and negative potential depending on the analyte of interest (Figure 1.3). 
Peptides are typically analysed in the positive ion mode and are dissolved in organic 
solvents to assist ionisation. The principle in ESI is that a spray of charged liquid 
droplets is produced by atomisation or nebulisation. ESI is achieved by applying a 
strong electrical field at the end of the capillary. As the solvent evaporates from the 
droplets, analyte ions are transferred into the gas phase. Heat and gas are applied to 
assist droplet desolvation which initiates a series of Raleigh instabilities (Coloumb 
fissions) which ultimately produce individual gas phase ions (Nguyen and Fenn, 
2007). ESI is the method of choice for LC-MS/MS analysis due to its compatibility 
with reverse phase liquid chromatography (RPLC) and its ability to produce multiply 
charged ions. Typical solvents include acetonitrile or methanol with 1% acetic acid or 
0.1% formic acid.  
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Figure 1.3 Diagram showing electro-spray ionisation. 
ESI is used to generate positive or negatively charged ions from RPLC. Liquid eluting from 
the LC is attached to a fused silica capillary emitter which has a pulled tip of diameter less 
than 10 μm. The liquid is forced through this constriction and for positive ions a high 
voltage is applied (~1.5kV) inducing the formation of a spray of positively charged droplets 
from a Taylor cone generated at the tip. Solvent-free ions are produced by the combined 
effect of Coulomb fission and ion evaporation. Multiply charged ions are then directed 
towards the MS by applying an electric field. 
 
1.10.5 Linear trap quadruple mass analyser (LTQ) 
The LTQ is a high-throughput instrument which features fast scan times and high 
sensitivity. Typically, ions enter the analyser and are focused into the ion trap by a 
series of multipoles made up of four parallel cylindrical metal rods (quadrupoles). A 
fixed direct current voltage (DC) and an oscillating radio frequency voltage (RF) are 
applied to each rod, creating a continuously varying electric field along the length of 
the poles. Ions are sequentially attracted or repelled by the poles and focus into a 
concise beam which accelerates the ions towards the trap. Within the ion trap, the 
oscillating amplitude (RF) is ramped from low to high voltage and a complementary 
alternating current (AC) is applied to the horizontal (x) rods (resonance ejection 
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voltage). The ions oscillate back and forth in the x direction and become increasingly 
unstable in order of m/z (low to high). Unstable ions are scanned from the trap through 
ejection slots in the x rods. The RF amplitude at which ions become unstable is m/z 
specific and thus the instrument interprets the signal as a particular mass. Ejected ions 
strike a conversion dynode in the detector and release secondary particles (for positive 
ion mode these include negative ions and electrons). The particles are transferred to a 
multiplier where they create an electron cascade as they move towards the anode 
which results in a measurable current that is proportional to the ion intensity. This 
generates a mass spectrum which is the signal intensity of the ions at each value of the 
m/z scale. 
1.10.6 Orbitrap mass analyser 
The orbitrap mass analyser has the ability to deliver low ppm mass accuracy and 
extremely high resolution all within a time scale compatible with nano-LC separation. 
The orbitrap is an ion trap instrument without the radio frequency (RF) or magnetic 
field to hold ions inside. Moving ions are instead trapped in an electro-static field 
(Hardman and Makarov, 2003, Scigelova and Makarov, 2006). The electrostatic 
attraction towards the central electrode is compensated by a centrifugal force that 
arises from the initial tangential velocity of ions. The electrostatic field which ions 
experience inside the orbitrap forces them to move in complex and spiral patterns. The 
axial components of these oscillations is independent of initial energy, angles and 
positions and can be detected as an image current on the two halves of an electrode 
encapsulating the orbitrap. The axial component of these ion oscillations is measured 
by a Fourier transform resulting in accurate reading of their m/z. As a result, the 
machine has a very high resolution and mass accuracy (Hu et al., 2005, Zubarev and 
Makarov, 2013, Scigelova and Makarov, 2006). 
1.10.7 Tandem Mass Spectrometry 
Mass spectrometry can obtain primary structure information in a process known as 
tandem mass spectrometry (MS/MS). MS/MS is carried out in the data-dependent 
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mode whereby the most intense precursor ions from a full MS scan are isolated for 
fragmentation into smaller product ions for mass analysis. In the LTQ Orbitrap XL™, 
the orbitrap is used for high precision MS1 scans, whilst the subsequent MS2 analysis 
occurs in the LTQ following CID fragmentation (Figures 1.4 and 1.5). Ions generated 
by ESI are transferred by axial ejection into an RF only quadrupole called the C-trap. 
The C-trap accumulates and stores the ions before injection into the orbitrap. The 
development of an additional collision cell provides additional flexibility to MS/MS 
experiments by allowing ions to be selected in the linear ion-trap and fragmented 
either in the ion trap by collision induced dissociation (CID) or by higher energy 
collision dissociation (HCD) in an additional gas-filled collision cell. The ions 
encounter frequent collisions with the dampening gas thus increasing their internal 
vibrational energy until they fragment. The product ions are ejected from the trap and 
detected. CID induces fragmentation at the amino bonds along the peptide backbone. 
A fragment must have at least one charge for it to be detected. If the charge is retained 
on the N terminal, the resulting ions are referred to as a, b or c ions. If the charge is 
retained on the carboxy terminal, the ion type is x, y or z. By using the m/z of the 
precursor ion as a guide, the masses of the product fragments are then matched against 
a database that is derived from the predicted peptide and fragment ion masses of all 
known protein sequences.  
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Figure 1.4 Schematic of tandem mass spectrometry (MS/MS). The sample is introduced 
into the mass spectrometer, ionised and then analysed by MS1. Ions from the MS1 spectra 
are then selectively fragmented and analysed by MS2 to give the spectra for the ion 
fragments. 
 
 
Figure 1.5 Schematic diagram of the LTQ Orbitrap mass spectrometer – Peptides are 
introduced mass spectrometer by ESI . Ions are separated by their mass to charge in the first 
stage (MS1). These pre-cursor ions are selected and fragmented at a second MS stage 
(MS2). These product ions are then separated and detected.  
 
CID 
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1.10.8  MS-based profiling 
Intact protein samples can be analysed directly by either 2DE, antibody-based 
methods or by MS using a so-called top-down approach. The commonly employed 
top down approaches in MS are MALDI-TOF and SELDI-TOF. The mass spectra 
obtained from these two methods does not provide the identity of the protein, but gives 
the relative abundance of the masses detected. The protein profiles are then analysed 
and selected masses of interest can be purified and identified. Top-down proteomics 
by MS/MS is not commonly used for profiling of complex protein mixtures, mainly 
because sufficient resolution and efficient fragmentation of large intact proteins 
cannot be achieved. However, the approach for characterising smaller, purified 
proteins has several advantages in that high sequence coverage of target proteins can 
be obtained, post-translational modifications can be better characterised and protein 
quantification is more reliable. 
The bottom-up approach (also known as shotgun proteomics) is the most commonly 
used approach for large-scale MS-based proteomic analysis of complex mixtures.. The 
basis of this approach is enzymatic cleavage of proteins to peptides using a protease 
such as trypsin. The generation of these smaller peptides helps in ionisation and 
fragmentation and provides sequence information for the final identification of the 
peptide. Chromatographic separation is applied to reduce the complexity of peptide 
mixtures prior to MS/MS. Particularly, RPLC separation is often linked directly to the 
mass spectrometer via an ESI source such that eluting/separated peptides can be 
analysed ‘on the fly’ by MS/MS. Peptide ion and fragment ion masses are then 
searched against sequence databases of all predicted open reading frames which have 
been digested in silico. The search returns peptide hits based on the probability of the 
mass matches which is dependent upon the mass accuracy of the instrument. Peptide 
hits are matched to protein sequences to confirm the identy of proteins present in the 
sample. 
Quantitative proteomics is important for understanding how global protein expression 
and modification ochestrates various biological processes and disease states. Bottom-
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up label-free quantification is based on the ion intensity of identified peptides with 
peptide matching between runs and samples based on the m/z and retention time This 
has drawbacks in terms of quantitative accuracy as matching is challenging and 
multiple repeat runs are necessary. Quantitation of proteins is achieved by averaging 
or taking the median intensities of the peptides matched to a particular protein, so 
information may be limited for lower abundance proteins where there are fewer 
matching peptides. Spectral counting is another method of label-free quantification 
whereby the number of spectral matches for peptides from a certain protein is used as 
a surrogate of that protein’s abundance (Liu et al., 2004). Quantitative proteomic 
analyses also use isotopic labelling of proteins or peptides across samples which can 
thereafter be differentiated and compared by MS. These labelling methods can be 
classified into metabolic labelling (e.g. SILAC) or enzymatic and chemical labelling 
(e.g. TMT, iTRAQ) and  allow multiplexing, whereby mixing of differentially labelled 
samples reduces variability during fractionation and reduces the number of samples 
that need to be analysed to provide an acceptable level of quantitative accuracy.  
Tandem mass tags (TMT) is the quantification method that will be used in this study. 
These tags are small chemical entities with identical structure and mass (isobaric) that 
are covalently attached to the amino groups of lysine residues and the N-termini of 
peptides (Thompson et al., 2003, Gygi et al., 1999, Coombs, 2011). Commercially 
available isobaric tags offer simultaneous analysis of up to 10 samples. In principle, 
each isobaric tag produces a unique reporter ion during MS/MS that are used for 
relative quantification of each labelled peptide. Thus in the first MS, labelled peptides 
are indistinguishable from each other. During the second MS, peptides are fragmented 
allowing each tag to produce a unique reporter ion based on isotopic labelling with a 
mixture of 12C/13C and 14N/15N. Protein quantitation is then accomplished by 
comparing the intensities of the reporter ions in the MS2. It is important to note that 
unlabelled peptides are not quantified (Thompson et al., 2003, Bantscheff et al., 2008). 
Isobaric tags have enabled protein identification and quantification from various cell 
types, tissues and body fluids and  are proving to be important tools in biomarker 
discovery research.  
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1.11 JUSTIFICATION OF RESEARCH 
Endometriosis is a gynaecological disorder that affects 6-10% of women of 
reproductive age. It is characterised by the presence of endometrial glands and stroma 
in ectopic locations such as the ovaries, fallopian tubes and rectovaginal septum 
(Fassbender et al., 2013). Common symptoms of endometriosis include severe 
dysmenorrhoea, non-menstrual pelvic pain, dyspareunia, dysuria, dyschezia and 
infertility (Meehan et al., 2010). Pain associated with this disease is a result of 
inflammation in the peritoneum, presence of adhesions and innervation of 
endometriotic lesions. (Bulun 2009 (Ballard et al., 2006). 
Endometriosis is not a life-threatening disease, but it impacts greatly on the quality of 
life of affected women (Chapron et al., 2003, Chapron et al., 2006). However, this 
impact has been poorly researched with available reports focusing on selected 
populations; mainly western nations; (Simoens et al., 2007) with small sample sizes, 
poorly selected control subjects and inadequate validation tools (Gao et al., 2006b). 
Despite this, it is recognised as a major cause of severe morbidity in women and 
impacts on their physical and emotional wellbeing. Psychologically, endometriosis 
and related symptoms may cause anxiety, depression and feelings of uncertainty, 
which in turn can interfere with a woman’s perceived sense of control, handling of 
adverse situations and resourcefulness.  
Physically, endometriosis pain can impair work-related and daily activities e.g. ability 
of the affected women to maintain a career (Gao et al., 2006a). It has been reported 
that 50% of women with endometriosis are bed-ridden several times each year, 
interfering with education, work and day to day living (Kjerulff et al., 1996). Loss of 
productivity has been estimated at 10.8 hours a week owing to reduced effectiveness 
while working (Nnoaham et al., 2011). Associated costs to society including those of 
delayed diagnosis, mistreatments and individual costs incurred when symptoms 
associated with this disease interfere with daily life are considerable, but poorly 
characterised (Gao et al., 2006a). The annual cost estimates in the US was reported as 
$22 billion in 2002. This was calculated from the estimated cost per patient; $1023-
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$2801 per year at a prevalence of 10% among women of reproductive age (Simoens 
et al., 2007). Indirect costs of the disease were not calculated in this study. Despite 
this significant health burden the disease is still poorly researched, diagnosed and 
treated. Infertility/subfertility which is a major consequence of the disease causes an 
extra burden to the patient due to the uncertainty of ever having a family. Sexual 
dysfunction due to dyspareunia can disrupt the relationship between a man and a 
woman (Gao et al., 2006b). This comes with an extra burden of social stigma 
especially in settings whereby infertility is considered shameful (Somigliana et al., 
2010). Efforts to assess the societal cost effects of endometriosis have been reported. 
The World Endometriosis Research Foundation (WERF) EndoCost study is the first 
prospective study from 12 centres in 10 countries to examine the direct and indirect 
costs of endometriosis (Simoens et al., 2011). The study measures direct health care 
costs like cost of medication and physician visits, direct non-health care costs and 
indirect costs associated with loss of productivity. The average costs of endometriosis 
were reported as €9579 per woman per year which equates to €3113 for direct health 
care costs. The inabilty to work due to symtoms is therefore twice the direct health 
costs. These cost estimates may be used to raise awareness of endometriosis with 
policy makers, health professionals and researchers inorder to emphasise the 
importance of early diagnosis and treatment.  
The gold standard of diagnosis is laparoscopy together with histological confirmation. 
Laparoscopy is an invasive procedure which is expensive and bears significant risks 
(Kennedy et al., 2005, Bulun, 2009). Efforts aimed at early diagnosis and treatment of 
endometriosis have been hindered by a lack of proper methods to study and manage 
the disease. The mean interval between first symptom appearance and diagnosis has 
been reported to be 7-10 years (Hadfield et al., 1996, Dmowski, 1984, Husby et al., 
2003, Ballard et al., 2006). Patients who present with severe pelvic pain that has not 
been relieved by pain medication or oral contraceptives and those seeking pregnancy 
for more than one year are the most common patients to whom laparoscopy is 
recommended in order to guide therapeutic interventions. The availability of a non-
invasive diagnostic test would therefore be important to establish endometriosis 
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instead of subjecting these women to uneccessary surgery whose outcomes might be 
negative for endometriosis. 
Development of a non-invasive test for diagnosis and follow-up has been identified as 
a top research priority (Rogers et al., 2009b, Rogers et al., 2013). The need for a non-
invasive test for asymptomatic women (i.e. screening) is still debatable because this 
will mean subjecting women to unnecessary and potentially harmful procedures. It is 
important to note that most subfertile women with or without pelvic pain, having 
regular cycles, a partner with a normal sperm count and quality, and normal pelvis on 
ultrasound imaging, may have endometriosis (Meuleman et al., 2009). A non-invasive 
test would therefore be important for such women. These women could be those with 
early stage disease and some cases of late stage disease not picked up by imaging 
methods and those with pelvic adhesions and/or other pelvic pathology who on 
diagnosis would benefit from laparoscopic treatment. 
Serum, plasma, urine, endometrial fluid, menstrual fluid, tissue biopsy and peritoneal 
fluid are samples that can be studied in the search for a non-invasive or minimally 
invasive biomarker (Vodolazkaia et al., 2012, Vodolazkaia et al., 2010, Casado-Vela 
et al., 2009, Kyama et al., 2007). The vital aim is therefore to develop a test in which 
no woman with endometriosis and/or any other pelvic pathology that would benefit 
from laparoscopic treatment are missed. A test with high sensitivity and specificity 
would be ideal for detecting or ruling out endometriosis in patients presenting with 
symptoms. At present no such test exists.  
The WERF Endometriosis Phenome and Biobanking Harmonisation Project 
(EPHECT) is a global initiative involving 34 clinical/academic and 3 industrial 
collaborators from 16 countries with a mission to develop a consensus on 
standardisation and harmonisation of phenotypic surgical, clinical data and biological 
sample collection methods in endometriosis research mainly to address large scale, 
cross centre, epidemiologically robust, translational biomarker and treatment target 
discovery research in endometriosis (Becker et al., 2014, Fassbender et al., 2014, 
Rahmioglu et al., 2014). This initiative outlines detailed international guildelines for 
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standardised clinical and personal phenotyping (phenome) data to be collected from 
women with endometriosis and controls to improve patient disease characterisation 
and standard operating procedures (SOPs) for biobanking of biological samples from 
women with endometriosis and controls with respect to collection, transport, 
processing and long term storage of samples collected from these women (Becker et 
al., 2014). 
High-throughput proteomic methods have been developed over the years and are now 
being used to study various diseases of the female reproductive system (Meehan et al., 
2010). These approaches have the potential to identify new disease biomarkers by 
comparing the abundance of hundreds or thousands of proteins simultaneously across 
cohorts of patients and controls. This has been the focus of many proteomic studies. 
Endometriosis is a complex disease, therefore it is may not be possible that a single 
marker will have sufficient diagnostic accuracy. A marker panel however could 
provide better diagnostic and/or prognostic power.  
Biological sampling is an important step for many biomarker studies. Different types 
of samples can be used depending on the type of study and subsequent downstream 
application. Sample quality is a critical factor in proteomic analyses to ensure 
reproducibility of data. Standardised techniques for sample collection, processing and 
storage are therefore important in any biomarker study design. Research into the 
human endometrium may be complex and challenging. This tissue is composed of 
many cell types (epithelial cells, stromal cells, fibroblasts, pre-decidual cells, 
leucocytes and cells of the vasculature. The endometrium is also regulated by cyclic 
hormones and other paracrine and autocrine factors which when combined with the 
individuals’ genetic and environmental background may result in alterations to 
biological processes. Endometrial tissue is inherently heterogeneous with respect to 
developmental, temporal and biological composition, therefore cell types within a 
single tissue can be highly variable e.g. ectopic endometriotic lesions contain 
relatively few endometrial cells that are often dispersed along with leucocytes among 
the cells of their recipient surface. Biological variability may therefore arise through 
differences in tissue composition of the collected samples and heterogeneity of 
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cellular compositions due to phase of menstrual cycle. This inherent variability needs 
to be considered when designing studies and analysing data. Standard operating 
procedures for sample collection should therefore be implemented and must be highly 
standardised and robust to ensure proper tissue acquisition, processing, utilisation, 
storage and distribution.  Laparoscopy together with histological dating is used to 
definitively diagnose endometriosis. Eutopic endometrial tissue, ectopic 
endometriosis tissue collected surgically and blood samples were collected for the 
purposes of this study. Tissue samples were used for the discovery of candidate 
biomarkers and selected markers were then tested in serum as potential non-invasive 
diagnostic markers of endometriosis.  
The endometrium can be obtained in five different ways; by use of an endometrial 
sampling device (Pipelle®), endometrial curettage, hysteroscopy resection, post-
hysterectomy excision and brushing. An endometrial sampling device is a thin plastic 
tube that is inserted into the uterus and used to aspirate the tissue. Curettage involves 
scraping ‘strips’ of the endometrium from the uterine lining with the use of a curette. 
In post-hysterectomy collection, the endometrium can be scraped off using a curette 
or scissors or aspirated using a Pipelle®. Endometrial brushing involves insertion of a 
disposable brush into the uterus that is used to collect the sample.  The collection 
method varies with the type of study, tissue of interest and available expertise. In this 
study, eutopic endometrium tissue samples were collected from women with and 
without disease by curettage during laparoscopy or after hysterectomy. Ectopic tissue 
was excised during surgery. 
Defining the phenotype of the study population is important to ensure that 
representative disease and sample types are being used. Heterogeneity resulting from 
improper classification of study participants may decrease both the sensitivity and 
power of the study. The impact of other pathological conditions affecting the 
endometrium must also be considered when defining phenotype. The presence of 
structural alterations (e.g. fibroids), cancer and immune changes may will affect the 
phenotype of the endometrium. Exposure to different medications e.g. those used to 
shrink the lesions before surgery, contraceptives that are also used to manage pain and 
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environmental toxins may also impact on tissue phenotype resulting in biological 
variability. The level of phenotypic heterogeneity between studies poses a challenge 
when it comes to reproducibility and replication of study findings.  
Many protein extraction protocols have been developed but selecting a suitable 
protocol mainly depends on the nature of the starting material and on the downstream 
applications. Protein analysis involves a number of processing steps; homogenisation 
for protein extraction, denaturation, reduction of disulphide bonds, alkylation of 
cysteine residues, enzymatic digestion, protein fractionation/separation, analysis by 
MS and data analysis to identify and quantify peptides. Due to the diverse biochemical 
properties of cellular proteins e.g. their charge, size, hydrophobicity, susceptibility to 
proteolysis, ligand interactions and sub-cellular localisation, no single protein 
extraction method can capture the full proteome. Comprehensive, uncontaminated and 
representative protein populations can be difficult to extract from tissue samples partly 
because of the presence of structural proteins and due to contamination with blood 
proteins arising during tissue sampling.  
1.12 Study Aims 
The main aim of this study was to identify novel biomarkers for the non-invasive 
diagnosis of endometriosis. The hypothesis was that ectopic endometrial tissue and 
eutopic endometrium from women with endometriosis secrete specific proteins into 
the blood stream that can be used for the detection of the disease. 
 
The specific objectives were to: 
1) Apply proteomic profiling technologies to a set of well-characterised tissue 
samples for the discovery of candidate biomarkers of endometriosis 
2) Investigate the differential expression of proteins in eutopic and ectopic 
endometrium of women with endometriosis compared to relevant controls 
3) Verify differentially expressed proteins in individual tissue samples 
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4) Test these and other proteins reported in the literature as putative biomarkers 
in serum collected from the same women 
5) Develop a model of best performing markers and validate the most promising 
candidates as biomarkers for the diagnosis of endometriosis in an independent 
cohort of women presenting with endometriosis and/or pelvic pain 
1.13 Study Design 
Patient tissue and serum samples used in this study were sourced from the UCLH 
Reproductive Medicine Unit following ethical approval (13/LO/0163) and informed 
consent . These samples were stratified into six clinical groups based on condition and 
menstrual cycle phase: 
a) Eutopic tissue control secretory phase (CS) – scheduled for risk-reducing 
surgery, asymptomatic, no disease at laparoscopy  
b) Eutopic tissue control proliferative phase (CP) - scheduled for risk-reducing 
surgery, asymptomatic, no disease at laparoscopy 
c) Eutopic tissue pain secretory phase (PS) - PID or chronic pelvic pain, no 
endometriosis at laparoscopy 
d) Eutopic tissue endometriosis secretory phase (ES) - diagnosed with 
endometriosis at laparoscopy 
e) Eutopic tissue endometriosis proliferative phase (EP) - diagnosed with 
endometriosis at laparoscopy 
f) Ectopic tissue endometriosis secretory phase (EcS) - diagnosed with 
endometriosis at laparoscopy. 
(Eutopic tissue pain proliferative phase (PP) was not represented due to the lack of 
women recruited who fitted this group (see Chapter 3). Ectopic tissue proliferative 
phase (EcP) was also not represented due to lack of samples; some of these lesions 
were ablated during surgery). 
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The study design is depicted in Figure 6. Tissues were collected during laparoscopy 
and flash frozen in liquid nitrogen and stored at -80°C. Samples were then processed 
as per an optimised protocol. Briefly, frozen tissue was ground whilst still frozen, 
lysed in denaturing buffer and then pooled into different clinical groups, as above, 
based on equal protein amount. Pooled tissue samples would be subjected to two 
previously optimised proteomic profiling strategies (peptide TMT coupled to 3D-LC-
MS/MS and 2D-DIGE coupled to LC-MS/MS) in an initial discovery phase to identify 
potential candidate biomarkers that differ in expression between normal and diseased 
endometrial tissue. Both strategies would employ immunodepletion of serum proteins 
in an attempt to remove contaminating proteins and improve coverage. A third 
strategy using TMT protein labelling and separation would also be tested as a 
complementary profiling method. Selected candidates from the discovery work, as 
well as promising biomarker candidates from the literature, would then be tested in a 
verification phase using serum samples collected from the same women. Individual 
candidates and combination models would be tested for their ability to discriminate 
between endometriosis and control groups and to assess the effect of the menstrual 
cycle phase. The work would also generate data regarding differences in protein 
expression in eutopic tissue from women with and without endometriosis and in 
eutopic versus ectopic tissue, that may provide insights into the molecular biology of 
the disease. 
Patient data was also collected for all subjects following informed consent. 
Specifically; age, ethnicity, disease history, treatment history (OCP, GnRH 
analogues), co-morbidities, type and severity of pain and histopathology (disease 
stage, stage of menstrual cycle, anatomic characteristics of disease lesions) data were 
collected. For all subjects serum C-reactive protein, progesterone, oestrogen and 
CA125 levels were measured at the Clinical Biochemistry laboratories of the UCLH 
NHS Foundation Trust using gold standard assays. This information would be 
correlated with candidate biomarker data to assess possible confounders and/or to 
improve diagnostic biomarker algorithms, and in the case of progesterone and 
oestrogen, to corroborate cycle stage.  
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Figure 1.6. Flow chart showing the study design and workflow. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Introduction 
This chapter explains in detail the methods used in this study including the patient 
recruitment process, sample selection criteria, sample processing, proteomics methods 
used to define potential markers, data analysis and verification of these markers in 
serum. Clinical specimens came from patients recruited to the UCLH Reproductive 
Medicine Unit (RMU) following ethical approval and informed consent. These were 
women with endometriosis and those without endometriosis. Endometrial tissue and 
blood samples were collected from these women at the time of laparoscopic surgery. 
Two main complementary quantitative proteomic based strategies were employed in 
this discovery work to define the protein expression profiles of tissue samples 
obtained from these women.  These were 2D-DIGE linked to LC-MS/MS and protein 
and peptide based TMT-labelling linked to multi-dimensional separation and LC-
MS/MS. A scoring system was employed to rank and select candidates that warranted 
further testing and verification. Verification of selected markers was evaluated using 
ELISA assays in serum samples taken from the same case and control women. 
Potential markers identified from the literature were also tested alongside markers 
identified from the discovery work and correlated with clinico-pathological features 
obtained during patient recruitment.  
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2.1.2 Patient recruitment 
Patients and samples were sourced from the UCLH Reproductive Medicine Unit 
(RMU) following ethical approval and informed consent. These patients were those 
referred to the RMU of UCLH by their general practitioners or other clinicians for 
investigation of pelvic pain or for diagnosis and/or treatment of endometriosis. These 
patients were routinely offered laparoscopic surgery for investigation and treatment 
or bilateral salpingoophorectomy for those with a strong family history of breast and 
ovarian cancer. The patient inclusion criteria for the study were as follows: cases were 
defined as women diagnosed with endometriosis at laparoscopy and confirmed 
histologically. Controls with pain were defined as symptomatic women with pelvic 
pain of unknown cause or chronic pelvic inflammatory disease (PID) without surgical 
evidence of endometriosis. Controls without pain were regularly cycling women with 
no known disease at the time of surgery undergoing bilateral tubal ligation and/or 
prophylactic bilateral salpingoophorectomy due to a familial risk of breast and ovarian 
cancer and with no visual evidence of endometriosis upon laparoscopy. Only pre-
menopausal women were recruited for this study. The following women were 
excluded from the study; women with a positive pregnancy test or unknown 
pregnancy status on the day of surgery, post-menopausal women, those with other 
benign conditions or malignant tumours (particularly fibroids and cancer were 
excluded as they may compromise the integrity of the endometrium), women on any 
hormonal medication <3 months prior to surgery and those whose surgical findings 
and pathological reports were inconsistent. Cycle phase was determined by a triple 
approach to ensure accuracy; chronologically, by histological dating and by sex 
steroid hormone determination. Women with unconfirmed menstrual cycle stage were 
also excluded.  
Additional patient data was collected including age, fertility history, treatment history 
(oral contraceptive use, GnRH analogues) phase of menstrual cycle, pain history, 
histopathology findings and anatomic characteristic of disease lesions. All patient 
records were handled according to NHS confidentiality practices. Samples were 
anonymised and sequentially numbered. A lab coding system and an excel database 
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were developed for recording anonymised patient and sample information (see 
appendix). 
2.1.3 Sample collection 
Sample collection and processing is a critical step in any study. The adoption of SOPs 
for tissue collection, processing and storage and standardised phenotypic and other 
patient data collection are crucial to optimise sample and study quality. The collection 
method employed should be one that is least likely to cause alterations to the molecular 
composition of the tissue of interest and also one that is versatile for downstream 
analysis. To limit variability in tissue composition, sampling should ideally provide a 
homogeneous histological specimen which should be of sufficient volume for the 
pathologist to identify the pathology in question and to provide material for the study. 
Limited sample amounts, heterogeneous cellular composition, presence of abundant 
structural proteins, blood contamination will all impact on the outcome of subsequent 
analysis. 
Standard operating procedures were developed for tissue and blood acquisition, 
processing, utilisation and storage. Human endometrial tissue biopsies were obtained 
by Pipelle or curettage from women of reproductive age undergoing laparoscopy as 
follows: eutopic endometrium from women undergoing prophylactic bilateral 
salpingoophorectomy without any evidence of endometriosis, eutopic endometrium 
from women with chronic pelvic pain of unknown cause or chronic pelvic 
inflammatory disease without laparoscopic evidence of endometriosis, eutopic 
endometrium from women undergoing laparoscopy for diagnosis and/or treatment of 
endometriosis and ectopic endometrial tissue from the latter group i.e. superficial 
lesions, endometriomas and deep infiltrating nodules were excised from the same 
women diagnosed and/or treated for endometriosis. 
Part of each tissue obtained was fixed in 10% buffered formalin for histological 
examination while the remaining tissue was washed in sterile phosphate buffered 
saline (PBS) to remove excess blood. The tissue was then dried using lint free paper, 
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transferred into labelled and weighed Eppendorf tubes and snap-frozen in liquid 
nitrogen. The samples were transported to the lab and stored at -80°C. 
Cycle stage for each patient was determined by endometrial dating by a trained 
pathologist without prior knowledge of sample group according to (Noyes et al. 1975). 
Endometriotic lesions were also confirmed histologically. Samples from patients with 
surgically diagnosed endometriosis, but inconclusive histological diagnosis were 
excluded. Samples were also excluded where there was insufficient tissue biopsy (<20 
mg wet weight). 
10 mL of blood was also collected from each patient before laparoscopic surgery by 
venepuncture into two BD vacutainer gel tubes. 5 mL of blood was sent to the clinical 
biochemistry lab of the UCLH NHS Foundation Trust for determination of oestradiol, 
progesterone, CA125 and CRP levels using standard assays, while the other half was 
allowed to stand at room temperature for one hour to allow clotting. This was then 
transported to the laboratory on wet ice and centrifuged at 3000 x g for 10 min at 4°C 
within 2 hrs of collection. Serum was aliquoted into labelled Eppendorf tubes and 
stored at -80°C. 
2.1.4 Sample preparation optimisation 
To enable accurate quantitation of global protein expression in biological samples, 
optimal sample preparation for MS-based analysis is a critical step in a proteomics 
workflow. A method was optimised for endometrial tissue lysate sample preparation. 
Test eutopic and ectopic endometrial tissue obtained by curettage from two women 
undergoing laparoscopy was used to optimise sample preparation methods, protein 
extraction and two-dimensional difference in-gel electrophoresis (2D-DIGE). 
Following excision during laparoscopy, tissues samples were first cleaned with sterile 
PBS to remove excess blood prior to freezing in liquid nitrogen and storage at -80°C. 
The representative samples used to optimise sample homogenisation and protein 
extraction for this study are shown in Table 2.1. 
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Table 2.1 Tissue samples used for sample preparation optimisation. 
Ect = ectopic endometrial tissue, EmE= Eutopic tissue 
 
Frozen tissues weights were determined by subtracting the weight of the Eppendorf 
tube plus tissue from the weight of the Eppendorf tube taken before collection. A 
method was then optimised for the most efficient tissue homogenisation and protein 
extraction procedure from these endometrial and endometriosis tissues. The best 
homogenisation was achieved by grinding the tissues under liquid nitrogen prior to 
re-suspension in urea/CHAPS denaturing buffer. This method was useful especially 
in the breakdown of ectopic endometrial tissues which can be very fibrous in nature. 
Other methods such as continuous vortexing or repeated passage through syringe 
needles failed to break down the tissue, or was virtually impossible to achieve. 
The ground tissue was then transferred into sterile tubes; care was taken not to leave 
any tissue material in the mortar. Protein extraction was then carried out using 2D 
lysis buffer containing 8 M urea, 4% CHAPS (w/v) and 10 mM Tris-HCL pH 8.3. 
Urea is a neutral chaotropic agent that is used to effectively disrupt the secondary 
structure of proteins by disrupting hydrogen bonds and hydrophilic interactions, 
enabling proteins to unfold with all ionisable groups exposed to the solution. CHAPS 
is a zwitterionic detergent that is used to disrupt hydrophobic interactions thereby 
Patient ID 
Phase of 
cycle Tissue Type Tissue Code Description 
001 Secretory Ect1 001S3 
Left pelvic side wall 
endometriosis 
001 Secretory Ect1 001S2 
Pouch of Douglas 
endometriosis 
001 Secretory Ect1 001S1 
Utero-sacral 
endometriosis 
001 Secretory Ect2 001E1 Left ovarian cyst 
001 Secretory EmE 001Eu Endometrium 
002 Unknown EmE 002Eu Endometrium 
002 Unknown Ect1 002S1 Superficial lesion 
002 Unknown Ect2 002E1 Ovarian cyst 
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facilitating cell lysis, protein extraction and solubilisation. A ratio of 10 μL of lysis 
buffer per mg of tissue was first used to extract the proteins at room temperature.  
To ensure maximum protein extraction, sonication was also performed for 20 min. 
The Eppendorf tubes with the samples were kept on ice during the procedure to avoid 
heating of the sample which causes urea breakdown and modification of proteins 
(carbamylation) evoking artefactual charge heterogeneity. Sonication was also 
efficient for separation of lipids that was observed as a fatty layer on top of the protein 
extract. Samples were then centrifuged to pellet insoluble material. The supernatant 
was separated and a Bradford protein assay performed to determine protein 
concentration as shown in Table 2.2 below. 
 
Table 2.2 Amount of protein obtained after extraction 
 
 
 
 
 
 
 
The starting extraction volume of 10μL/mg of tissue was reviewed and was reduced 
to 5μL/mg for subsequent experiments to ensure a sufficiently high protein 
concentration for optimum downstream labelling and 2D-DIGE. 
Tissue code 
Protein concentration 
(μg/μL) 
Total yield of protein 
(μg) 
001S1 0.463 125 
001S2 1.127 2073 
001E1 1.888 3228 
001S3 0.974 1499 
001Eu 1.965 2731 
002Eu 1.038 800 
002E1 0.948 6325 
002S1 1.353 2110 
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2.1.5 Protein extraction of endometrial tissue lysates 
Protein extraction was carried out as per the optimised protocol above. Each snap-
frozen tissue sample was weighed and homogenised by grinding in liquid nitrogen 
into a fine powder. Ground tissue was then lysed using 2D lysis buffer (8M urea, 4% 
w/v CHAPS and 10mM Tris-HCL pH 8.3) at a ratio of 5 μL of lysis buffer to 1 mg of 
tissue at room temperature in order to extract the proteins. Sonication was carried out 
to ensure maximum tissue breakdown and protein extraction. Samples were then 
centrifuged at 3,000 g for 10 min at 4°C to pellet any insoluble material. The 
supernatant was separated for further protein analysis and the pellet discarded. Protein 
concentration was determined using a Bradford microtitre plate assay (Thermo 
Scientific Ltd). Standard curves were constructed using dilutions of bovine serum 
albumin (BSA). All samples were then normalised to the same (lowest) protein 
concentration using lysis buffer. 
2.1.6 Quality assessment of endometrial tissue lysates 
To assess the quality of tissue samples 10 μg protein from each sample was mixed 
with 5x sample buffer (300 mM Tris-HCL, pH 6.8, 10% SDS, 30% glycerol, 0.025% 
bromophenol blue and 1.3 v/v β-mercaptoethanol) and loaded onto a NuPAGE® 
Novex® 4-12% Bis-Tris 1.5 mm, 15-well pre-cast gel (Invitrogen). The gels were run 
at 70 mA for 1 hour and stained with Instant Blue gel stain (Expedion). The stained 
gels were imaged on a GS-800™ densitometer (BioRad) 
2.1.7 Sample pooling  
A sample pooling strategy was used for 2D-DIGE analysis. Protein extracted from 
each sample was pooled in equal amounts into six sample groups created as indicated 
in Table 2.3 below. There were insufficient samples in the pain-proliferative stage 
(PP) to warrant inclusion in the analysis. 
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Table 2.3 Sample groups used for 2D-DIGE analysis 
 
 
2.2 Endometrial tissue profiling by 2D-DIGE 
2.2.1 Introduction 
Two-dimensional difference gel electrophoresis (2D-DIGE) was developed to 
overcome the inherent problem of poor reproducibility of 2DE. 2D-DIGE relies on 
direct labelling of lysine groups on proteins with fluorescent CyDyes before 2D 
separation. An important aspect of the use of 2D-DIGE technology is the ability to 
label 3 samples with 3 distinct CyDyes and electrophorese the samples on the same 
2D gel. This reduces spot pattern variability and the number of gels that need to be 
run and facilitates accurate spot matching.  The CyDye DIGE fluor minimal dye has 
an N-succinimidyl ester reactive group. It is designed to form a covalent bond with 
the Ɛ-amino group of lysines and N-terminal residues in proteins via an amide linkage. 
The single positive charge of the CyDye replaces the single positive charge of the 
lysine at neutral and acidic pH minimising changes to the pI of the protein. The 
labelling reaction is dye limiting with the ratio of CyDye to protein ensuring that the 
dyes label approximately 1-2% of lysine residues. Therefore, each labelled protein 
molecule carries around one dye label and will thus have a minimal effect on the 
molecular weight meaning that the labelled protein will co-migrate with the unlabelled 
protein and run as a single spot. This minimal labelling is also performed to prevent 
Clinical group Cycle phase Tissue type Pool 
No. of 
samples 
per pool 
Healthy controls Secretory Eutopic endometrium CS 4 
Healthy controls Proliferative Eutopic endometrium CP 7 
Pain Secretory Eutopic endometrium PS 7 
Endometriosis Secretory Ectopic endometrium EcS 12 
Endometriosis Secretory Eutopic endometrium ES 19 
Endometriosis Proliferative Eutopic endometrium EP 9 
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protein precipitation due to increased hydrophobicity with the addition of dye 
moieties. The ratio has been optimised to detect less abundant proteins whilst at the 
same time keeping the highly abundant proteins in the linear dynamic range for 
quantitative image analysis. The labelling reaction is quenched by addition of lysine. 
The use of a Cy2-labelled internal standard pool containing equal amounts of all 
samples and run on every gel against the Cy3- and Cy5-labelled test samples facilitates 
spot matching across gels and improves quantitative accuracy. The individual protein 
data from the controls and the diseased group samples are normalised against the Cy2 
dye labelled standard. 
Herein, 2D-DIGE was used as a profiling approach for discovery of markers of 
endometriosis from the tissue samples. A preliminary experiment on test samples 
showed the feasibility of the method for this sample type. In the main experiment, 2D-
DIGE technology was coupled to LC-MS/MS to identify and quantify differentially 
expressed proteins in endometriosis and control tissue lysates that could be later tested 
in serum as potential biomarkers of the disease. 
2.2.2 Preliminary 2D-DIGE analysis of endometrial tissue lysates 
A preliminary analysis was carried out to test the feasibility of the method in profiling 
endometrial tissue lysates. A method was therefore optimised for lysate pooling, 
CyDye labelling and 2D electrophoresis using the previously described test samples 
(Table 2.1). Samples (100 µg total protein) were labelled using Cy3 or Cy5.  An 
internal standard comprising equal amounts of all samples was labelled using Cy2. 
These samples were mixed together appropriately and separated on four 2D gels 
according to protein isoelectric point in the first dimension and by relative molecular 
weight in the second dimension (Table 2.4).  
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Table 2.4 Experimental design for preliminary 2D-DIGE analysis. 
 
. 
 
 
 
Resolved and labelled proteins were then detected at appropriate excitation and 
emission wavelengths using a Typhoon 9400™ Imager and the signals compared. 
Automated spot detection and normalisation was performed and abundance ratios 
(Cy3/Cy2 and Cy5/Cy2) compared for each gel using the Differential In-gel Analysis 
(DIA) module of the DeCyder software. Since each sample spot map is co-detected 
with a standard spot map, all of the spots were compared internally to the same pooled 
standard.  
2.2.3 Optimisation of high-abundant protein depletion in tissue lysates 
Protein concentrations in biological samples may vary over 10 orders of magnitude. 
Low abundant protein detection is hampered by the presence of those proteins present 
at very high concentrations. This was a particular issue with the tissue lysates used 
herein which were significantly contaminated with blood. Highly abundant proteins 
often prevent optimal focusing, limit the loading capacity of lower abundance proteins 
and tend to mask considerable areas on 2D gels. Moreover, in data-dependent LC-
MS/MS experiments, peptides from high abundant proteins will be preferentially 
sampled at the cost of reduced proteomics coverage.  Immuno-depletion is one method 
to reduce the most abundant proteins in a sample to alleviate these problems. 
Depletion of high abundant serum proteins in tissue lysates was carried out using 
Protein Purify 12 (PP12) Human Serum Protein Immunodepletion resin (R&D) which 
depletes the 12 most abundant serum proteins. 500 μL of PP12 immunodepletion resin 
was incubated with diluted endometrial tissue lysate at two different protein amounts 
(200 μg and 500 μg). Samples were incubated and allowed to mix on a rotary shaker 
Gel Cy3 Cy5 Cy2 
1 001Eu 002Eu Pool 
2 001E1 002E1 Pool 
3 001S3 002S1 Pool 
4 001S2 001S1 Pool 
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for 30 min. Equal amounts of the mixture were then pipetted onto the upper chamber 
of three Spin-X Filter Units, centrifuged for 2 min, washed with PBS and centrifuged 
again. The filtrates were then concentrated to 25 μL using 5 kDa Molecular Weight 
Cut-Off (MWCO) Vivaspin Columns. Protein concentrations were then determined 
using the Bradford method. Depleted samples were run on a 1D gel against undepleted 
samples and neat serum to examine the level of depletion. 
2.2.4 2D-DIGE profiling of endometrial tissue lysates 
Protein extraction and sample immunodepletion of pooled samples (for 2D-DIGE) 
was carried out according to an optimised protocol. 1.5 mg protein from each pool 
was depleted using 1.5 mL of PP12 immunodepletion resin (R&D). Samples were first 
diluted 8-fold using PBS in 10 mL polypropylene columns (Thermo Scientific) and 
then incubated with the resin on a rotary shaker for 1 hr at room temperature. The 
flow-through was transferred to 20 mL 5 kDa MWCO filtration units and concentrated 
to 100 μL. To remove salt from the samples, a buffer exchange was carried out by 
diluting the samples to 1 mL with 10 mM Tris pH 8.5 and the samples then re-
concentrated to 25 μL. Samples were diluted again to 500 μL and finally concentrated 
to 100 μL. Samples were then dried down in a Speed Vac and re-suspended in 2D 
lysis buffer (8M Urea, 4% CHAPS, 1.5 mM Tris pH 8.5). The protein concentration 
of each pool was determined using the Bradford method. All pools were adjusted to 
the same protein concentration. 
2.2.5 Protein labelling with CyDyes for 2D-DIGE 
80 μg protein from each pool was labelled in triplicate with NHS-cyanine dyes (Cy3, 
Cy5 and Cy2) (GE Healthcare) at a dye to protein ratio of 6 pmol of dye per microgram 
of protein on ice for 30 min in the dark. Cy2 was used to label an internal standard 
pool which was prepared by mixing equal amounts of proteins from each pool (Table 
2.5). Reactions were quenched by adding a 20-fold molar excess of L-lysine to dye 
and incubating on ice for 10 min in the dark. Equal amounts of proteins from pairs of 
differentially labelled (Cy3 and Cy5) samples and Cy2 labelled standard were mixed 
96 
 
appropriately and reduced by addition of dithiothreitol (DTT) (65 mM final 
concentration). Carrier ampholines and pharmalyte mixture was added to a final 
concentration of 2% v/v and 1 μL of 2% bromophenol blue. The final volume was 
made up to 450 μL with 2D lysis buffer containing 65 mM DTT. Immobiline IPG 
strips (24 cm; pH 3-10 NL) (GE Healthcare) were rehydrated with the labelled 
samples overnight on a re-swelling tray overlaid with mineral oil. 
Table 2.5 2D-DIGE tissue profiling: experimental design. 
Nine gels were run to compare the six different groups of pooled samples in triplicate with 
each gel containing the Cy2-labelled standard pool. E=endometriosis group; P=pain group; 
C=control group; Eu=eutopic tissue; Ec=ectopic tissue. S=secretory phase; P=proliferative 
phase. 
 
2.2.6 2D gel electrophoresis and gel imaging 
IEF was performed using a Multiphor II apparatus (GE Healthcare) for a total of 80 
kVh at 16°C. Strips were equilibrated for 15 min in equilibration buffer (6M urea, 
30% (v/v) glycerol, 50 mM Tris-HCl pH 6.8, 2% (w/v) SDS) containing 65 mM DTT 
and alkylated thereafter for another 15 min in the same buffer containing 240 mM 
iodoacetamide. For second dimension separation, equilibrated strips were transferred 
onto 10% SDS-PAGE gels cast between 20 x 24 cm x 1 mm low fluorescence glass 
plates. Gels were bonded to the inner plate at casting using bind saline (GE 
Gel No. Cy3 Cy5 Cy2 
1 EEuS PEuS Pool 
2 EEcS EEuS Pool 
3 EEuS CEuS Pool 
4 EEuP CEuP Pool 
5 CEuS EEcS Pool 
6 PEuS CEuS Pool 
7 EEuP PEuS Pool 
8 EEcS CEuP Pool 
9 CEuP EEuP Pool 
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Healthcare) according to the manufacturer’s instructions. Strips were overlaid with 
0.5 % (w/v) low melting point agarose in running buffer containing bromophenol blue. 
Gels were run in an Ettan Dalt 12 tank (GE Healthcare) for 16 hrs at 2.2 W per gel or 
until the dye front had run off the bottom of the gel. Images were acquired by scanning 
the gels on a Typhoon™ 9400 multi-wavelength fluorescence imager (GE 
Healthcare). The photomultiplier tube voltage was adjusted on each channel (Cy2, 
Cy3 and Cy5) for preliminary low resolution scans (1000 μm) to give maximum pixel 
values within 10% for each channel and below the saturation level. A final high 
resolution scan (100 μm) was then performed. Sequential scanning of Cy2, Cy3 and 
Cy5 labelled proteins was achieved using the following laser excitation/emission 
filters: 488/520 nm, 532/580 nm and 633/670 nm, respectively. The images were 
cropped in ImageQuant software (GE Healthcare) and exported into DeCyder 
software (GE Healthcare) for image analysis.  
2.2.7 Image analysis 
Images were curated and analysed using DeCyder Software V6 (GE Healthcare). This 
software performs the following functions: Differential In-gel Analysis (DIA) and 
Biological Variance Analysis (BVA). DIA assesses the differential expression of spots 
in the same gel by defining spot boundaries and calculating spot volume/abundance 
for the three channels (Cy2, Cy3 and Cy5) and performs in-gel normalization. BVA 
is used to match spots from multiple samples across gels, using the standard for 
calculating standardised abundances for all matched spots across the sample and 
performing statistical analysis. Differences in spot abundances between the different 
conditions under study were compared by applying a student t-test. Spots displaying 
changes in abundance were then filtered by specifying a 1.5 threshold of average fold-
change with P values of <0.05. Pick lists for spots of interest were created and 
exported to an Ettan spot picking robot (GE Healthcare). 
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2.2.7 Colloidal Coomassie Blue staining 
Prior to staining, gels were fixed in 35% (v/v) ethanol, 2% (v/v) phosphoric acid in 
distilled water. Gels were then washed for 30 min with distilled water and stained with 
Colloidal Coomassie Instant Blue (Expedion) overnight on a shaking platform. 
Stained gels were then imaged on the Typhoon 9400™ scanner using the red laser and 
no emission filters. 
2.2.8 SYPRO-Ruby fluorescence staining 
Gels were fixed overnight in 30% (v/v) methanol, 7.5% (v/v) acetic acid in distilled 
water. Gels were then washed for 30 min in distilled water and incubated overnight in 
Sypro Ruby stain (Molecular Probes) in the dark on a shaking platform. Post stained 
gels were washed in distilled water to remove excess stain and thereafter scanned on 
the Typhoon™ Scanner using the appropriate laser and emission filter. 
2.2.9 Spot-picking and trypsin digestion 
Automated spot picking was achieved by matching post-stained images with CyDye 
images using DeCyder software. A pick-list of co-ordinates was then created for spots 
of interest relative to a pair of reference markers fixed to the glass plates at casting. 
Spots of interest were then excised using an Ettan automated spot picker (GE 
Healthcare) with a 2 mm picking head from gels submerged in 1-2 mm of distilled 
water. Spots were collected in a 96 well-plate, the water drained and gel plugs stored 
at -20°C prior to trypsin digestion and MS analysis.  
Gel plugs were transferred to MS Lo-Bind Eppendorf tubes and in-gel digestion was 
carried out by first washing the gel pieces three times in 200 µL of 50% acetonitrile 
(ACN) and then in 200 µL of 100% ACN to de-stain them. The pieces were dried in 
a SpeedVac for 20 min, reduced for 45 min with 200 µL of 10 mM DTT in 5 mM 
ammonium bicarbonate (AmBiC) pH 8.0 at 50°C. Gel pieces were then washed twice 
in 200 µL of 50% ACN and once in 200 µL of 100% ACN and dried in a SpeedVac. 
Gels were then digested overnight at 37°C with 50 ng modified trypsin (Promega) in 
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5 mM AmBiC. The supernatant was collected and peptides extracted twice with 200 
µL of 5% trifluoroacetic acid (TFA) in 50% ACN and the supernatants pooled. Peptide 
extracts were vacuum dried and stored at -20°C prior to MS analysis. 
2.2.10 Sample clean-up  
Peptides were desalted using reversed phase C18 ZipTips™ (Merck Millipore) 
according to the manufacturer’s instructions. Briefly, the peptides were re-suspended 
in 0.1% (v/v) formic acid (FA). The C18 tip was conditioned twice with elution buffer 
containing 50% methanol and 0.1% (v/v) TFA and equilibrated twice with washing 
solution containing 5% (v/v) methanol and 0.1% (v/v) TFA. Peptides were then bound 
onto the C18 material by carefully aspirating and dispensing the sample at least 10 
times. The tip was then washed 5 times with wash solution and peptides eluted by 
aspirated and dispensing (10 times) with elution buffer (50% methanol and 0.1% TFA) 
into fresh MS Lo-Bind Eppendorf tubes. Samples were dried down in a SpeedVac 
prior to MS analysis. 
2.2.11 Reversed-phase liquid chromatography (RPLC) 
Peptides were re-suspended in 6 μL of 0.1% (v/v) FA and resolved by nano-flow 
capillary RPLC using an Ultimate 3000 System (Dionex Corp. Thermo Scientific 
Ltd). Samples were first injected onto an Acclaim PepMap 100 C18 pre-column (5 
μm, 100A, 300 μm i.d x 5 mm) (Dionex Corp. Thermo Fisher Scientific Ltd) and 
washed for 3 min with 90% buffer A (H2O + 0.1% (v/v) FA) at a flow rate of 25 
μL/min. RP chromatographic separation was then performed on an Acclaim PepMap 
100 C18 Nano-LC column (3 μm, 100A, 75 μm i.d x 25 cm) (Dionex Corp, Thermo 
Fisher Scientific Ltd) with a 60 min linear gradient of 10-50% buffer B (100% ACN 
+ 0.1% (v/v) FA) at a flow rate of 300 nL/min.  
2.2.11 Tandem Mass Spectrometry 
Tandem MS/MS was performed on an LTQ-Orbitrap XL™ mass spectrometer 
(Thermo-Scientific Ltd) equipped with a picoview PV550 nano-electrospray ion 
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source (New Objective Inc.). The MS was operated in the data-dependent mode to 
automatically switch between MS (full ion scan) and MS/MS (fragment ion scan) 
acquisition. Survey full scan MS spectra (m/z 390-1700) were acquired in the orbitrap 
with a resolution of 60,000 at m/z 400. The most intense (top 6 ions per survey scan) 
were sequentially isolated for fragmentation (MS/MS) in the linear ion-trap (LTQ) by 
collision induced dissociation and dynamically excluded for 60 sec. To maintain 
accurate mass measurement, the lock mass option was enabled with 
polydimethylcyclosiloxane at m/z 455.120025 set as an internal calibrant.  
2.2.12 Protein identification and quantification 
Acquired mass spectra were processed using Mascot Distiller version 2.5 (Matrix 
Science Ltd) and searched against the Uniprot database. The following parameters and 
search filters were used; MS tolerance was set to +/- 10 ppm, the fragment MS/MS 
tolerance was set to 0.5 Da, two missed cleavages were allowed, 
carbamidomethylation of cysteines was set as a fixed modification, methionine 
oxidation, acetylation (protein N-term), deamidation (asparagine and glutamine) were 
set as variable modifications. MudPit scoring was enabled and peptides were required 
to score >20 with a Mascot significant threshold of P <0.05. Peptides were also 
required to be bold red and therefore were statistically the strongest assignments. At 
least 2 peptide matches were required for a positive protein identification. The protein 
identifications were then matched to specific spots in DeCyder and experimental 
molecular weights and pIs checked with theoretical values. 
2.3 Endometrial tissue profiling using a protein based labelling and fractionation 
method 
2.3.1 Introduction 
A protein labelling and separation strategy was explored in an attempt to improve the 
depth of coverage in profiling the endometrial tissue proteome. Protein amino group 
labelling of denatured protein samples using isobaric tandem mass tags (TMT) was 
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coupled to multi-dimensional protein separation by strong anion exchange (SAX) 
chromatography and one-dimension gel electrophoresis, prior to digestion and LC-
MS/MS The premise was that the heterogeneous nature of proteins would afford a 
better separation versus their more homogeneous peptide components and where 
peptides from abundant proteins would not be spread across the entire LC-MS/MS 
experiment, being sampled repeatedly in preference to lower abundant species. 
However, complete labelling of intact proteins may be challenging and blocking of 
trypsin sites by lysine TMT labelling would require a different digestion approach.  
2.3.2 Samples used for optimisation of protein TMT labelling 
Endometrial tissue samples from four patients previously collected at laparoscopy and 
stored at -80°C were used in this experiment (Table 2.6). Patients selected for this 
experiment were diagnosed with two forms of endometriosis; deep infiltrating 
endometriosis and ovarian endometriosis. Ectopic and eutopic endometrial tissue were 
collected from each patient. All patients were on GnRH treatment and were not 
selected for the main profiling experiments.  
Table 2.6 Tissue samples used for optimisation of a protein-based profiling strategy. 
DIE= Deep infiltrating endometriosis; Ect = ectopic endometrial tissue; EmE= eutopic 
endometrium 
 
Patient ID Tissue type Tissue description Phase of cycle Treatment 
007 DIE Recto-vaginal nodule Inactive endometrium GnRH 
 Ect 2 Endometrioma   
 EmE Endometrium   
021 DIE Recto-vaginal nodule Inactive endometrium GnRH 
 EmE Endometrium   
051 DIE Recto-vaginal nodule Inactive endometrium GnRH 
 EmE Endometrium   
057 Ect 2 Endometrioma Inactive endometrium GnRH 
 EmE Endometrium   
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Protein extraction was carried out according to the optimised protocol presented in the 
previous sections. Three pools were created by mixing equal amounts of protein from 
the 9 samples to create eutopic endometrial (EU), deep infiltrating endometriosis (D1) 
and endometrioma (E1) pools. 
2.3.3 Immunodepletion and protein denaturation  
Samples containing 500 μg protein were diluted with PBS (final urea concentration of 
1 M) and 500 μL of PP12 immunodepletion resin was added.  and incubated on a 
rotary shaker for 30 minutes. The flow-through was collected using Spin-X Filter 
Units, and then concentrated to 100 μL using 5 kDa MWCO Vivaspin filter units (GE 
Healthcare). Samples were diluted to 500 μL with 8M urea in 20 mM 
triethylammonium bicarbonate (TEAB) at pH 8.3 to denature the protein and then 
concentrated to 25 μL. Samples were diluted again to 500 μL as above and 
concentrated to 100 μL. A protein assay (Bradford) was carried out to determine 
protein concentration of each pool after depletion. Pools were normalised to the same 
concentration with 8M urea in 20 mM TEAB pH 8.3.  
2.3.4 TMT protein labelling and gel-based separation 
SDS (0.1% v/v final concentration) and EDTA (1 mM final concentration) were added 
to 100 µg protein from each of the immunodepleted pools. Samples were then reduced 
with 1 mM TCEP from a stock solution of 0.5 M TCEP at pH 7.0 for 1 hr at room 
temperature.  0.8 mg of amine-reactive Tandem Mass Tag reagents (TMT-126, TMT-
127 and TMT-128) (Thermo-Scientific Ltd.) were resuspended in 41 μL of acetonitrile 
and used to label the pools (pool D1-TMT-126, pool E1-TMT-127, pool EU-TMT-
128) for 1 hr at room temperature. Samples were then incubated with 0.25 % 
hydroxylamine for 30 minutes at RT to quench the reaction. TMT labelled pools were 
then combined in equal amounts (300 µg total protein) then mixed with 5x sample 
buffer and run in triplicate (100 µg per lane) on a large 10% SDS-PAGE gel at 10 mA 
overnight. The gel was stained with Instant Blue Coomassie stain. Each lane was cut 
into 48 bands and digested with Glu-C and trypsin as described below. 
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2.3.5 Enzymatic digestion  
Excised gel pieces were washed three times in 50 % (v/v) ACN and dried in a 
SpeedVac. The dried pieces were then reduced in 10 mM DTT in 5 mM AmBiC, pH 
8.0, for 45 minutes at 50°C and then alkylated with 50 mM iodoacetamide in 5 mM 
AmBic for 1 hr in the dark at room temperature. The gel pieces were then washed in 
50% ACN and dried in a SpeedVac until completely dry and incubated with 100 ng 
Glu-C protease (Roche) at 25°C overnight. 50 ng of sequencing grade modified 
trypsin (Promega) in 10 µL 5 mM AmBic was then added to each of the gel pieces 
which were further incubated at 37°C overnight. Peptides were then extracted twice 
using 30 µL 50% ACN/5% TFA. The supernatant was then transferred into clean 
Eppendorfs and the samples dried in a SpeedVac. Dried samples were re-suspended 
in 10 µL of 0.1% TFA, and desalted using C18 ZipTips® (Merck Millipore) as 
described previously (Section 2.2.10).  
2.3.6 Reverse-phase liquid chromatography tandem MS analysis 
Samples were resuspended in 6 µL of 0.1% FA and analysed on an LTQ Orbitrap XL 
mass spectrometer (Thermo Scientific) coupled to an Ultimate 3000 nano-LC system 
(Dionex). The mass spectrometer was operated in the data-dependent mode to 
automatically switch between orbitrap MS and ion trap MS/MS acquisition. For 
identification of TMT labelled peptides, the three most abundant ions were selected 
for collision induced dissociation (CID) and then the same precursor ions triggered 
higher energy collision dissociation (HCD) fragmentation. 
2.3.7 Optimisation of fractionation by strong anion exchange (SAX) 
chromatography  
A method for protein fractionation by SAX before and after TMT labelling was 
explored as a potential separation method for improving coverage. Briefly, 150 μL of 
DEAE Ceramic HyperD F slurry (Pall Corporation) was prepared in a column and 
used to fractionate 300 μg of immunodepleted TMT labelled tissue lysate protein. 
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Elution buffers of increasing sodium chloride concentration in 20 mM TEAB pH 8.3 
(50 mM, 100 mM, 200mM and 1M NaCl) were used to elute bound proteins from the 
column in a sequential fashion using 200 µL of each buffer. To resolve eluted proteins, 
each fraction and the flow through were run on a NuPAGE® Novex® 4-12% Bis-Tris 
1.5 mm, 10 well pre-cast gel (Invitrogen). The gels were run at 70 mA for 1 hour and 
stained with Instant Blue gel stain (Expedeon). The stained gels were imaged on a GS-
800™ densitometer (BioRad). The same fractionation was repeated without TMT 
labelling of proteins using 200 mM, 400 mM, 600 mM, 800 mM and 1M NaCl elution 
steps. 
2.4 Profiling of endometrial tissues using protein TMT labelling and 
fractionation 
Protein extraction and immunodepletion for TMT protein labelling of pooled samples 
was carried out according the optimised protocol (sections 2.3.3 and 2.3.4). 6-plex 
TMT reagents were used to label 100 µg of denatured protein from each pool as 
follows: pool CS-TMT126, pool CP-TMT127, pool PS-TMT128, pool EcS-TMT129, 
pool ES-TMT130 and pool EP-TMT131 and then combined together. TMT-labelled 
proteins were fractionated by strong anion exchange chromatography. A SAX column 
was prepared in a spin filter unit using 300 μL of DEAE ceramic HyperD F slurry 
(Pall Corporation). The column was centrifuged at 3,000 rpm for 2 min to remove the 
storage solution and then washed with 300 μL of 1 M NaCL in 20 mM TEAB pH 8.5 
and centrifuged at 3,000 rpm for 2 min. The column was again washed three times 
with 300 μL of 200 mM TEAB pH 8.5, and then equilibrated by washing with 300 μL 
of 20 mM TEAB pH 8.5 followed by centrifuging at 3000 rpm for 2 min. The pooled 
sample was then introduced into the column and incubated with the resin on a rotary 
shaker for 5 min. Un-bound proteins were removed by centrifuging at 3,000 rpm for 
2 min followed by washing with 300 μL of 20 mM TEAB. The two fractions were 
combined as the flow through (FT). Bound proteins were then sequentially eluted two 
times using 300 μL each of increasing salt concentration buffers of 400 mM NaCl, 
600 mM NaCl and 1M NaCl. The two eluates were combined for each step. The flow 
through and three eluates were concentrated to 50 μL each using 5 kDa MWCO 
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Vivaspin filter devices (GE Healthcare). The fractions were then run on a large format 
hand-cast 10% SDS-PAGE gel to resolve the eluted proteins. The gel was stained 
using InstantBlue Coomassie stain (Expedeon) and each lane cut into 50 bands and 
digested with Glu-C (Roche) then trypsin (Promega) as described in section 2.3.5. 
Samples were desalted using C18 ZipTips as before, dried down and re-suspended in 
6 µL 0.1% FA prior to LC-MS/MS analysis.  
Samples were analysed in an LTQ Orbitrap XL mass spectrometer (Thermo 
Scientific) equipped with a picoview PV550 nano-electrospray ion source (New 
Objective Inc.) and coupled to an Ultimate 3000 nano-liquid chromatography system 
(Dionex). Samples were injected onto an Acclaim PepMap 100 C18 pre-column (5 
μm, 100A, 300 μm i.d x 5 mm) (Dionex Corp. Thermo Fisher Scientific Ltd) and 
washed for 3 min with 10% buffer B (ACN + 0.1% (v/v) FA) at a flow rate of 25 
μL/min. RP chromatographic separation was performed on an Acclaim PepMap 100 
C18 Nano-LC column (3 μm, 100A, 75 μm i.d x 25 cm) (Dionex Corp, Thermo Fisher 
Scientific Ltd) with a 90 min linear gradient of 10-50% buffer B at a flow rate of 300 
nL/min. The instrument was operated in the data-dependent mode to automatically 
switch between MS (full ion scan) and MS/MS (fragment ion scan) acquisition. 
Survey full scan MS spectra (m/z 390-1700) were acquired in the orbitrap with a 
resolution of 60,000 at m/z.  
For identification of TMT labelled peptides, the most intense (top 3 per survey scan) 
were sequentially isolated for fragmentation in the linear ion-trap by CID and 
dynamically excluded for 60 sec. Wide band activation was enabled to account for 
potential neutral loss of water. The same ions were also fragmented by HCD for 
detection of TMT reporter ions in the orbitrap using a collision energy of 40%. To 
maintain accurate mass measurement, the lock mass options was enabled and the 
polydimethylcyclosiloxane at m/z 455.120025 was set as an internal calibrate.  
Raw data files produced in Xcalibur software (Thermo Scientific) were processed 
using Mascot Distiller version 2.4 searching against the SwissProt database. For 
searching, taxonomy was human; the MS tolerance was set to +/-10 ppm and the 
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MS/MS tolerance was set to 0.5 Da. Enzyme specificity was set to trypsin and Glu-C. 
Two missed cleavages were allowed. TMT 6-plex modification of peptides and 
carbamidomethylation of cysteines were set as fixed modifications. Protein N-
terminal acetylation, methionine oxidation and deamidation (N/Q) were set as variable 
modifications. Search result filters were as follows: only peptides with a score of >20 
and below the Mascot significance threshold filter of P<0.05 were included. The 
extent of labelling was calculated by comparing the numbers of labelled versus 
unlabelled peptides. Protein grouping was enabled such that when a set of peptides in 
one protein were equal to or completely contained within the set of peptides of another 
protein, the two proteins were put together in a protein group. Quantitative 
information was calculated from reporter ion intensities taking the median value of 
peptide ratios to calculate protein group ratios for the following comparisons; ES/CS, 
ES/PS, EP/CP, EcS/ES and PS/CS.  
2.5 Endometrial tissue profiling using peptide-based labelling and fractionation 
2.5.1 Introduction 
This work also explored a peptide TMT labelling and fractionation approach for 
profiling endometrial tissues for biomarker discovery. Three-dimensional separation 
of peptides was employed to maximise coverage by MS analysis, using SAX 
chromatography, off-line high pH RPLC and low pH nano-RPLC coupled to tandem 
mass spectrometry. The strategy was applied to the 6 tissue lysate pools described in 
Table 2.3. 
2.5.2 Enzyme digestion and TMT labelling of immunodepleted pools 
For peptide based profiling, 100 μg of each immunodepleted tissue lysate pool was 
resuspended in 100 mM TEAB, pH 8.5 and 0.1% SDS. Samples were reduced in 1 
mM TCEP for 1 hr at 55°C and alkylated in 7.5 mM iodoacetamide for 1 hr at RT in 
the dark. Samples were then digested overnight at 37°C using 4 µg of modified porcine 
trypsin (Promega).  
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Samples were labelled with TMT reagents. Briefly 100 μg of each digested sample 
was labelled with 0.8 mg of each TMT reagent (resuspended in 41 μL of ACN) as 
follows: pool CS -TMT126, pool CP - TMT127, pool PS - TMT128, pool EcS - 
TMT129, pool ES - TMT130 and pool EP - TMT131 for 1 hr at RT. Samples were 
then incubated with 0.25% hydroxylamine for 30 minutes at RT to quench the 
reaction. The six TMT labelled samples were then combined together. 
2.5.3 Sample clean-up 
SDS was removed using detergent removal spin columns (Pierce). Briefly, six spin 
columns were prepared by first centrifuging for 1 min at 1,500 x g to remove storage 
buffer, followed by equilibration using 400 μL of PBS. This was done three times and 
the supernatants discarded. 100 μL of sample was then loaded onto each column, 
incubated for 2 min at RT and collected by centrifugation for 2 min at 1,500 x g into 
fresh Eppendorf tubes. The samples were recombined and dried down in a SpeedVac. 
The dried sample was then re-suspended in 1 mL acidified water containing 2% 
phosphoric acid. Samples were then desalted using 1cc Oasis HLB cartridges 
(Waters). The cartridge was first conditioned using 1 mL of 100% methanol followed 
by equilibration using 1 mL of distilled water. 1 mL of sample was then loaded onto 
the cartridge and washed using 1 mL of 5% methanol in water. Bound peptides were 
then eluted using 1 mL of 100% methanol. The sample was then dried down in 
SpeedVac and re-suspended in 300 μL of 100 mM TEAB pH 8.5 for SAX 
chromatography. 
2.5.4 Strong anion exchange chromatography of labelled peptides 
TMT-labelled peptides were fractionated by SAX chromatography. The SAX column 
was prepared in a spin filter unit using 300 μL of DEAE ceramic HyperD F slurry 
(Pall Corporation). The column was centrifuged at 3,000 rpm for 2 min to remove 
storage solution and then washed with 200 μL of 1 M NaCl in 100 mM TEAB pH 8.5 
and centrifuged at 3,000 rpm for 2 min to remove the supernatant. The column was 
again washed three times with 200 µL of 200 mM TEAB pH 8.5, and then equilibrated 
108 
 
by washing with 100 mM TEAB pH 8.5 followed by centrifuging at 3,000 rpm for 2 
min to remove the supernatant. The pooled sample was then introduced into the 
column and incubated with the resin on a rotary shaker for 5 min. Un-bound peptides 
were removed by centrifuging at 3,000 rpm for 2 min followed by washing with 200 
µL of 100 mM TEAB. The two fractions were combined as the flow-through (FT). 
Bound peptides were then sequentially eluted using 200 μL twice of increasing salt 
concentration buffer; 100 mM TEAB plus 400 mM NaCl, 600 mM NaCl and 1M 
NaCl. The two eluates at each salt concentration were combined and desalted using 
1cc Oasis HLB cartridges (Waters), lyophilised and stored at -20°C. 
2.5.5 High pH reversed-phase liquid chromatography 
Peptide fractions were resuspended in 42 μL of 20 mM ammonium formate pH 8.5 
and separated by high pH RPLC using an Agilent 1100 series microflow pump. 
Briefly, 40 µL of resuspended peptides were injected onto a Poroshell 300SB-C18 (5 
μm, 2.1 x 75 mm) column (Agilent). Solvents consisted of 20 mM ammonium formate 
pH 8.5 in water as mobile phase A and 20 mM ammonium formate pH 8.5 in 80% 
acetonitrile as mobile phase B. Peptide separation was accomplished using a linear 
gradient of 0-45% mobile phase B at a flow rate of 200 µL/min for 55 min. 30 fractions 
were collected for each SAX fraction (total 120 fractions). Each fraction was dried 
down in a SpeedVac and resuspended in 200 μL of 0.1% FA and redried prior to MS 
analysis. 
2.5.6 LC-MS/MS 
Fractions were resuspended in 6 μL 0.1% FA prior to tandem MS. Tandem MS/MS 
was performed on an LTQ-Orbitrap XL™ mass spectrometer (Thermo-Scientific Ltd) 
with the same parameters as described in section 2.4 with data-dependent acquisition 
of the top 3 ions by CID and HCD for optimal reporter ion measurement. The orbitrap 
was operated using Xcalibur software and parameters were optimised for acquisition 
of high quality spectra for identification and quantification of TMT-tagged peptides. 
Fragmentation was optimal with a HCD normalised collision energy set at 40%. 
109 
 
Product ions were detected in the orbitrap at a resolution of 7,500. This resulted in 
prominent reporter ions in HCD MS/MS spectra.  
Proteome Discoverer version 2.4 was used for protein identification and quantification 
using Mascot for searching the SwissProt database. Search parameters were as 
described above, except that only trypsin was used as the enzyme and one missed 
cleavage was allowed. A co-isolation threshold of 25% was set in the quantification 
method to limit the recording of reporter ion ratios from multiple peptides. Protein 
groups with a ratio above 1.5 or below 0.67 in each comparison were considered to be 
differentially expressed. Proteins were also assigned a ‘biomarker score’ based on 
fold-change, ratio count, variability, number of unique peptide sequences, whether 
they were a possible serum protein contaminant and their membership of a particular 
expression cluster group, each of which represented the broad pattern of expression 
across the tissue groups; Graphical Proteomics Data Explorer (GProX) was used to 
cluster the proteins based on their reporter ion ratios across the different comparisons. 
2.6 Gene ontology and pathway enrichment analysis 
Gene ontology and pathway enrichment analysis   of the changing proteins was carried 
out with the aim of defining potential biological and molecular networks involved in 
endometriosis. Gene ontology is a framework that describes gene products in terms of 
their molecular and biological functions and cellular localisations. GO Slim is a 
summarised version of the GO ontology and was used to provide a broader 
classification of gene product functions. Differentially expressed proteins 
(≥1.5/≤0.67-fold) were imported into WebGestalt (Wang J et al., 2013) and each 
clinical group analysed separately for enrichment of GO biological process, molecular 
function and cellular component, GO Slim terms, protein interaction networks, KEGG 
pathways and disease association. Significantly enriched terms were identified using 
a hypergeometric test with a Benjamini-Hochberg (BH) correction at a significance 
of P <0.05. The top 10 GO terms with the most significant P values were reported. In 
each comparison, the protein lists were analysed separately as up- or down-regulated 
proteins.  
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2.7 Verification of proteins identified from proteomic profiling  
2.7.1 Introduction 
The main goal of biomarker verification is to determine whether there is adequate and 
consistent evidence for the potential clinical application of a given candidate to 
warrant further validation studies. In this study, univariate tests of significance and a 
‘biomarker score’ were used to filter the discovery data for the selection of proteins 
that displayed potential as endometriosis biomarker candidates. These candidates as 
well as markers identified from previous reports in the literature were verified in 
individual serum samples from the discovery set using commercial ELISA kits. Data 
analysis involved significance testing and Receiver Operating Characteristic (ROC) 
curve analysis of single markers in the different clinical groups irrespective of cycle 
phase, as well as in the different phases of the cycle. Candidates were also correlated 
with measurements of progesterone, oestradiol, CRP and CA125, clinico-pathological 
features and epidemiological data obtained in the course of the study. Multivariate 
tests were also conducted by incorporating multiple markers into models to assess 
performance. Models showing the highest diagnostic accuracies would be selected for 
further validation in an independent cohort. 
2.7.2 Assay optimisation and preliminary analysis 
Commercial ELISA kits purchased from R&D Systems were used to assay follistatin 
(FST), soluble intercellular adhesion molecule-1 (sICAM1), macrophage 
chemoattractant protein-1 (MCP1), macrophage inhibitory factor (MIF), soluble 
interleukin-1 receptor type 2 (IL1R2) and vascular endothelial growth factor (VEGF). 
The kits used to assay lumican (LUM), glycodelin (PAEP), tropomyosin beta chain 
(TPM2), tenascin C (TNC) and carboxypeptidase M (CPM) were purchased from 
Boster, Bioserve Diagnostics, Abcam and Clone Corp, respectively (Table 2.7). The 
assay kits were first tested for their reproducibility and technical sensitivity to ensure 
the particular protein of interest could be accurately detected in serum samples before 
using them on the full sample set. Trial runs were performed with a series of serum 
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dilutions coupled with various diluting reagents and incubation times to determine the 
most distinguishable signal on the linear portion of the standard curve. A serum pool 
for testing was prepared by mixing 20 μL of each serum sample from the discovery 
set. Different dilutions of this serum pool were optimised by testing each dilution in 
duplicate alongside the standards in the different assays. Each assay was calibrated by 
running a standard curve using a series of standards according to the manufacturer’s 
instructions. Intra-assay CVs for the different assays are reported in the table below. 
Table 2.7 ELISA assays, optimal dilutions and intra-assay CVs. 
Assay Company Optimal dilution Intra-assay CV% 
CPM Clone Corp 1:20 5 
FST R&D 1:2 5.6 
sICAM R&D 1:50 2 
PAEP Bioserv 1:5 13.6 
IL1R-II R&D 1:50 1.5 
LUM Boster 1:20 10.6 
MCP1 R&D 1:10 5.5 
MIF R&D 1:10 4.5 
TNC Abcam 1:50 0.7 
VEGF R&D 1:2 4.6 
CA125 Roche 1:1 4 
 
2.7.4 Proseek Proximity Extension Assay (PEA) platform  
PEA technology is a high-throughput immunoassay that was used to analyse a panel 
of 92 oncology-related protein biomarkers across a subset of discovery samples; 15 
randomly selected serum samples each from the endometriosis and pain groups were 
assessed using the Proseek® Multiplex Oncology II panel (Olink Biosciences). 
Briefly, target-specific antibody pairs are linked to a single strand DNA 
oligonucleotide. When the two probes are in close proximity due antibody pair binding 
to their target, a PCR target sequence is formed by ligation of the two DNA probes. 
The resulting sequence is subsequently detected and quantified using real-time QPCR. 
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A normalised protein expression value was provided by reference to controls added 
to the samples. 
2.8 Statistical analysis  
Data analysis was carried using MS Excel 2013, Graphpad Prism software version 
5.0.1 and the R statistical software environment. Where the protein of interest was 
undetectable in the sample, the adjusted concentration of this protein was considered 
to be one-half the limit of quantification of the particular assay. For baseline 
characteristics, the D’Agostini and Pearson omnibus test was applied to test for 
normality. The unpaired t-test was chosen to compare mean values for normally 
distributed data, whereas for non-normally distributed data, the mean values were 
compared by the Mann-Whitney test. For each clinical group, the data was analysed 
independently of cycle phase and then according to cycle phase to assess whether any 
of the markers were dependent on the menstrual cycle. A P value of <0.05 was 
considered significant. To determine the diagnostic performance of each biomarker, a 
ROC curve analysis was performed with the area under the curve (AUC) reported for 
each comparison (control vs endometriosis and pain vs endometriosis). Markers were 
also analysed for correlations to clinico-pathological parameters and to each other, 
reporting the Spearman correlation coefficients. It is highly likely that a panel of 
markers as opposed to single markers would increase the sensitivity and specificity of 
a non-invasive test of endometriosis. A multi-variate analysis was therefore carried 
out to assess the performance of combination of these biomarkers. A script in R studio 
was applied to combine 2 or 3 candidate markers into models, testing all combinations 
and reporting the best models based on AUC. The sensitivities at 80% and 90% 
specificity were reported. 
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CHAPTER 3: PATIENT RECRUITEMENT AND SAMPLE COLLECTION 
CHALLENGES 
3.1 Introduction 
Patients and samples were sourced from the UCLH Reproductive Medicine Unit 
(RMU) following ethical approval. Initially samples were to be collected from 80 
patients who were to be selected from the total number of consenting patients who 
were recruited for the study. They were to be stratified as follows: 20 patients 
diagnosed with endometriosis, 20 patients diagnosed with chronic pelvic 
inflammatory disease, 20 patients diagnosed with pelvic pain of unknown cause and 
20 control patients with no known disease at the time of surgery undergoing bilateral 
tubal ligation (BTL) or prophylactic bilateral salpingo-oophorectomy (BSO) and all 
in the secretory phase of the menstrual cycle. However, these criteria were later 
reviewed due to a lower than expected number of consenting patients. It was also not 
possible to obtain samples only from women in the secretory phase due to surgical 
scheduling and lower than expected consent rates. There were no consenting patients 
undergoing BTL so all healthy controls had been referred for BSO as a prophylactic 
measure due to a high familial risk of breast and ovarian cancer. Patients were then 
stratified according to menstrual cycle phase as controls with no known disease in the 
secretory phase (n=9) and proliferative phase (n=11). The pain group also had to be 
combined to include women with chronic pelvic pain of unknown cause and women 
with chronic pelvic inflammatory disease (n=12). All patients selected for the pain 
group were in the secretory phase. In the endometriosis group, eutopic endometrial 
tissue as well as superficial peritoneal lesions, ovarian endometriomas and deep 
infiltrating endometriosis ectopic tissue were collected from each patient diagnosed 
with endometriosis. Samples from patients in this group were stratified according to 
menstrual cycle phase as eutopic endometrium and the corresponding ectopic tissue 
in the proliferative (n=14) and secretory phases (n=28). Superficial implants and deep 
infiltrating endometriosis ectopic tissue samples only were used in this study. The 
rationale being that imaging techniques are sensitive for diagnosis of ovarian 
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endometriomas, but are less accurate for diagnosing endometriosis elsewhere in the 
pelvis. 
Biomarker discovery ideally involves the analysis of a larger number of different 
samples. However patient recruitment and the accrual of enough tissue samples 
proved to be a challenge. Particularly many of the women with advanced stage 
endometriosis were on some form of treatment at the time of laparoscopy (mostly 
GnRH analogues or oral contraceptives). This meant that eutopic endometrial biopsies 
were compromised as the endometrium is highly down-regulated by these treatments. 
It is also important to note that in some instances it was not possible to obtain ectopic 
samples, especially from patients with subtle peritoneal disease. These endometriosis 
lesions were ablated and not excised during laparoscopy. Finally, to avoid too much 
variability in the sample set, patients diagnosed with endometriosis alongside other 
benign conditions such as fibroids, non-endometriosis cysts and cancer were 
excluded. Figure 3.1 below shows a flow chart of the recruitment and patient journey 
through the study. 
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Figure 3.1 Recruitment and flow of participants through the study in the discovery 
phase. 
 
In total, 122 pre-menopausal women were consented to this study. 109 women met 
the inclusion criteria. This set was divided into cases who were women diagnosed with 
endometriosis (n=62). The control group comprised of women with pelvic pain (n=24) 
and women with no known disease and no pain (n=23). Table 3.1 shows the 
characteristics of subjects included in the study and the clinical grouping. The 
remaining women were diagnosed with other pelvic conditions, mostly fibroids and 
non-endometrial ovarian cysts.  
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Table 3.1 Characteristics of subjects included in the study and clinical grouping 
 
For discovery profiling, tissue samples from patients were stratified into six groups 
based on condition and cycle phase with 6-20 tissue samples pooled into each group. 
3.2 Sample processing optimisation 
Conditions for extraction, separation and identification of the proteins extracted from 
endometrial and endometriosis tissue were optimised. The best extraction was 
achieved by combining mechanical homogenisation through grinding in liquid 
nitrogen followed by chemical lysis and extraction in buffered urea/CHAPS. 
3.3 Quality control assessment of endometrial tissue lysates 
Endometrial tissue is a highly heterogeneous tissue containing different cell types. 
Due to the ‘bloody’ nature of the post-surgical tissue specimens obtained, tissue 
samples were washed using PBS, dried, placed in clean Eppendorf tubes before snap-
freezing in liquid nitrogen. This step was not sufficient to remove all the blood in the 
samples. It was therefore our aim to assess the extent of this blood ‘contamination’ 
prior to sample analysis and also to examine sample integrity. Thus 10 µg of protein 
 
Control Pain Endometriosis 
Number 23 24 62 
Age (years)    
Mean (SD) 37.61 (8.16) 31.83 (6.67) 35.52 (6.38) 
Median (range) 36 (20-51) 32 (19-48) 35 (20-52) 
Symptoms    
Subfertility 4 9 18 
Pain 0 24 55 
Cycle phase    
Proliferative 11 11 14 
Secretory 9 12 28 
Inactive 3 1 20 
Treatment    
GnRH 0 1 11 
OCP 0 1 6 
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of the lysates selected for the main profiling experiments were run on 1D gels and 
stained to assess the extent of contamination and general protein integrity. The gel 
images below (Figure 3.2) illustrate the presence of albumin (blue arrows) in almost 
all samples and of red blood cell haemoglobin (yellow arrows). Several samples also 
appeared to be degraded or contained low levels of higher molecular weight proteins. 
Thus these samples (annotated with an asterisk in Figure 3.2) were excluded from the 
main profiling experiments. Additionally, the protein yields for some samples was 
deemed too low for subsequent downstream applications. This quality assessment thus 
confirmed the heterogeneity of the samples and differential contamination with blood 
proteins.  
For proteomic profiling, a pooling approach for the individual tissue lysates was used. 
The advantages of pooling are that protein expression in a pool matches the mean 
expression of the individual samples making up the pool and reduces the number of 
samples for analysis. Pooling is also ideal where limited amounts of material per 
biological sample are available. However, individual biological variation cannot be 
accurately assessed and subsequent verification of changes in individual samples 
becomes paramount. In conclusion, patients were recruited and a set of samples 
accrued. These samples were assessed for their quality and the most homogeneous 
samples selected for pooling prior to proteomic profiling. 
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Figure 3.2 1D gel images of tissue sample lysates. 
10 µg of undepleted protein from each sample was run. * indicates samples excluded from 
main profiling experiments due to low protein amount. Most samples were contaminated by 
serum album (blue arrows). Yellow arrows show haemoglobin, an indication of red blood 
cell contamination. 
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CHAPTER 4: 2D-DIGE PROFILING OF ENDOMETRIAL TISSUE FOR 
BIOMARKER DISCOVERY 
4.1 Introduction 
This chapter reports the use of two-dimensional difference in-gel electrophoresis (2D-
DIGE) for the profiling of endometrial tissues collected as part of the study. The 
method was used to compare intact protein expression between endometriosis and 
control tissue samples to identify potential tissue biomarkers. 
4.2 Preliminary 2D-DIGE analysis  
A preliminary 2D-DIGE analysis was carried out in order to assess the feasibility of 
the technique in the profiling of endometrial and endometriosis tissue samples. It was 
possible to identify multiple protein spots from these tissue lysates as indicated by the 
gel images in Figure 4.1. Gels were loaded with 100 µg of differentially labelled 
protein representing pairs of samples. Generally, fewer protein spots were identified 
from ectopic tissue compared to eutopic tissue, although all samples had broadly 
similar patterns. The gel images produced were compared to gel images from serum 
samples. It was apparent that high-abundance serum proteins were present in the 
samples, possibly masking some lower abundance tissue-derived proteins and 
effectively reducing the protein load. High abundance and multiple isoforms of 
proteins such as albumin also complicated spot detection. It was therefore decided that 
an immunodepletion step should be incorporated into the main workflow in order to 
remove some of these highly abundant serum proteins to improve the sample load of 
tissue proteins and proteomic coverage.  
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Figure 4.1 2D-DIGE images of test samples. 
The number in parentheses next to the gel number reports the number of detected spots in 
that gel. Arrows on gel 1 indicate the contaminating serum protein albumin 
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4.3 Preliminary analysis of high-abundance serum protein depletion 
Sample depletion was carried out in order to remove some of the high abundant serum 
proteins revealed by 2D-DIGE. Curettage, which involves ‘scraping’ strips of 
endometrium, was used to collect endometrial biopsies during laparoscopy. As a 
consequence, most samples will have some level of blood contamination. To remove 
excess blood, tissue samples were washed in PBS prior to snap freezing, but this did 
not remove all of the blood. Protein Purify 12 (PP12) immunodepletion resin can be 
used to remove ~90% of the most abundant proteins from serum/plasma namely, 
albumin, IgG, IgA, IgM, transferrin, haptoglobin, fibrinogen, apolipoproteins AI and 
AII, α2-macroglobulin, α-1-antitrypsin and α1-acid glycoprotein. These proteins 
represent approximately 95% of the protein concentration in serum. Their removal 
would allow visualisation of other proteins that co-migrate or co-fractionate with the 
high-abundance proteins and allow increased loading of lower abundant proteins. 
With this in mind, 500 µL of PP12 slurry was used to deplete 200 µg and 500 µg of 
tissue protein extract. Flow-through depleted samples were then concentrated and 20 
µg of the depleted samples were run on a 1D SDS-PAGE gel alongside 20 μg of 
undepleted sample and 20 μg of undepleted serum for comparison. Protein bands were 
visualised using colloidal Coomassie brilliant blue staining (Figure 4.2). 
The image supports the notion that there are major contaminating proteins from blood 
in the tissue extracts, particularly serum albumin. By depleting these proteins, lower 
abundance (tissue-derived) proteins were now revealed when an equal load of protein 
was used. This ‘contamination’ was significant, given that the yields of proteins after 
depletion were 20% and 25% of the 200 µg and 500 µg starting amounts, respectively. 
The depletion step was thus incorporated into the main profiling workflow, in an 
attempt to improve proteomic coverage of tissue proteins.   
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Figure 4.2 Gel image of immunodepleted tissue lysate sample. 
Arrow indicates position of serum albumin 
 
4.4 Identification of differentially expressed proteins in endometrial and 
endometriosis tissue 
A comparison of protein expression levels in pooled tissue samples from 
endometriosis and controls was undertaken using 2D-DIGE. Each type of sample pool 
(eutopic tissue from pain, endometriosis and control groups in secretory and 
proliferative phases and ectopic tissue from endometriosis cases) was labelled in 
triplicate using CyDyes. Cy2 was used to label an internal standard comprising an 
equal mixture of all samples in the experiment. The standard was run on all gels 
thereby allowing accurate spot matching and normalisation across all gels. Protein 
components of these endometrial lysates were sufficiently resolved in the pH range of 
4-8 (Figure 4.3). Spot detection and quantitation were performed automatically on 
overlaid Cy2/Cy3 and Cy2/Cy5 image pairs for each gel, followed by semi-automated 
gel to gel matching and statistical analysis. For a given spot, an average standardised 
abundance was determined as the average of the spot volume ratios between the 
standard and the test sample. Following inter-gel matching, the quantitative 
comparison of the gel images yielded 1,500 matched spots.   
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Figure 4.3 Overlaid 2D-DIGE images showing endometrial tissue lysate profiles. 
80 µg of each pool was labelled in triplicate with Cy3 (red), Cy5 (blue) and Cy2 (green) 
which was used to label an internal standard. 
 
Analysis of variance was applied and data was filtered to retain spots with a significant 
difference P <0.05 at >1.5-fold change for spots that were matched in all spot maps. 
This resulted in 72 differentially expressed spots of which some occurred in a series 
of 2-4 clusters of spots. Clusters could mean that the protein/s were present as multiple 
isoforms in the gels differing in their isoelectric points. Spots of interest identified 
through this analyses were also verified to have a 3D profile characteristic of a protein 
spot and features detected from non-protein sources like dust particles and background 
were filtered out. 
Gel 01 ES1/PS1  Gel 02 EcS1/ES2  Gel 03 ES3/CS1  
Gel 04 EP1/CP1  Gel 05 CS2/EcS2  Gel 06 PS2/CS3  
Gel 07 EP2/PS3  Gel 09 CP3/EP3  Gel 08 EcS3/CP2  
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Post staining of gels with colloidal Coomasie blue and matching of images to the 
master CyDye image (Gel 4) resulted in 52 well-defined Coomassie-detectable protein 
spots which were picked from gels and digested with trypsin for downstream 
identification by LC-MS/MS. Mass lists generated from the acquired spectra were 
compared against theoretically expected tryptic peptide masses in the SwissProt 
database searched using the Mascot search engine. The identifications were scored 
according to algorithms that take into account mass accuracy and peptide coverage. 
Following MS analysis, 613 proteins were identified with confidence from the 52 gel 
spots. Abundant serum proteins e.g. albumin and possible contaminants such as 
cytokeratins were excluded, resulting in a final list of 84 differentially expressed 
proteins; three low-abundance spots lacked identification. The identified proteins 
were also verified by comparison of their theoretical molecular weights and isoelectric 
points with gel positions on the master gel. A simple scoring system was also 
developed to prioritise candidates as possible biomarkers and was based on the 
proteins displaying the same direction of differential regulation between 
endometriosis and both control groups and in the ectopic versus eutopic tissue. A 
summary of the results with fold-changes and P values are presented in Table 4.1. 
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Table 4.1 List of proteins that were identified as significantly up/down regulated (P <0.05 and >1.5-fold change). 
         ES/CS ES/PS EP/CP EcS/ES   
Master 
Spot 
No. Acc No. Protein Name Score 
Peptide 
Matches 
Peptide 
Sequences 
Pred 
Mass 
Gel 
pI 
Gel 
Mass 
Av. 
Ratio T-test 
Av. 
Ratio T-test 
Av. 
Ratio T-test 
Av. 
Ratio T-test 
Biomarker 
Score 
708 P51884 Lumican  LUM   394 15 7 38747 3.74 73000 1.86 0.0051 2.25 0.0043 1.63 0.16 2.09 0.0083 4 
708 P01011 Alpha-1-antichymotrypsin  SERPINA3   69 2 2 47792 3.74 73000 1.86 0.0051 2.25 0.0043 1.63 0.16 2.09 0.0083 4 
833 P51884 Lumican  LUM   314 14 7 38747 3.87 65000 2.05 0.025 2.36 0.029 1.04 0.78 1.80 0.0064 4 
833 P08670 Vimentin  VIM   92 5 4 53676 3.87 65000 2.05 0.025 2.36 0.029 1.04 0.78 1.80 0.0064 4 
833 O95302 Peptidyl-prolyl cis-trans isomerase FKBP9    114 5 3 63500 3.87 65000 2.05 0.025 2.36 0.029 1.04 0.78 1.80 0.0064 4 
833 O75781 Paralemmin-1  PALM   97 2 2 42221 3.87 65000 2.05 0.025 2.36 0.029 1.04 0.78 1.80 0.0064 4 
1363 O75874 
Isocitrate dehydrogenase [NADP] cytoplasmic  
IDH1   
474 23 11 46915 6.59 41000 -1.24 0.011 -1.97 0.00053 -2.40 0.00089 -3.39 4.60E-06 4 
1463  No identification      8.38 37000 -1.58 0.0067 -1.43 0.051 -1.61 0.049 -1.90 0.0057 4 
1543 P07951 Tropomyosin beta chain  TPM2   1066 37 12 32945 3.5 33000 3.17 0.001 2.13 0.0039 1.10 0.11 4.65 0.0014 4 
1543 P08670 Vimentin  VIM   376 15 10 53676 3.5 33000 3.17 0.001 2.13 0.0039 1.10 0.11 4.65 0.0014 4 
1548 P07951 Tropomyosin beta chain  TPM2   885 33 10 32945 3.77 30000 4.15 1.00E+00 2.36 0.0057 1.15 0.19 4.15 0.00022 4 
1548 P08670 Vimentin  VIM   268 15 11 53676 3.77 30000 4.15 2.10E-06 2.36 0.0057 1.15 0.19 4.15 0.00022 4 
1548 P51858 Hepatoma-derived growth factor  HDGF   77 3 2 26886 3.77 30000 4.15 2.00E+00 2.36 0.0057 1.15 0.19 4.15 0.00022 4 
1689 Q32P51 
Heterogeneous nuclear ribonucleoprotein A1-
like 2  HNRNPA1L2   
113 2 2 34375 9.56 24000 -1.43 0.046 -1.48 0.031 -1.34 0.03 -5.71 0.0002 4 
1981 P02647 Apolipoprotein A-I  APOA1   1190 40 16 30759 4.2 15000 1.70 0.065 3.07 0.0065 1.43 0.067 1.59 0.13 4 
1981 P12111 Collagen alpha-3(VI)chain  COL6A3   206 9 7 345167 4.2 15000 1.70 0.065 3.07 0.0065 1.43 0.067 1.59 0.13 4 
1981 P60709 Actin, cytoplasmic 1  ACTB   244 7 6 42052 4.2 15000 1.70 0.065 3.07 0.0065 1.43 0.067 1.59 0.13 4 
1981 P04792 Heat shock protein beta-1  HSPB1   101 6 4 22826 4.2 15000 1.70 0.065 3.07 0.0065 1.43 0.067 1.59 0.13 4 
492 P06396 Gelsolin  GSN   195 10 4 86043 5.17 88000 -1.02 0.69 -1.56 0.0052 -1.92 0.00025 -2.92 0.0043 3 
492 P21333 Filamin-A  FLNA   149 6 6 283301 5.17 88000 -1.02 0.69 -1.56 0.0052 -1.92 0.00025 -2.92 0.0043 3 
492 P07900 Heat shock protein HSP 90-alpha  HSP90AA1   148 5 5 85006 5.17 88000 -1.02 0.69 -1.56 0.0052 -1.92 0.00025 -2.92 0.0043 3 
492 O75369 Filamin-B  FLNB   105 4 4 280157 5.17 88000 -1.02 0.69 -1.56 0.0052 -1.92 0.00025 -2.92 0.0043 3 
497 P07900 Heat shock protein HSP 90-alpha  HSP90AA1   103 4 3 85006 5.7 90000 -1.04 0.67 -1.63 0.016 -1.55 0.00037 -2.17 0.013 3 
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604 P11021 78 kDa glucose-regulated protein  HSPA5   3062 99 34 72402 4.09 80000 -1.20 0.061 -1.74 0.0027 -1.62 0.0022 -9.47 0.00075 3 
604 P51884 Lumican  LUM   101 4 2 38747 4.09 80000 -1.20 0.061 -1.74 0.0027 -1.62 0.0022 -9.47 0.00075 3 
604 P14923 Junction plakoglobin  JUP   79 3 3 82434 4.09 80000 -1.20 0.061 -1.74 0.0027 -1.62 0.0022 -9.47 0.00075 3 
883 O60701 UDP-glucose 6-dehydrogenase  UGDH   753 29 14 55674 7.52 65000 -1.53 0.00022 -1.53 0.00011 1.02 0.84 -1.46 0.21 3 
883 P14866 
Heterogeneous nuclear ribonucleoprotein L  
HNRNPL   
575 20 6 64720 7.52 65000 -1.53 0.00022 -1.53 0.00011 1.02 0.84 -1.46 0.21 3 
883 P04040 Catalase  CAT   242 13 8 59947 7.52 65000 -1.53 0.00022 -1.53 0.00011 1.02 0.84 -1.46 0.21 3 
883 P30038 
Delta-1-pyrroline-5-carboxylate 
dehydrogenase, mitochondrial  ALDH4A1   
91 4 3 62137 7.52 65000 -1.53 0.00022 -1.53 0.00011 1.02 0.84 -1.46 0.21 3 
962 P78371 T-complex protein 1 subunit beta  CCT2   169 3 2 57794 5.9 59000 1.25 0.013 1.52 0.01 1.55 0.022 2.56 0.003 3 
1149 P31943 
Heterogeneous nuclear ribonucleoprotein H  
HNRNPH1   
827 28 10 49484 5.34 51000 -1.21 0.26 -1.64 0.033 -1.77 1.60E-05 -2.08 0.036 3 
1149 P05091 
Aldehyde dehydrogenase, mitochondrial  
ALDH2   
105 5 4 56859 5.34 51000 -1.21 0.26 -1.64 0.033 -1.77 1.00E+00 -2.08 0.036 3 
1210 P61158 Actin-related protein 3  ACTR3   119 4 4 47797 5.8 50000 1.02 0.99 -1.73 0.018 -4.03 0.0047 -1.93 0.027 3 
1210 P36957 
Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex, mitochondrial  DLST   
139 4 4 49067 5.8 50000 1.02 0.99 -1.73 0.018 -4.03 0.0047 -1.93 0.027 3 
1210 P35998 26S protease regulatory subunit 7  PSMC2   66 3 3 49002 5.8 50000 1.02 0.99 -1.73 0.018 -4.03 0.0047 -1.93 0.027 3 
1210 Q9BQE3 Tubulin alpha-1C chain  TUBA1C   47 2 2 50548 5.8 50000 1.02 0.99 -1.73 0.018 -4.03 0.0047 -1.93 0.027 3 
1212 Q5VTE0 
Putative elongation factor 1-alpha-like 3  
EEF1A1P5 PE=5  
365 17 9 50495 9 46000 -1.14 0.26 -1.76 0.0083 -2.11 0.0061 -8.86 0.00022 3 
1368 O75874 
Isocitrate dehydrogenase [NADP] cytoplasmic  
IDH1   
916 39 17 46915 7.5 42000 -1.33 0.0027 -2.15 9.00E-05 -3.09 4.90E-05 -4.11 2.10E-05 3 
1370 P00558 Phosphoglycerate kinase 1  PGK1   1016 38 19 44985 7.7 42000 -1.47 2.80E-05 -1.57 1.80E-05 1.07 0.69 -1.61 1.00E-01 3 
1370 P62333 26S protease regulatory subunit 10B  PSMC6   73 3 3 44430 7.7 42000 -0.47 1.00E+00 -0.57 1.00E+00 1.07 0.69 -1.61 1.00E-01 3 
1371 Q9UBG3 Cornulin  CRNN   205 8 4 53730 7.24 41000 -1.33 0.0032 -2.33 0.00018 -4.01 1.00E+00 -3.98 0.00016 3 
1371 P04083 Annexin A1  ANXA1   314 7 6 38918 7.24 41000 -1.33 0.0032 -2.33 0.00018 -4.01 2.10E-05 -3.98 0.00016 3 
1666 P04083 Annexin A1  ANXA1   1136 34 16 38918 6.87 25000 -1.05 0.24 -1.72 7.70E-05 -1.69 1.80E-05 -2.97 5.50E-08 3 
1666 Q9H9H4 
Vacuolar protein sorting-associated protein 37B  
VPS37B   
75 3 2 31345 6.87 25000 -1.05 0.24 -1.72 2.00E+00 0.31 2.00E+00 -0.97 5.50E-08 3 
1666 O00151 PDZ and LIM domain protein 1  PDLIM1   52 2 2 36505 6.87 25000 -1.05 0.24 -1.72 1.00E+00 -0.69 1.00E+00 -1.97 5.50E-08 3 
1997 P01834 Ig kappa chain C region IGKC 104 4 2 11773 4.2 15000 1.10 0.14 1.85 0.00037 1.44 0.0019 2.15 0.0011 3 
1997 P01593 Ig kappa chain V-I region AG 118 3 2 12099 4.2 15000 1.10 0.14 1.85 0.00037 1.44 0.0019 2.15 0.0011 3 
403 P55072 
Transitional endoplasmic reticulum ATPase  
VCP   
175 6 3 89950 4 100000 -1.22 0.027 -1.57 0.0065 -1.15 0.042 -2.75 1.50E-05 2 
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404 P55072 
Transitional endoplasmic reticulum ATPase  
VCP   
1177 36 16 89950 4.34 95000 -1.17 0.00077 -1.68 0.0054 -1.20 0.018 -2.16 0.0082 2 
745 P54652 Heat shock-related 70 kDa protein 2  HSPA2   603 25 13 70263 5 67000 1.64 0.037 1.52 0.18 1.21 0.25 -1.18 0.37 2 
745 P38646 Stress-70 protein, mitochondrial  HSPA9   105 4 3 73920 5 67000 1.64 0.037 1.52 0.18 1.21 0.25 -1.18 0.37 2 
754 P02545 Prelamin-A/C  LMNA   927 38 19 74380 7 65000 -1.12 0.23 -1.60 0.016 -1.25 0.044 -1.90 0.0047 2 
754 Q9NSD9 
Phenylalanine--tRNA ligase beta subunit  
FARSB   
173 8 6 66701 7 65000 -1.12 0.23 -1.60 0.016 -1.25 0.044 -1.90 0.0047 2 
754 Q9Y3Z3 
Deoxynucleoside triphosphate 
triphosphohydrolase  SAMHD1   
94 6 6 72896 7 65000 -1.12 0.23 -1.60 0.016 -1.25 0.044 -1.90 0.0047 2 
754 P51888 Prolargin  PRELP   167 6 4 44181 7 65000 -1.12 0.23 -1.60 0.016 -1.25 0.044 -1.90 0.0047 2 
767 Q02413 Desmoglein-1  DSG1   91 4 4 114702 7.31 70000 -1.12 0.068 -1.80 0.026 -1.39 0.062 -1.92 0.00056 2 
767 P02545 Prelamin-A/C  LMNA   101 3 3 74380 7.31 70000 -1.12 0.068 -1.80 0.026 -1.39 0.062 -1.92 0.00056 2 
864 P15924 Desmoplakin  DSP   604 20 16 334021 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 P10809 
60 kDa heat shock protein, mitochondrial  
HSPD1   
866 17 9 61187 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 P07339 Cathepsin D  CTSD   291 8 7 45037 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 P07355 Annexin A2  ANXA2   154 4 4 38808 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 Q13867 Bleomycin hydrolase  BLMH   76 3 2 53155 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 Q96QA5 Gasdermin-A  GSDMA   78 3 2 49619 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
864 P04040 Catalase  CAT   70 2 2 59947 4.43 65000 -1.11 0.28 -1.53 0.02 -1.37 0.0016 -2.45 0.028 2 
899 P04040 Catalase  CAT   1337 42 16 59947 7.64 61000 -1.64 0.0017 -1.82 0.0013 1.11 0.11 -1.37 0.13 2 
899 P14618 Pyruvate kinase PKM    506 15 8 58470 7.64 61000 -1.64 0.0017 -1.82 0.0013 1.11 0.11 -1.37 0.13 2 
899 Q99832 T-complex protein 1 subunit eta  CCT7   45 2 2 59842 7.64 61000 -1.64 0.0017 -1.82 0.0013 1.11 0.11 -1.37 0.13 2 
899 O60701 UDP-glucose 6-dehydrogenase  UGDH   82 2 2 55674 7.64 61000 -1.64 0.0017 -1.82 0.0013 1.11 0.11 -1.37 0.13 2 
998 P50995 Annexin A11  ANXA11   186 6 5 54697 8.04 57000 -1.32 0.046 -1.89 0.0072 -1.28 0.12 -2.43 0.04 2 
998 P00390 Glutathione reductase, mitochondrial  GSR   132 5 4 56791 8.04 57000 -1.32 0.046 -1.89 0.0072 -1.28 0.12 -2.43 0.04 2 
998 P34897 
Serine hydroxymethyltransferase, 
mitochondrial  SHMT2   
59 2 2 56414 8.04 57000 -1.32 0.046 -1.89 0.0072 -1.28 0.12 -2.43 0.04 2 
1150 P25705 
ATP synthase subunit alpha, mitochondrial  
ATP5A1   
402 14 7 59828 8.47 51000 -1.57 0.041 1.04 0.91 -1.25 0.029 -1.80 0.024 2 
1150 P14618 Pyruvate kinase PKM    39 2 2 58470 8.47 51000 -1.57 0.041 1.04 0.91 -1.25 0.029 -1.80 0.024 2 
1213 Q5VTE0 
Putative elongation factor 1-alpha-like 3  
EEF1A1P5 
256 9 5 50495 9.41 48000 -1.11 0.28 -1.68 0.011 -1.34 0.034 -9.97 8.00E-05 2 
1234 P17661 Desmin  DES   428 15 11 53560 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
1234 P60709 Actin, cytoplasmic 1  ACTB   552 11 6 42052 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
1234 P01009 Alpha-1-antitrypsin  SERPINA1   449 9 5 46878 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
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1234 P07437 Tubulin beta chain  TUBB   205 7 6 50095 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
1234 O60664 Perilipin-3  PLIN3   119 3 2 47217 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
1234 Q8TBC4 
NEDD8-activating enzyme E1 catalytic subunit  
UBA3   
50 2 2 52504 4.29 47000 -1.54 0.017 1.69 0.036 1.65 0.042 2.34 0.009 2 
1270 P06733 Alpha-enolase  ENO1   2245 68 20 47481 7.14 46000 -1.20 0.04 -1.79 8.90E-05 -1.18 0.083 -2.40 4.20E-04 2 
1270 Q9NVA2 Septin-11  SEPT11   205 7 4 49652 7.14 46000 -1.20 0.04 -1.79 1.00E+00 -1.18 0.083 -2.40 4.20E-04 2 
1319 P49411 Elongation factor Tu, mitochondrial  TUFM   1156 30 18 49852 7.14 43000 -1.27 0.011 -1.55 8.80E-05 -1.21 0.047 -2.92 6.50E-04 2 
1319 P06733 Alpha-enolase  ENO1   741 14 8 47481 7.14 43000 -1.27 0.011 -1.55 1.00E+00 -1.21 0.047 -2.92 6.50E-04 2 
1319 Q02413 Desmoglein-1  DSG1   216 7 7 114702 7.14 43000 -1.27 0.011 -1.55 2.00E+00 -1.21 0.047 -2.92 6.50E-04 2 
1319 P15924 Desmoplakin  DSP   67 5 5 334021 7.14 43000 -1.27 0.011 -1.55 3.00E+00 -1.21 0.047 -2.92 6.50E-04 2 
1319 P14923 Junction plakoglobin  JUP   132 3 3 82434 7.14 43000 -1.27 0.011 -1.55 4.00E+00 -1.21 0.047 -2.92 6.50E-04 2 
1319 Q08554 Desmocollin-1  DSC1   64 2 2 101406 7.14 43000 -1.27 0.011 -1.55 5.00E+00 -1.21 0.047 -2.92 6.50E-04 2 
1323 P60709 Actin, cytoplasmic 1  ACTB   242 8 5 42052 4.8 42000 -1.17 0.16 -1.71 0.0068 -1.88 0.0024 -1.06 0.65 2 
1323 P14923 Junction plakoglobin  JUP   61 3 3 82434 4.8 42000 -1.17 0.16 -1.71 0.0068 -1.88 0.0024 -1.06 0.65 2 
1323 P12277 Creatine kinase B-type  CKB   231 3 2 42902 4.8 42000 -1.17 0.16 -1.71 0.0068 -1.88 0.0024 -1.06 0.65 2 
1323 Q14240 Eukaryotic initiation factor 4A-II  EIF4A2   64 3 2 46601 4.8 42000 -1.17 0.16 -1.71 0.0068 -1.88 0.0024 -1.06 0.65 2 
1351 P00558 Phosphoglycerate kinase 1  PGK1   1922 58 19 44985 8.46 41000 -1.24 0.01 -1.77 0.011 -1.18 0.082 -4.95 0.00021 2 
1351 P50454 Serpin H1  SERPINH1   241 9 4 46525 8.46 41000 -1.24 0.01 -1.77 0.011 -1.18 0.082 -4.95 0.00021 2 
1351 P22695 
Cytochrome b-c1 complex subunit 2, 
mitochondrial  UQCRC2   
62 3 2 48584 8.46 41000 -1.24 0.01 -1.77 0.011 -1.18 0.082 -4.95 0.00021 2 
1515 P02675 Fibrinogen beta chain  FGB   546 23 10 56577 4.75 33000 -1.35 0.052 2.26 0.013 -1.46 0.01 1.52 0.048 2 
1515 P60709 Actin, cytoplasmic 1  ACTB   288 9 7 42052 4.75 33000 -1.35 0.052 2.26 0.013 -1.46 0.01 1.52 0.048 2 
1675 P02647 Apolipoprotein A-I  APOA1   1592 49 19 30759 4.3 28000 -1.21 0.064 -1.56 0.0025 -1.19 0.022 -2.24 0.0096 2 
1675 Q15181 Inorganic pyrophosphatase  PPA1   222 4 3 33095 4.3 28000 -1.21 0.064 -1.56 0.0025 -1.19 0.022 -2.24 0.0096 2 
1693 P04406 
Glyceraldehyde-3-phosphate dehydrogenase  
GAPDH   
1331 39 15 36201 7.5 28000 -1.21 0.005 -1.50 0.00069 -1.15 0.065 -2.93 6.70E-05 2 
1693 P40926 Malate dehydrogenase, mitochondrial  MDH2   695 22 11 35937 7.5 28000 -1.21 0.005 -1.50 0.00069 -1.15 0.065 -2.93 6.70E-05 2 
1693 P22626 
Heterogeneous nuclear ribonucleoproteins 
A2/B1  HNRNPA2B1   
400 17 9 37464 7.5 28000 -1.21 0.005 -1.50 0.00069 -1.15 0.065 -2.93 6.70E-05 2 
1850 P00915 Carbonic anhydrase 1  CA1   1838 49 10 28909 7.41 18000 -1.58 0.00092 -1.43 0.031 -1.51 0.00073 1.24 0.085 2 
1850 P25789 Proteasome subunit alpha type-4  PSMA4   66 3 2 29750 7.41 18000 -1.58 0.00092 -1.43 0.031 -1.51 0.00073 1.24 0.085 2 
1850 Q13126 
S-methyl-5~-thioadenosine phosphorylase  
MTAP   
126 3 2 31729 7.41 18000 -1.58 0.00092 -1.43 0.031 -1.51 0.00073 1.24 0.085 2 
1905  No identification      7.91 17000 -1.63 0.025 -1.01 0.91 -2.32 0.0059 1.23 0.31 2 
1924 P68871 Hemagloblin subuint beta HBB 1024 29 9 16102 8.25 16000 -1.71 0.014 1.00 0.92 -1.60 0.06 1.41 0.011 2 
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1924 P69905 Hemagloblin subuint alpha HBA1 290 13 5 15305 8.25 16000 -1.71 0.014 1.00 0.92 -1.60 0.06 1.41 0.011 2 
1924 P00915 Carbonic anhydrase 1  CA1   96 4 2 28909 8.25 16000 -1.71 0.014 1.00 0.92 -1.60 0.06 1.41 0.011 2 
1929 P68871 Hemagloblin subuint beta HBB 1564 41 11 16102 8.05 16000 -1.92 0.00051 -1.15 0.13 -1.85 0.029 1.44 0.0068 2 
1929 P69905 Hemagloblin subuint alpha HBA1 471 18 7 15305 8.05 16000 -1.92 0.00051 -1.15 0.13 -1.85 0.029 1.44 0.0068 2 
1929 P00915 Carbonic anhydrase 1  CA1   58 4 3 28909 8.05 16000 -1.92 0.00051 -1.15 0.13 -1.85 0.029 1.44 0.0068 2 
1932 P68871 Hemagloblin subuint beta HBB 558 19 9 16102 9 15000 -1.86 0.0019 -1.20 0.052 -2.18 0.025 1.27 0.095 2 
1932 P69905 Hemagloblin subuint alpha HBA1 204 7 4 15305 9 15000 -1.86 0.0019 -1.20 0.052 -2.18 0.025 1.27 0.095 2 
1942 P68871 Hemagloblin subuint beta HBB 849 26 10 16102 7.64 16000 -1.62 0.0011 -1.05 0.56 -1.99 0.014 1.06 0.61 2 
1942 P69905 Hemagloblin subuint alpha HBA1 250 8 5 15305 7.64 16000 -1.62 0.0011 -1.05 0.56 -1.99 0.014 1.06 0.61 2 
1947 P68871 Hemagloblin subuint beta HBB 621 17 8 16102 8.21 16000 -1.84 0.0011 -1.08 0.27 -1.74 0.012 1.09 0.58 2 
1947 P69905 Hemagloblin subuint alpha HBA1 445 17 7 15305 8.21 16000 -1.84 0.0011 -1.08 0.27 -1.74 0.012 1.09 0.58 2 
1948 P69905 Hemagloblin subuint alpha HBA1 245 9 5 15305 8.8 16000 -2.03 0.015 -1.12 0.39 -1.65 0.19 1.44 0.08 2 
1968 P68871 Hemagloblin subuint beta HBB 461 14 6 16102 7.54 16000 -1.52 0.0025 1.10 0.36 -1.79 0.057 -1.10 0.52 2 
1968 P69905 Hemagloblin subuint alpha HBA1 140 4 3 15305 7.54 16000 -1.52 0.0025 1.10 0.36 -1.79 0.057 -1.10 0.52 2 
2005 P04792 Heat shock protein beta-1  HSPB1   913 28 12 22826 6.88 34000 1.52 0.0036 -1.06 0.75 -1.29 0.07 1.92 0.0011 2 
2167 P08559 
Pyruvate dehydrogenase E1 component 
subunit alpha, somatic form, mitochondrial  
PDHA1   
66 3 2 43952 4.99 15000 -1.81 0.05 1.21 0.12 1.26 0.42 -1.46 0.0018 2 
2167 P06733 Alpha-enolase  ENO1   52 2 2 47481 4.99 15000 -1.81 0.05 1.21 0.12 1.26 0.42 -1.46 0.0018 2 
2175 P04792 Heat shock protein beta-1  HSPB1   813 29 12 22826 5.11 15000 1.67 0.0025 -1.39 0.23 -1.02 0.93 2.08 0.01 2 
2179   No identification         4 73000 1.55 0.23 2.42 0.038 1.22 0.68 3.17 0.00013 2 
Numerous spots were matched to more than one protein. Shading indicates altered expression (green increased; red decreased). Proteins of interest are shaded 
yellow. 
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4.5 Discussion 
Since multiple proteins were identified in many of the spots, it was difficult to assign 
which protein was responsible for the differences in expression. To address this, 
proteins were selected based on abundance, the number of matched peptides and 
matching of the theoretical and experimental molecular weight and isoelectric points. 
A total of 84 differentially expressed proteins were identified from the profiling. The 
differentially expressed proteins comprised cytoskeletal proteins, metabolic enzymes, 
extracellular matrix proteins, muscle proteins, serum proteins, haemoglobin and those 
involved in protein folding. 
The proteins of interest were ranked based on a score, which was higher if the protein 
showed the same directionality of altered expression between endometriosis and both 
controls groups, and did not change between the control groups (PS/CS). Thus, a 
protein was assigned a score of 4 if its expression displayed a significant increase (P 
≤0.05, ≤1.5-fold change) in the four comparisons ES/CS, ES/PS, EP/CP and EcS/ES. 
These proteins included; lumican, tropomyosin β chain and heterogeneous nuclear 
ribonucleoprotein A-1-like 2. 
Expression of lumican was higher in the endometriosis group compared to both the 
control and pain groups (ES/CS av. ratio=1.86, P=0.0051; ES/PS av. ratio=2.25, 
P=0.0043). Expression was also higher in the ectopic endometrial tissue compared to 
the eutopic endometrium in the secretory phase (EcS/ES av. ratio=2.09, P=0.008). 
Expression also differed between phases, with higher differential expression seen in 
the secretory phase. Lumican was also identified from several spots.   
Lumican is an extracellular matrix protein that is expressed in different tissues e.g. 
muscle, cartilage and cornea. It is a member of the small leucine rich proteoglycan 
(SLRP) family which comprises of 17 genes that share structural homologies e.g. 
cysteine residues, leucine rich repeats and at least one glycosaminoglycan chain. 
Members of this family have been reported to play a role in cell migration and 
proliferation during embryonic development, tissue repair and tumour growth. In 
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vitro, SLRPs have been shown to regulate collagen fibrillogenesis  (Ezura et al., 2000), 
a process important in development, tissue repair and metastasis. Altered expression 
of lumican has been demonstrated in several cancer types such as breast, colorectal, 
neuroendocrine, uterine, cervical, pancreatic, and lung (Koninger et al., 2004, Leygue 
et al., 1998, Lu et al., 2002, Shinji et al., 2005), with conflicting data on its role in 
promoting or abrogating tumour progression.  
The exact molecular function of lumican is poorly understood. It has been shown to 
down-regulate the proteolytic activities of MMP14 and MMP9 associated with 
endothelial cell membranes, thereby exerting an angiostatic effect (Brezillon et al., 
2013). In the endometrium, lumican is present in the ECM of pre-menopausal fertile 
women. Its expression has been reported to increase during the transition of the 
endometrium from the late proliferative to early secretory phase. The level of its 
expression decreases in menopausal women and in other pathological states. Its 
presence in the endometrium has been demonstrated in mice where it is spatially and 
temporally modulated in the pre-implantation period (San Martin et al., 2003). The 
role if any of lumican in endometriosis is unclear. The expression pattern in tissues 
shown from this profiling may suggest that lumican is involved in the proliferation, 
invasion and/or adhesion of ectopic endometrial cells to neighbouring peritoneal 
organs. Its usefulness as a biomarker of endometriosis is yet to be established. 
Tropomyosins are actin binding proteins that form the major structural constituent of 
microfilaments. High molecular weight tropomyosins (TPM1 and TPM2) are thought 
to play a role in stabilising the organisation of actin filaments, which in turn play a 
role in muscle contraction and the maintenance of cell shape, cell motility, cell-cell 
and cell-matrix interactions (Shah et al., 2001). The loss of tropomyosin expression 
reported in tumour cells may prevent proper assembly of microfilaments and thereby 
contribute to the invasive and metastatic properties of cancer cells (Shah et al., 2001). 
The role of tropomyosins in endometriosis is not well studied. Herein, TPM2 
expression was highest in ectopic endometrial tissue compared to eutopic tissue (av. 
ratio=4.65, P=0.001) and was increased in endometriosis compared to control and 
pain groups in the secretory phase, suggesting differential expression across the cycle. 
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Its differential expression possibly points to an involvement in cellular structural 
change occurring in the endometrium allowing refluxed endometrial cells to invade 
and adhere to peritoneal organs, eventually leading to disease development. Its 
potential as a biomarker of endometriosis has not been evaluated. 
Heterogeneous nuclear ribonucleoprotein A1-like 2 belongs to the A/B subfamily of 
ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs); RNA 
binding proteins that are associated with pre-mRNA in the nucleus and appear to 
influence pre-mRNA processing and other aspects of mRNA metabolism and 
transport. These proteins may have a primary role in the expression of specific 
myometrial protein species in parturition (Pollard et al., 2000). In this experiment, 
HNRNPA12 was down-regulated in both endometriosis compared to healthy and pain 
controls in the secretory phase (av. ratio= -1.43, P=0.04, av.ratio= -1.48, P=0.03 
respectively). A significant down-regulation of this protein was also observed in the 
ectopic tissue compared to eutopic endometrium in the secretory phase (av. ratio=-
5.71, P=0.0002). The potential role of this protein in endometriosis is unknown. 
4.6 Conclusion 
Gel-based proteomics is a well-established technique for global protein separation and 
quantification for profiling biological and clinical samples. Development of the 2D-
DIGE technique was a milestone in increasing the reproducibility of 2D-PAGE for 
more accurate quantification. 2D-DIGE was used successfully herein to profile 
endometrial and endometriosis tissue samples with the aim of identifying potential 
tissue biomarkers. One of the main challenges experienced in this analysis was 
contamination of the tissue samples with blood and serum proteins. Highly abundant 
serum proteins were identified in the preliminary analysis and were effectively 
lowering the load of tissue-derived proteins and could possibly obscure lower 
abundance proteins. To address this problem, an immunodepletion step was 
incorporated into the main workflow. Although this was not sufficient to remove all 
of these proteins (as evidenced by the presence of significant levels of serum albumin 
and other proteins targeted by the depletion), the complexity of the spot patterns was 
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improved. The identification of haemoglobin and several serum proteins as being 
differentially expressed, further highlights this contamination issue. This will have 
undoubtedly increase the false discovery rate and complicate candidate selection for 
verification. Another major challenge experienced was the presence of multiple 
cytokeratins and cytokeratin-related proteins. This may be due to contamination 
during sample processing, although one cannot rule out the possibility that these are 
bona fide endogenous proteins.  
The heterogeneous cellular composition of the tissues was evidenced by the presence 
of high abundance structural proteins known to be expressed by different cell types 
and these may also mask lower abundance proteins during the analysis. A possible 
explanation is the fibrous nature of some of the ectopic tissue samples which were 
nodular in nature and contained large amounts of fibro-muscular tissue. Another 
possible explanation for the differential expression of these proteins could be the use 
of ectopic tissue samples from different sites. This presents a challenge in that while 
some lesions may have clearly defined endometrial tissue, including glands and 
stroma, other lesions could only be clusters of a few cells and a single gland. This 
results in variability of the cellular composition of these different endometriosis lesion 
types thereby compromising the quality of the analysis. Whilst the pooling approach 
would average out some of this heterogeneity, it is possible that outlier samples may 
skew the data leading to a high false discovery rate in terms of identifying potential 
biomarkers.  
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CHAPTER 5: MS-BASED PROTEOMIC PROFILING OF ENDOMETRIAL 
TISSUE LYSATES 
5.1 Introduction 
The aim of the work presented in this chapter was to explore protein Tandem Mass 
Tag (TMT) labelling and separation as a potential method improving quantitative 
coverage in profiling endometrial and endometriosis tissue biopsies for biomarker 
discovery. The fractionation of intact proteins by molecular weight and charge 
potentially offers better separation than peptide-based methods due to the greater 
degree of heterogeneity of protein species versus their peptide components. 
Additionally multiple peptides from abundant proteins will be preferentially sampled 
across the entire chromatographic space in data-dependent mode at the expense of 
lower abundant peptides, thus reducing coverage of the proteome. However, the high 
level of TMT labelling required may be hard to achieve for proteins versus peptides 
due to secondary structure constraints. Lysine labelling will also block some tryptic 
sites so additional proteases should be used. Profiling with protein separation is also 
likely to be complementary to peptide-based profiling approaches when datasets are 
combined. A peptide-based labelling and separation approach that has previously 
shown high proteomic coverage in this lab was also used to profile the six 
immunodepleted tissue pools that were first digested with trypsin prior to TMT 
labelling and separation. A three dimensional separation approach was used to 
maximise the number of peptides for analysis by mass spectrometry. First dimension 
separation of peptides was achieved by SAX liquid chromatography, with the six 
collected fractions further separated in a second dimension by off-line high pH 
reverse-phase liquid chromatography prior to low pH nano-RPLC-MS/MS.   
5.2 Optimisation of protein TMT labelling and SAX fractionation 
Four steps were incorprated into this workflow namely; immunodepletion of abundant 
serum proteins from the tissue lysates, protein denaturation and labelling using TMT 
reagents for relative quantification,  SAX chromatography and SDS-PAGE for 
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separation, followed bydigestion and LC-MS/MS analysis. Tissue homogenisation 
and protein extraction was achieved as previously described (Chapter 2). Optimisation 
of protein labelling was carried out using pools of equal amounts of protein from each 
of three types of tissue lysate, namely; pool D1 (deep infiltrating endometriosis), pool 
E1 (ovarian endometriosis) and pool EU (eutopic endometrium). As well as 
optimising the strategy, this would allow the determination of any differences in 
protein levels in the different forms of endometriosis. 
Immunodepletion was carried out on pooled samples to improve coverage as 
previously described. Briefly, PP12 immunodepletion resin was used to deplete 500 
μg total protein from each pool giving a final protein yield of ~20%. Test samples 
were fractionated using SAX and 1D-SDS-PAGE prior to digestion. Different 
concentrations of elution buffers were tested. In the first test, pooled lysate was 
fractionated after immunodepletion without TMT labelling and proteins eluted from 
the SAX resin using 50 mM, 100 mM, 200 mM and 1M NaCl in 20 mM TEAB (Figure 
5.1A). 
Generally most proteins were eluted from the resin by 200 mM NaCl, however 
retention was still apparent. For this reoson, the elution steps were expanded at the 
higher salt concentrations in a second experiment where TMT labelling was 
incorporated. This generated somewhat improved separation although it was apparent 
that the more prominent protein bands were present across multiple fractions (Fig 5.1 
B). This also suggested that labelling affects the charge and hence retention of 
proteins. 
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Figure 5.1 Representative 1D gel images of SAX protein fractionation. 
 
Bands were cut from the 400 mM and 600 mM lanes on the second gel, digested 
sequentially with Glu-C then trypsin and analysed by LC-MS/MS. TMT labelling 
efficiency was determined to be ~95% with a total of 365 proteins identified. 
However, only 217 (60%) of the proteins had quantitative information. This was due 
to the identification of proteins using matched peptides that lacked a lysine residue 
and hence were not  labelled with a TMT tag. Proteins displaying a median reporter 
ion ratio of ≥1.5-fold were considered to be differentially regulated when comparing 
the pairs of tissue types; 108 proteins were differentially expressed in the comparison 
between ectopic ovarian tissue and eutopic tissue, whilst 50 proteins were 
differentially expressed between the DIE tissue compared to eutopic tissue (Fig. 5.2) 
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Figure 5.2 Graphical representation of differentially expressed proteins.The number of 
proteins displaying a fold-change of >1.5 for the different tissue comparisons are shown. 
 
The experiment was repeated on the full set of sample pools which were labelled with 
6-plex TMT tags for comparison of the CS, PS, ES, EcS, CP and EP groups using the 
higher NaCl concentrations for SAX elution. The fractions were run on a 1D-SDS-
PAGE gel (Fig 5.3). There were no clear protein bands seen from the gel indicating 
considerable protein loss. This loss might have occurred during concentration of the 
samples after immunodepletion and/or during denaturation, labelling and clean-up, 
and may have been exacerbated by poor SAX fractionation. 
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Figure 5.3 1D gel image of SAX fractions in the main protein profiling experiment. 
 
Despite the protein loss, 100 gel slices were excised from lanes 400 mM and 600 mM 
of the gel and digested with Glu-C and trypsin and analysed by LC-MS/MS. A total 
of 187 proteins were identified of which 109 (58%) proteins had quantitative 
information. This was somewhat lower coverage compared to the optimisation 
experiments because of the protein loss. Table 5.1  shows proteins identified and 
quantified across the different comparisons.. A scoring system was used to rank the 
proteins to aid in selection of proteins of interest. Proteins that showed the same 
directionality of altered expression (>1.5-fold) between endometriosis and both 
controls groups and between ectopic and eutopic tissue would be assigned a total score 
of 4, although no protein achieved this score. 
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Table 5.1 Quantified proteins from TMT-protein profiling of endometrial tissues. 
Accession Description 
Protein 
Score 
# 
Proteins 
# Unique 
Peptides 
# 
Peptides 
# 
PSMs 
Ratio 
130/126 
ES/CS 
130/126 
Count 
130/126 
Variability [%] 
Ratio 
130/128 
ES/PS 
130/128 
Count 
130/128 
Variability [%] 
Ratio 
131/127 
EP/CP 
127/131 
Count 
127/131 
Variability [%] 
Ratio 
129/130 
EcS/ES 
129/130 
Count 
129/130 
Variability [%] 
Biomarker 
Score 
P05546 Heparin cofactor 2 SERPIND1 54.22 1 1 1 2 1.748 1  1.197 1  4.444 1  3.394 1  3 
P09493 Tropomyosin alpha-1 chain TPM1 64.01 1 2 2 3 1.684 2 120.3 2.733 2 271.6 0.954 2 41.3 5.118 2 131.4 3 
P30740 
Leukocyte elastase inhibitor 
SERPINB1 
697.04 1 7 7 25 1.542 21 30.3 1.636 21 14 1.706 21 28.5 0.679 21 42.5 3 
P07355 Annexin A2 ANXA2 75.78 2 2 2 3 0.892 3 15 0.388 3 52.9 0.521 3 11.9 0.652 3 65.8 3 
Q9Y342 Plasmolipin PLLP 31.48 1 1 1 1 0.826 1  0.46 1  0.43 1  0.177 1  3 
P07384 Calpain-1 catalytic subunit CAPN1 64.34 1 2 2 2 0.663 1  0.573 1  0.695 1  0.601 1  3 
P53618 Coatomer subunit beta COPB1 25.64 1 1 1 1 0.494 1  0.392 1  0.799 1  0.325 1  3 
P06396 Gelsolin GSN 66.1 1 1 1 1 0.358 1  0.43 1  0.175 1  1.089 1  3 
P02679 Fibrinogen gamma chain FGG 39.38 1 1 1 1 6.887 1  5.607 1  0.435 1  0.951 1  2 
P08729 Keratin, type II cytoskeletal 7 KRT7 1602.97 5 8 12 41 6.179 11 62.5 2.185 11 42.5 1.497 11 69.3 0.133 11 90.7 2 
P02458 Collagen alpha-1(II) chain COL2A1 116.95 1 1 1 6 4.74 5 22 0.592 5 8.4 1.073 5 39.2 2.864 5 22.7 2 
P13647 Keratin, type II cytoskeletal 5 KRT5 1110.76 3 5 9 51 4.709 4 72.5 4.247 4 110 1.195 4 17.1 0.197 4 88.4 2 
P35908 Keratin, type II cytoskeletal 2 KRT2 19495.96 3 21 28 320 4.696 7 108.7 5.332 7 109.7 1.2 7 7.5 0.203 7 129.1 2 
P02538 
Keratin, type II cytoskeletal 6A 
KRT6A 
1737.7 3 2 10 70 4.696 7 108.7 5.332 7 109.7 1.2 7 7.5 0.203 7 129.1 2 
P48668 
Keratin, type II cytoskeletal 6C 
KRT6C 
1705.22 3 2 10 70 4.696 7 108.7 5.332 7 109.7 1.2 7 7.5 0.203 7 129.1 2 
Q03135 Caveolin-1 CAV1 30.59 1 1 1 1 1.916 1  1.247 1  1.307 1  4.173 1  2 
Q99715 Collagen alpha-1(XII) chain COL12A1 509.02 1 7 7 16 1.693 2 110.5 1.046 2 0.1 3.484 2 302.2 1.073 2 12 2 
P30041 Peroxiredoxin-6 PRDX6 128.49 1 1 1 4 1.693 4 12.7 0.967 4 8.6 1.745 4 8.9 1.08 4 34.5 2 
P61026 Ras-related protein Rab-10 RAB10 62.03 1 1 1 2 1.352 1  0.91 1  0.491 1  0.266 1  2 
P21333 Filamin-A FLNA 264.64 1 2 2 6 1.212 3 28.4 0.685 3 33.1 1.828 3 25.7 2.546 3 7.1 2 
P00738 Haptoglobin HP 168.08 1 4 4 7 1.082 6 6 1.176 6 14.1 1.686 6 26.4 3.881 6 24.5 2 
Q14315 Filamin-C FLNC 162.96 1 4 4 5 1.066 1  0.339 1  9.174 1  4.701 1  2 
P08758 Annexin A5 ANXA5 373.11 1 4 4 11 0.897 11 26.7 0.886 11 20.4 0.508 11 39.9 0.475 11 32 2 
Q06830 Peroxiredoxin-1 PRDX1 37.72 1 1 1 1 0.534 1  0.646 1  0.687 1  0.542 1  2 
P04264 Keratin, type II cytoskeletal 1 KRT1 33659.78 2 41 44 1000 0.524 2 9.4 2.113 2 111.4 0.603 2 21.8 0.669 2 98 2 
P01833 
Polymeric immunoglobulin receptor 
PIGR 
587.34 1 4 4 23 0.452 18 21.4 2.452 18 30.2 0.451 18 46.7 0.286 18 46.4 2 
P01009 Alpha-1-antitrypsin SERPINA1 608.07 1 9 9 23 0.318 7 100.8 1.039 7 17.9 1.647 7 1.2 2.977 7 126.2 2 
P19652 Alpha-1-acid glycoprotein 2 ORM2 54.64 1 1 2 2 0.218 1  1.629 1  0.357 1  4.093 1  2 
Q04695 
Keratin, type I cytoskeletal 17 
KRT17 
307.13 10 1 7 12 6.296 1  1.075 1  0.861 1  0.214 1  1 
P08779 
Keratin, type I cytoskeletal 16 
KRT16 
1241.61 14 1 9 68 4.1 4 28 0.946 4 7.8 0.811 4 30.7 0.147 4 132.3 1 
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P08727 
Keratin, type I cytoskeletal 19 
KRT19 
2225.31 10 7 17 127 3.382 37 72.3 0.805 37 35.3 0.864 37 27 0.248 37 59.8 1 
P27797 Calreticulin CALR 146.6 1 2 2 6 2.669 4 29.8 1.267 4 31 1.238 4 4 0.364 4 31.5 1 
P05787 Keratin, type II cytoskeletal 8 KRT8 5450.61 5 25 32 188 2.636 127 35.7 0.815 127 23.8 0.87 127 27.9 0.192 126 93.3 1 
Q6KB66 
Keratin, type II cytoskeletal 80 
KRT80 
489.22 2 1 5 23 2.48 15 77.5 0.738 15 27.2 0.98 15 36.7 0.349 15 151.8 1 
P02545 Prelamin-A/C LMNA 616.83 1 14 14 30 2.466 18 46.9 1.255 18 22.3 1.015 18 32.6 1.011 18 23.5 1 
P09012 
U1 small nuclear ribonucleoprotein 
A SNRPA 
158.8 1 3 3 5 2.37 1  1.186 1  0.829 1  0.418 1  1 
P05783 
Keratin, type I cytoskeletal 18 
KRT18 
5206.97 9 27 29 174 2.272 41 95.8 0.972 41 43.4 0.572 41 31.6 0.383 41 137.7 1 
P00488 
Coagulation factor XIII A chain 
F13A1 
139.56 1 1 1 5 2.158 3 48.1 1.203 3 5.4 0.503 3 4.6 0.989 3 24.5 1 
P67936 Tropomyosin alpha-4 chain TPM4 22.49 1 1 1 1 2.001 1  1.061 1  1.225 1  0.574 1  1 
P62995 
Transformer-2 protein homolog 
beta TRA2B 
551.69 1 3 3 13 1.999 11 31.7 1.136 11 17.8 1.314 11 23.9 0.409 11 80.2 1 
P08670 Vimentin VIM 117.17 7 3 4 8 1.93 7 93.7 1.154 7 48 0.955 7 28.5 0.539 7 145.8 1 
Q16629 
Serine/arginine-rich splicing factor 7 
SRSF7 
141.89 1 3 3 5 1.914 3 0.5 1.191 3 9.3 1.366 3 34.5 0.562 3 223.5 1 
P35237 Serpin B6 SERPINB6 808.17 1 8 8 27 1.66 11 29 0.985 11 22.2 1.404 11 22.8 0.96 11 37.6 1 
Q9NVD7 Alpha-parvin PARVA 657.83 1 3 3 13 1.435 3 20.4 0.944 3 0.3 0.887 3 4.3 1.636 3 18 1 
P01008 Antithrombin-III SERPINC1 3745.15 1 17 17 89 1.414 21 42.2 1.435 21 47.3 1.247 21 46.9 1.605 21 50.5 1 
O00264 
Membrane-associated 
progesterone receptor component 
1 PGRMC1 
529.48 1 3 3 16 1.372 16 9.3 1.746 16 20 0.864 16 10.5 0.308 16 39.2 1 
P51884 Lumican LUM 113.54 1 1 1 6 1.333 5 63.2 0.537 5 52.7 1.01 5 9.1 18.962 5 53.1 1 
P34741 Syndecan-2 SDC2 42.95 1 1 1 1 1.322 1  3.383 1  1.443 1  0.194 1  1 
P11142 
Heat shock cognate 71 kDa protein 
HSPA8 
2026.68 1 6 6 84 1.191 56 42.8 0.824 56 29.4 1.919 56 34.6 0.676 56 77.4 1 
Q15043 Zinc transporter ZIP14 SLC39A14 119.81 1 2 2 4 1.132 1  0.422 1  0.113 1  0.272 1  1 
P68871 Hemoglobin subunit beta HBB 1770.45 5 7 7 93 1.129 23 36.1 1.578 23 40 0.816 23 27.1 0.886 23 33.9 1 
P08107 
Heat shock 70 kDa protein 1A/1B 
HSPA1A 
888.11 2 2 2 167 1.019 1  0.61 1  1.374 1  0.812 1  1 
P02787 Serotransferrin TF 567.05 1 2 2 12 0.982 1  0.592 1  0.978 1  0.882 1  1 
P02792 Ferritin light chain FTL 2602.39 1 12 12 85 0.936 18 15.9 1.382 18 12 1.684 18 12.4 3.358 18 21.7 1 
Q14974 Importin subunit beta-1 KPNB1 327.89 1 2 2 7 0.931 1  1.131 1  0.573 1  1.164 1  1 
P48637 Glutathione synthetase GSS 234.04 1 1 1 7 0.927 7 3.5 1.021 7 3.5 2.198 7 101.4 1.164 7 3.4 1 
O15258 Protein RER1 37.81 1 1 1 1 0.921 1  1.038 1  1.506 1  1.171 1  1 
P05141 ADP/ATP translocase 2 SLC25A5 52.75 1 1 1 1 0.918 1  0.347 1  0.88 1  1.102 1  1 
O15260 Surfeit locus protein 4 SURF4 338.68 1 4 4 12 0.906 3 1.6 0.648 3 10.4 1.179 3 173.5 1.165 3 4.5 1 
P07942 Laminin subunit beta-1 283.15 2 3 3 10 0.901 8 46.6 0.499 8 10.8 1.368 8 38.1 1.016 8 59 1 
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O60884 
DnaJ homolog subfamily A member 
2 DNAJA2 
40.2 1 1 1 1 0.899 1  0.47 1  1.096 1  1.157 1  1 
P35579 Myosin-9 MYH9 321.49 1 3 3 12 0.892 7 7.5 0.48 7 31.7 1.174 7 5.5 0.735 7 44.8 1 
O75400 
Pre-mRNA-processing factor 40 
homolog A PRPF40A 
449.21 1 2 2 18 0.886 18 23.4 0.597 18 30.1 0.747 18 50.5 0.703 17 77.1 1 
Q01130 
Serine/arginine-rich splicing factor 2 
SRSF2 
157.17 1 2 2 6 0.861 6 55.4 0.652 6 17.6 0.857 6 11.4 0.701 3 89.3 1 
P17612 
cAMP-dependent protein kinase 
catalytic subunit alpha PRKACA 
187.51 2 2 2 5 0.855 4 62.9 0.644 4 57 0.91 4 3.1 0.668 4 24.1 1 
Q00610 Clathrin heavy chain 1 CLTC 59.17 1 1 1 3 0.724 2 38.3 0.613 2 105 0.687 2 8.1 0.722 2 80.5 1 
Q86VP6 
Cullin-associated NEDD8-
dissociated protein 1 CAND1 
84.6 1 1 1 1 0.67 1  0.446 1  0.71 1  1.39 1  1 
P01011 Alpha-1-antichymotrypsin SERPINA3 7285.6 1 20 20 215 0.614 101 64.9 1.076 101 27 1.247 101 19.4 1.367 101 34.7 1 
P01024 Complement C3 653.1 1 4 4 13 0.609 2 116.1 0.561 2 40.6 0.789 2 16.9 2.592 2 79.3 1 
P43652 Afamin AFM 153.57 1 1 1 7 0.367 4 36.9 1.064 4 8.9 0.855 4 60.3 1.852 4 41.2 1 
P02675 Fibrinogen beta chain FGB 44.97 1 1 1 1 1.444 1  1.015 1  0.942 1  1.228 1  0 
P63267 
Actin, gamma-enteric smooth 
muscle ACTG2 
5945.74 5 2 9 224 1.41 134 49.4 1.045 134 22.2 0.826 134 32.4 1.164 134 27.3 0 
P02790 Hemopexin HPX 120.54 1 2 2 4 1.357 3 3.1 1.268 3 3.9 1.067 3 7.2 2.572 3 20.8 0 
P14866 
Heterogeneous nuclear 
ribonucleoprotein L HNRNPL 
220.81 1 1 1 6 1.321 6 28.3 1.078 6 48.8 0.943 6 23.5 0.514 6 86 0 
P11021 
78 kDa glucose-regulated protein 
HSPA5 
390.59 1 4 4 9 1.318 4 17.2 1.055 4 11.2 1.148 4 36.9 0.303 4 46.7 0 
P07910 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 HNRNPC 
307.02 1 1 1 9 1.279 7 25.8 0.729 7 12.4 0.95 7 27.4 0.249 7 12.6 0 
P60709 Actin, cytoplasmic 1 ACTB 9252.18 7 7 13 271 1.258 167 47.8 1.045 167 18.7 0.842 167 38.5 1.164 167 22.2 0 
P13611 Versican core protein VCAN 72.25 1 1 1 2 1.215 2 8.8 1.238 2 2.3 0.99 2 19.8 0.787 2 4.4 0 
P27824 Calnexin CANX 4600.94 1 4 4 149 1.162 122 34.3 0.969 122 33.9 1.247 122 35 0.433 122 46.4 0 
P14625 Endoplasmin HSP90B1 31.49 1 1 1 1 1.084 1  0.697 1  1.05 1  0.168 1  0 
Q9BYX7 
Putative beta-actin-like protein 3 
POTEKP 
855.11 1 1 2 33 1.071 12 31.8 0.967 12 27.6 0.742 12 30.7 1.313 12 29.6 0 
P0CG48 Polyubiquitin-C UBC 330.11 4 4 4 19 1.038 14 15.4 0.869 14 18.2 0.721 14 23 0.718 14 27.3 0 
P09211 Glutathione S-transferase P GSTP1 664.79 1 3 3 20 1.032 10 23 0.888 10 30.7 1.038 10 38.9 0.724 10 40.5 0 
P07900 
Heat shock protein HSP 90-alpha 
HSP90AA1 
221.63 3 2 4 7 0.946 2 4.5 0.708 2 12.1 0.876 2 22.9 0.778 2 65.6 0 
Q15084 
Protein disulfide-isomerase A6 
PDIA6 
671.87 1 2 2 30 0.934 11 9.2 1.098 11 15 1.042 11 91.2 1.164 11 7.7 0 
P46940 
Ras GTPase-activating-like protein 
IQGAP1 
258.82 1 3 3 6 0.931 4 4.5 1.031 4 21.9 1.242 4 0.5 1.127 4 20.4 0 
P02751 Fibronectin FN1 1978.06 1 11 11 59 0.93 7 6.4 0.884 7 36.2 0.824 7 16.2 1.322 7 19 0 
P14384 Carboxypeptidase M CPM 38.45 1 1 1 1 0.929 1  1.092 1  0.745 1  1.164 1  0 
P08697 Alpha-2-antiplasmin SERPINF2 285.26 1 3 3 8 0.928 1  0.672 1  1.255 1  1.141 1  0 
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P02730 
Band 3 anion transport protein 
SLC4A1 
693.08 1 4 4 40 0.927 3 0 0.836 3 2.2 1.25 3 0 1.154 3 0.1 0 
P08236 Beta-glucuronidase GUSB 4745.09 1 21 21 109 0.927 16 0.2 1.045 16 6 1.247 16 15.3 1.164 16 0.8 0 
P08962 CD63 antigen CD63 48.71 1 1 1 1 0.927 1  1.045 1  1.247 1  1.164 1  0 
P02452 Collagen alpha-1(I) chain COL1A1 40 1 1 1 1 0.927 1  1.045 1  1.247 1  1.164 1  0 
P39656 DDOST 53.76 1 1 1 1 0.927 1  1.045 1  1.247 1  1.164 1  0 
P07099 Epoxide hydrolase 1 EPHX1 112.01 1 1 1 3 0.927 1  1.045 1  1.247 1  1.164 1  0 
Q13228 
Selenium-binding protein 1 
SELENBP1 
883.46 1 10 10 40 0.927 22 29.1 0.929 22 31.3 1.271 22 8.1 1.893 22 42.4 0 
Q13813 
Spectrin alpha chain, non-
erythrocytic 1 SPTAN1 
845.54 1 7 8 37 0.927 10 4.3 1.045 10 4.9 1.316 10 7.9 1.164 10 0.1 0 
P29401 Transketolase TKT 92.73 1 1 1 4 0.927 3 37.7 0.928 3 16.7 0.709 3 18.8 1.151 3 1.7 0 
P24821 Tenascin TNC 702.7 1 5 5 22 0.915 9 11.1 1.111 9 12.5 1.261 9 16 1.205 9 5.1 0 
P50395 
Rab GDP dissociation inhibitor beta 
GDI2 
2045.57 2 5 5 60 0.912 51 24.1 0.694 51 66.8 0.827 51 47.1 1.119 51 11 0 
P12814 Alpha-actinin-1 ACTN1 537.49 4 6 6 26 0.908 14 28.1 0.922 14 54.4 0.763 14 47.5 1.102 14 43.1 0 
P02794 Ferritin heavy chain FTH1 697.43 1 9 9 26 0.902 3 19.3 1.275 3 26.3 1.043 3 45.5 1.692 3 15.7 0 
P13667 
Protein disulfide-isomerase A4 
PDIA4 
128.17 1 2 2 6 0.899 4 21 0.819 4 13.7 0.706 4 35.5 0.247 4 19.8 0 
P05155 
Plasma protease C1 inhibitor 
SERPING1 
45.87 1 1 1 1 0.895 1  1.241 1  1.287 1  2.35 1  0 
Q05707 
Collagen alpha-1(XIV) chain 
COL14A1 
2474.99 1 11 11 79 0.85 31 13.3 0.974 31 18.5 0.767 31 66.7 3.781 31 73.7 0 
P68104 Elongation factor 1-alpha 1 EEF1A1 203.01 3 3 3 11 0.837 8 30.3 0.705 8 14.2 0.876 8 4.6 0.491 8 145 0 
P02768 Serum albumin ALB 51389.16 1 24 24 1529 0.837 167 20 0.982 167 32.4 1.247 167 45.8 2.04 167 61.4 0 
P26641 Elongation factor 1-gamma EEF1G 228.61 1 3 3 9 0.77 8 53.3 0.768 8 33.1 0.805 8 16.5 0.421 8 216.2 0 
P54725 
UV excision repair protein RAD23 
homolog A 
105.1 1 2 2 4 0.754 1  0.754 1  0.855 1  1.07 1  0 
Data was generated using Proteome Discoverer version 2.4. Protein changes are shown as median peptide reporter ion ratios for peptides matching that 
protein. Up-regulation in the different comparisons is displayed in shades of red and down-regulation is displayed in shades of blue. The protein score, 
numbers of proteins in the protein group, unique peptides, matched peptides, peptide spectral matches, reporter ion count, variability and ‘biomarker score’ 
are shown. 
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The proteins identified were enriched for classical serum proteins (n=18) and 
cytokeratins (n=12) reflecting contamination of the samples with blood and also 
perhaps contaminatio n from sample handling/processing. Extracelluar matrix 
proteins, cytoskeletal proteins, chaperones, mRNA processing poroteins and  several 
muscle-specific proteins were also represented, the latter indicative of the presence of 
myometrial cells in the samples. When comparing endometriosis and controls in the 
secretory phase, 28 proteins were identified as being overexpressed in, whilst 11 were 
under-expressed (Table 5.2). In the comparison of the endometriosis and pain groups, 
14 proteins were over-expressed, whilst 23 were under-expressed.12 and 13 proteins 
were similarly differentially regulated in proliferative phase endometriosis versus 
control samples . There were six non-serum proteins with a highest biomarker score 
of 3; tropomyosin alpha-1 chain (TPM1), annexin A2 (ANXA2), plasmolipin (PLLP), 
calpain-1 catalytic subunit (CAPN1), coatomer subunit beta (COPB1) and gelsolin 
(GSN). 
Table 5.2 Summary of numbers of differentially expressed proteins in each 
comparison 
 Over-expression Under-expression Total 
ES vs. CS 28 11 39 
ES vs. PS 14 23 37 
EP vs. CP 12 13 25 
EcS vs. ES 21 36 57 
TPM1 was up-regulated in endometriosis compared to pain in the secretory phase. 
This protein was also observed in the 2D-DIGE profiling, showing similar changes 
across the groups. Differential lumican expression was also found, although its altered 
expression in endometriosis versus pain was somewhat different between the 
experiments. Other proteins of interest included plasmolipin (PLLP) and membrane-
associated progesterone receptor component 1 (PGRMC1).  
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5.2.1 Profiling of endometrium tissues using a TMT peptide-based 3D-LC-
MS/MS strategy 
Profiling of pooled samples in the six clinical groups using a 3D-LC-MS/MS 
workflow with TMT peptide labelling identified a much more respectable 1,581 
proteins groups, of which 1,433 (91%) had quantitative information across all six 
clinical groups. The full list of protein IDs, peptide information and fold-changes 
across the six groups can be found in Additional Information. There were a 
considerable number of protein changes identified (Table 5.3 and Figure 5.4). Ineed 
the average overall percentage of proteins changing in expression greater than 1.5-
fold was 28% and as high as 49%.  For example, 474 proteins were differentially 
expressed at >1.5-fold between the secretory phase endometriosis and control groups 
with 232 proteins over-expressed and 242 under-expressed in this comparison. The 
largest differences were seen when comparing secretory phase ectopic and eutopic 
tissue with 313 proteins over-expressed and 386 under-expressed. This may be 
attributed to greater sample heterogeneity for the ectopic tissue samples and also 
variable levels of blood contamination. The lowest number of changes (14%) was 
observed in the proliferative phase endometriosis versus control group, possibly 
indicating that these samples are more homogeneous. 
Table 5.3 Summary of number of differentially expressed proteins (>1.5-fold) 
in each tissue comparison 
  
Over-expressed Under-expressed Total 
ES vs. CS 232 242 474 
ES vs. PS 298 97 395 
EP vs. CP 82 120 202 
EcS vs. ES 313 386 699 
PS vs. CS 191 337 528 
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Figure 5.4 Graphical display of the number of differentially expressed proteins in each 
comparison (>1.5 fold) 
 
A scoring system was devised to rank the proteins to aid in selection of biomarker 
candidates for verification. This involved summing of individual scores for each 
expression ratio, reporter ion count, variability and number of unique peptide 
sequences for each protein. An expression pattern score was added to this by reference 
to membership of one of five expression cluster groups, with a higher score given to 
those proteins differentially expressed in the endometriosis group versus both control 
groups, irrespective of cycle stage (Figure 5.5). The top scoring proteins are shown in 
Table 5.4. 
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Figure 5.5 Protein expression pattern clustering. 
GPRoX software was used to generate proteinexpression pattern clusters based on 
abundance ratios across the groups. Clusters were given a cluster score (lower panel) which 
was incorprated into the biomarker score.
Cluster Score Name 
Cluster 1 8 cycle-independent; up-regulated proteins; ectopic down 
Cluster 2 1 pain-specific; down-regulated 
Cluster 3 6 cycle-specific 
Cluster 4 4 cycle-independent; low fold-changes; ectopic up 
Cluster 5 2 pain specific; up-regulated 
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Accession Description 
Biomarker 
Score 
Classical 
serum 
protein 
RBC 
Protein POI 
Σ# Proteins 
in group Score ΣCoverage # AAs 
MW 
[kDa] 
calc. 
pI 
Σ# Unique 
Peptides 
Σ# 
Peptides 
Σ# 
PSMs 
Ratio 
130/126 
ES/CS 
Ratio 
130/128 
ES/PS 
Ratio 
131/127 
EP/CP 
Ratio 
129/130 
EcS/ES 
Ratio 
128/126 
PS/CS 
P02042 Hemoglobin subunit delta HBD - 
[HBD_HUMAN] 
24.2 
 
1 
 
2 53600 92.52 147 16.0 8.05 7 14 3664 3.357 3.512 0.921 0.936 1.005 
P14384 Carboxypeptidase M CPM - [CBPM_HUMAN] 24 
  
1 1 154 6.32 443 50.5 7.36 2 2 6 1.619 2.525 2.451 0.319 0.633 
P02549 Spectrin alpha chain, erythrocytic 1 SPTA1 - 
[SPTA1_HUMAN] 
24 
 
1 
 
1 1342 13.93 2419 279.8 5.05 22 22 38 2.907 3.041 0.938 0.633 0.871 
P02671 Fibrinogen alpha chain FGA - [FIBA_HUMAN] 23.8 1 
  
1 3116 30.83 866 94.9 6.01 25 26 103 8.515 13.491 0.920 0.862 0.809 
P02730 Band 3 anion transport protein SLC4A1 - 
[B3AT_HUMAN] 
23.6 
 
1 
 
1 1223 14.93 911 101.7 5.19 9 9 33 2.639 3.066 0.921 0.533 1.074 
P02675 Fibrinogen beta chain FGB - [FIBB_HUMAN] 23.4 1 
  
1 1208 46.03 491 55.9 8.27 16 16 62 5.924 9.261 0.855 1.264 0.737 
P32119 Peroxiredoxin-2 PRDX2 - [PRDX2_HUMAN] 23.2 
   
1 2422 52.53 198 21.9 5.97 14 15 112 2.649 3.043 1.032 0.815 0.847 
P69905 Hemoglobin subunit alpha HBA1 - 
[HBA_HUMAN] 
23.2 
 
1 
 
2 111145 78.17 142 15.2 8.68 15 15 4226 2.924 3.171 1.001 0.895 1.127 
P19013 Keratin, type II cytoskeletal 4 KRT4 - 
[K2C4_HUMAN] 
23 
   
7 678 19.66 534 57.2 6.61 5 11 28 2.931 8.667 2.032 0.317 0.298 
P68871 Hemoglobin subunit beta HBB - 
[HBB_HUMAN] 
23 
 
1 
 
2 142146 84.35 147 16.0 7.28 9 16 6548 2.853 3.499 0.942 0.892 0.937 
P11277 Spectrin beta chain, erythrocytic SPTB - 
[SPTB1_HUMAN] 
23 
 
1 
 
2 1333 11.00 2137 246.3 5.27 17 19 42 2.560 3.382 0.911 0.837 0.830 
P26599 Polypyrimidine tract-binding protein 1 PTBP1 
- [PTBP1_HUMAN] 
22.6 
  
1 3 264 23.92 531 57.2 9.17 7 8 11 2.646 2.771 0.953 0.377 0.787 
P02679 Fibrinogen gamma chain FGG - 
[FIBG_HUMAN] 
22.4 1 
  
1 1117 32.89 453 51.5 5.62 11 11 50 7.880 13.703 0.727 0.563 0.459 
P04040 Catalase CAT - [CATA_HUMAN] 22.2 
   
1 1220 29.79 527 59.7 7.39 12 12 38 2.772 2.800 1.043 1.150 1.176 
P00918 Carbonic anhydrase 2 CA2 - [CAH2_HUMAN] 22.2 
   
1 836 36.92 260 29.2 7.40 8 9 32 2.485 3.316 0.819 1.243 0.800 
P00491 Purine nucleoside phosphorylase PNP - 
[PNPH_HUMAN] 
21.4 
   
1 166 10.73 289 32.1 6.95 3 3 6 3.715 3.221 0.942 0.573 1.195 
P16157 Ankyrin-1 ANK1 - [ANK1_HUMAN] 21.2 
 
1 
 
1 301 4.25 1881 206.1 6.01 5 5 10 3.054 3.352 0.945 0.866 0.871 
P29373 Cellular retinoic acid-binding protein 2 
CRABP2 - [RABP2_HUMAN] 
21 
  
1 1 83 21.74 138 15.7 5.40 2 2 3 2.078 1.612 2.544 1.436 1.382 
Q14764 Major vault protein MVP - [MVP_HUMAN] 21 
  
1 1 151 4.03 893 99.3 5.48 3 3 7 0.143 0.158 0.425 10.978 0.894 
P69891 Hemoglobin subunit gamma-1 HBG1 - 
[HBG1_HUMAN] 
20.8 
 
1 
 
2 17502 64.63 147 16.1 7.20 1 10 1756 3.547 3.546 0.905 1.098 1.007 
P69892 Hemoglobin subunit gamma-2 HBG2 - 
[HBG2_HUMAN] 
20.8 
 
1 
 
2 17579 64.63 147 16.1 7.20 1 10 1759 3.546 3.545 0.905 1.099 1.007 
O75884 Putative hydrolase RBBP9 - [RBBP9_HUMAN] 20.4 
  
1 1 78 17.20 186 21.0 6.20 2 2 2 0.305 0.293 1.006 4.505 1.028 
Q01995 Transgelin TAGLN - [TAGL_HUMAN] 20.2 
  
1 2 2119 69.15 201 22.6 8.84 17 17 95 1.105 1.324 2.171 18.832 1.240 
Q01105 Protein SET - [SET_HUMAN] 20.2 
   
2 937 33.79 290 33.5 4.32 6 6 29 0.914 0.919 1.084 0.330 0.881 
A8MVG2 Putative selection and upkeep of 
intraepithelial T-cells protein 1 homolog 
SKINTL - [SKIT1_HUMAN] 
20.2 
   
1 1125 3.21 218 25.4 5.87 1 1 138 4.314 6.142 0.829 0.700 0.773 
P00738 Haptoglobin HP - [HPT_HUMAN] 20 1 
  
1 714 35.22 406 45.2 6.58 15 15 33 1.459 2.619 1.699 3.321 0.577 
P00915 Carbonic anhydrase 1 CA1 - [CAH1_HUMAN] 20 
   
1 5011 57.47 261 28.9 7.12 14 14 263 2.086 2.902 0.933 1.285 0.627 
Q00796 Sorbitol dehydrogenase SORD - 
[DHSO_HUMAN] 
20 
   
1 181 11.48 357 38.3 7.97 4 4 9 0.538 0.752 0.543 0.299 0.695 
O94788 Retinal dehydrogenase 2 ALDH1A2 - 
[AL1A2_HUMAN] 
19.4 
   
3 301 23.94 518 56.7 6.05 9 10 12 0.838 0.898 1.542 0.456 0.903 
Q13308 Inactive tyrosine-protein kinase 7 PTK7 - 
[PTK7_HUMAN] 
19.2 
   
1 362 2.71 1070 118.3 7.09 3 3 13 0.510 0.677 1.497 0.293 0.807 
P16949 Stathmin STMN1 - [STMN1_HUMAN] 19.2 
   
3 293 41.61 149 17.3 5.97 7 7 16 1.044 0.926 1.411 0.471 0.994 
P10909 Clusterin CLU - [CLUS_HUMAN] 19.2 1 
  
1 649 13.14 449 52.5 6.27 7 7 22 0.281 1.831 1.179 4.014 0.146 
Q6SPF0 Atherin SAMD1 - [SAMD1_HUMAN] 19 
  
1 1 25 2.23 538 56.0 7.58 1 1 1 3.178 3.470 1.757 0.566 0.903 
P06703 Protein S100-A6 S100A6 - [S10A6_HUMAN] 19 
  
1 1 762 55.56 90 10.2 5.48 5 5 47 1.379 1.653 0.795 3.364 0.774 
P0DJI8 Serum amyloid A-1 protein SAA1 - 
[SAA1_HUMAN] 
19 1 
  
2 77 11.48 122 13.5 6.79 1 1 2 9.667 10.125 0.594 1.832 0.942 
Q13263 Transcription intermediary factor 1-beta 
TRIM28 - [TIF1B_HUMAN] 
18.6 
  
1 1 320 5.99 835 88.5 5.77 7 7 19 0.841 0.800 1.135 0.497 1.086 
P09466 Glycodelin PAEP - [PAEP_HUMAN] 18.6 
  
1 1 698 12.78 180 20.6 5.57 2 2 18 0.622 0.863 0.950 0.210 0.705 
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P04843 Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 RPN1 - 
[RPN1_HUMAN] 
18.6 
   
1 1752 30.31 607 68.5 6.38 15 16 70 0.893 1.171 0.936 0.396 0.865 
P11171 Protein 4.1 EPB41 - [41_HUMAN] 18.6 
 
1 
 
1 273 6.48 864 97.0 5.58 4 4 7 2.388 3.231 0.833 0.823 0.764 
P02751 Fibronectin FN1 - [FINC_HUMAN] 18.4 
   
1 251 4.07 2386 262.5 5.71 8 8 9 2.706 1.288 0.630 2.104 2.005 
P07741 Adenine phosphoribosyltransferase APRT - 
[APT_HUMAN] 
18.2 
   
1 729 32.78 180 19.6 6.02 4 5 31 2.260 1.612 0.921 1.436 1.258 
P07305 Histone H1.0 H1F0 - [H10_HUMAN] 18.2 
   
1 120 8.76 194 20.9 10.84 2 2 6 3.084 1.811 0.828 2.121 1.675 
Q96KP4 Cytosolic non-specific dipeptidase CNDP2 - 
[CNDP2_HUMAN] 
18.2 
   
1 1519 48.84 475 52.8 5.97 16 16 43 0.724 1.078 0.535 0.333 0.710 
P0CG48 Polyubiquitin-C UBC - [UBC_HUMAN] 18.2 
   
4 681 44.67 685 77.0 7.66 4 4 23 0.282 1.407 0.430 4.231 0.230 
P06401 Progesterone receptor PGR - 
[PRGR_HUMAN] 
18 
  
1 1 37 1.39 933 98.9 6.49 1 1 1 1.415 1.762 2.420 0.321 0.792 
P49959 Double-strand break repair protein MRE11A 
- [MRE11_HUMAN] 
18 
   
1 42 1.84 708 80.5 5.90 1 1 2 22.475 11.335 1.253 0.161 1.956 
Q92598 Heat shock protein 105 kDa HSPH1 - 
[HS105_HUMAN] 
18 
   
1 26 0.82 858 96.8 5.39 1 1 1 5.432 3.687 1.231 0.390 1.453 
P21964 Catechol O-methyltransferase COMT - 
[COMT_HUMAN] 
18 
   
1 31 2.95 271 30.0 5.47 1 1 1 2.446 3.077 0.955 0.326 0.784 
Q8IZ73 RNA pseudouridylate synthase domain-
containing protein 2 RPUSD2 - 
[RUSD2_HUMAN] 
18 
   
1 35 1.28 545 61.3 7.17 1 1 3 24.809 15.889 0.571 0.367 1.540 
P00167 Cytochrome b5 CYB5A - [CYB5_HUMAN] 18 
   
1 692 55.97 134 15.3 4.96 7 7 29 0.835 0.880 0.205 0.979 0.948 
P14678 Small nuclear ribonucleoprotein-associated 
proteins B and B' SNRPB - [RSMB_HUMAN] 
17.8 
   
2 83 9.58 240 24.6 11.19 3 3 4 0.779 1.058 1.350 0.072 0.677 
Q14980 Nuclear mitotic apparatus protein 1 NUMA1 
- [NUMA1_HUMAN] 
17.8 
   
1 311 6.05 2115 238.1 5.78 10 11 15 0.930 0.743 1.327 0.452 1.063 
P05387 60S acidic ribosomal protein P2 RPLP2 - 
[RLA2_HUMAN] 
17.8 
   
1 219 46.09 115 11.7 4.54 4 5 6 0.292 1.764 1.118 0.268 0.204 
P14625 Endoplasmin HSP90B1 - [ENPL_HUMAN] 17.8 
   
2 2266 37.24 803 92.4 4.84 27 29 86 0.805 1.027 1.071 0.482 0.768 
P50454 Serpin H1 SERPINH1 - [SERPH_HUMAN] 17.6 1 
  
1 2078 42.58 418 46.4 8.69 17 17 82 0.955 0.963 1.539 0.678 0.904 
P17661 Desmin DES - [DESM_HUMAN] 17.6 
   
4 4279 67.23 470 53.5 5.27 24 30 216 0.904 0.930 1.381 3.056 1.063 
P59665 Neutrophil defensin 1 DEFA1 - 
[DEF1_HUMAN] 
17.6 
   
2 137 20.21 94 10.2 6.99 3 3 11 0.325 2.476 1.315 4.989 0.133 
P02787 Serotransferrin TF - [TRFE_HUMAN] 17.6 1 
  
1 2077 49.86 698 77.0 7.12 29 29 75 0.778 1.501 1.184 3.285 0.503 
P09651 Heterogeneous nuclear ribonucleoprotein 
A1 HNRNPA1 - [ROA1_HUMAN] 
17.6 
   
2 2159 38.44 372 38.7 9.13 9 13 68 0.468 1.240 1.127 0.316 0.303 
P49756 RNA-binding protein 25 RBM25 - 
[RBM25_HUMAN] 
17.6 
   
1 156 2.37 843 100.1 6.32 3 3 12 2.260 1.599 1.122 1.436 1.382 
Q00610 Clathrin heavy chain 1 CLTC - 
[CLH1_HUMAN] 
17.6 
   
2 1215 17.79 1675 191.5 5.69 22 22 55 0.628 0.801 0.994 0.545 0.842 
Q05682 Caldesmon CALD1 - [CALD1_HUMAN] 17.4 
   
1 677 7.06 793 93.2 5.66 6 6 25 1.162 0.950 1.260 7.685 1.223 
Q14257 Reticulocalbin-2 RCN2 - [RCN2_HUMAN] 17.4 
   
1 539 27.76 317 36.9 4.40 6 6 14 1.054 0.889 1.200 0.488 0.990 
P02545 Prelamin-A/C LMNA - [LMNA_HUMAN] 17.4 
   
1 3831 50.30 664 74.1 7.02 39 41 174 0.918 0.801 1.052 3.330 1.148 
P01011 Alpha-1-antichymotrypsin SERPINA3 - 
[AACT_HUMAN] 
17.4 1 
  
1 933 15.37 423 47.6 5.52 7 7 34 0.731 1.056 1.013 3.257 0.716 
Q7KZ85 Transcription elongation factor SPT6 SUPT6H 
- [SPT6H_HUMAN] 
17.4 
   
1 53 0.98 1726 198.9 4.91 1 2 6 2.143 3.101 0.960 0.843 0.682 
P23284 Peptidyl-prolyl cis-trans isomerase B PPIB - 
[PPIB_HUMAN] 
17.4 
   
1 692 53.70 216 23.7 9.41 13 13 33 0.837 0.929 0.925 0.565 0.821 
Q9HC84 Mucin-5B MUC5B - [MUC5B_HUMAN] 17.2 
  
1 1 471 3.31 5762 596.0 6.64 12 12 18 0.193 3.853 0.386 0.650 0.088 
P46783 40S ribosomal protein S10 RPS10 - 
[RS10_HUMAN] 
17.2 
   
1 74 10.91 165 18.9 10.15 2 2 3 0.516 1.987 1.734 0.241 0.263 
P27635 60S ribosomal protein L10 RPL10 - 
[RL10_HUMAN] 
17.2 
   
2 125 11.68 214 24.6 10.08 3 3 4 1.097 1.136 1.441 0.242 0.952 
P13667 Protein disulfide-isomerase A4 PDIA4 - 
[PDIA4_HUMAN] 
17.2 
   
1 776 26.36 645 72.9 5.07 16 16 31 0.976 0.969 1.191 0.543 0.982 
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Q13247 Serine/arginine-rich splicing factor 6 SRSF6 - 
[SRSF6_HUMAN] 
17.2 
   
3 242 18.02 344 39.6 11.43 6 6 12 0.882 0.930 0.966 0.446 0.982 
P27797 Calreticulin CALR - [CALR_HUMAN] 17.2 
   
1 1868 29.02 417 48.1 4.44 11 11 71 1.036 1.223 0.954 0.540 0.877 
P04921 Glycophorin-C GYPC - [GLPC_HUMAN] 17.2 
 
1 
 
1 366 20.31 128 13.8 4.84 1 1 6 2.281 2.069 0.929 1.555 0.983 
P54819 Adenylate kinase 2, mitochondrial AK2 - 
[KAD2_HUMAN] 
17.2 
   
1 515 24.27 239 26.5 7.81 5 5 13 0.902 1.066 0.901 0.378 0.743 
Q9NR12 PDZ and LIM domain protein 7 PDLIM7 - 
[PDLI7_HUMAN] 
17 
  
1 1 56 2.41 457 49.8 8.41 1 1 1 0.286 0.390 1.499 60.688 0.724 
P51884 Lumican LUM - [LUM_HUMAN] 17 
  
1 1 1340 41.72 338 38.4 6.61 13 13 51 1.021 0.952 1.216 14.892 1.033 
P60660 Myosin light polypeptide 6 MYL6 - 
[MYL6_HUMAN] 
17 
  
1 4 2726 88.74 151 16.9 4.65 12 12 92 1.378 0.878 1.148 5.003 1.382 
P85037 Forkhead box protein K1 FOXK1 - 
[FOXK1_HUMAN] 
17 
   
1 31 1.23 733 75.4 9.32 1 1 2 0.462 2.505 5.066 0.477 0.182 
P12111 Collagen alpha-3(VI) chain COL6A3 - 
[CO6A3_HUMAN] 
17 
   
1 687 5.19 3177 343.5 6.68 12 12 27 1.933 1.254 1.209 18.478 1.597 
P36955 Pigment epithelium-derived factor SERPINF1 
- [PEDF_HUMAN] 
17 1 
  
1 506 12.44 418 46.3 6.38 4 4 14 2.224 1.587 1.171 1.458 1.381 
P60174 Triosephosphate isomerase TPI1 - 
[TPIS_HUMAN] 
17 
   
1 2705 80.07 286 30.8 5.92 22 22 83 0.853 1.052 1.069 0.635 0.775 
P27105 Erythrocyte band 7 integral membrane 
protein STOM - [STOM_HUMAN] 
17 
 
1 
 
1 138 10.42 288 31.7 7.88 2 2 5 3.050 3.058 1.033 0.941 0.984 
Q9BT73 Proteasome assembly chaperone 3 PSMG3 - 
[PSMG3_HUMAN] 
17 
   
1 35 8.20 122 13.1 7.88 1 1 1 2.647 3.041 0.989 1.794 0.858 
P49411 Elongation factor Tu, mitochondrial TUFM - 
[EFTU_HUMAN] 
17 
   
1 1069 28.32 452 49.5 7.61 10 10 29 0.948 0.903 0.981 0.622 1.002 
A8MYA2 Uncharacterized protein CXorf49 - 
[CX049_HUMAN] 
17 
   
1 4395 2.33 514 54.4 9.03 1 1 627 2.260 1.612 0.921 1.436 1.382 
P16452 Erythrocyte membrane protein band 4.2 
EPB42 - [EPB42_HUMAN] 
17 
 
1 
 
1 228 2.75 691 77.0 8.09 1 1 15 2.722 2.844 0.827 0.573 0.944 
P05023 Sodium/potassium-transporting ATPase 
subunit alpha-1 ATP1A1 - [AT1A1_HUMAN] 
17 
   
6 424 8.31 1023 112.8 5.49 8 8 17 0.779 0.658 0.600 0.565 0.716 
P02766 Transthyretin TTR - [TTHY_HUMAN] 16.8 1 
  
1 1022 69.39 147 15.9 5.76 8 8 23 0.974 1.938 1.293 4.226 0.496 
O60701 UDP-glucose 6-dehydrogenase UGDH - 
[UGDH_HUMAN] 
16.8 
   
1 305 21.05 494 55.0 7.12 7 7 10 0.911 1.047 1.191 0.426 0.716 
P09012 U1 small nuclear ribonucleoprotein A SNRPA 
- [SNRPA_HUMAN] 
16.8 
   
2 102 9.22 282 31.3 9.83 3 3 5 0.792 1.132 1.174 0.305 0.669 
P06748 Nucleophosmin NPM1 - [NPM_HUMAN] 16.8 
   
1 995 47.28 294 32.6 4.78 11 11 51 0.821 0.962 1.022 0.524 0.834 
P09525 Annexin A4 ANXA4 - [ANXA4_HUMAN] 16.8 
   
1 2615 63.32 319 35.9 6.13 21 22 104 0.856 1.037 0.881 0.642 0.716 
Q15293 Reticulocalbin-1 RCN1 - [RCN1_HUMAN] 16.8 
   
1 390 23.87 331 38.9 5.00 7 7 18 0.774 0.975 0.753 0.538 0.689 
P07951 Tropomyosin beta chain TPM2 - 
[TPM2_HUMAN] 
16.6 
  
1 1 4277 49.65 284 32.8 4.70 6 25 178 0.988 1.032 1.239 9.162 0.913 
P06702 Protein S100-A9 S100A9 - [S10A9_HUMAN] 16.6 
   
1 286 34.21 114 13.2 6.13 3 3 7 0.406 7.751 2.632 7.255 0.061 
P09455 Retinol-binding protein 1 RBP1 - 
[RET1_HUMAN] 
16.6 1 
  
1 290 48.15 135 15.8 5.11 6 6 8 0.425 1.697 1.731 0.749 0.287 
Q99729 Heterogeneous nuclear ribonucleoprotein 
A/B HNRNPAB - [ROAA_HUMAN] 
16.6 
   
1 58 2.41 332 36.2 8.21 1 1 2 0.656 1.233 1.594 0.078 0.525 
P08865 40S ribosomal protein SA RPSA - 
[RSSA_HUMAN] 
16.6 
   
1 363 29.49 295 32.8 4.87 7 7 15 1.022 1.106 1.363 0.691 1.055 
P09493 Tropomyosin alpha-1 chain TPM1 - 
[TPM1_HUMAN] 
16.6 
   
1 4361 47.18 284 32.7 4.74 8 25 186 1.004 1.007 1.245 10.119 0.964 
P20774 Mimecan OGN - [MIME_HUMAN] 16.6 
   
1 731 31.88 298 33.9 5.63 9 9 28 0.831 0.798 1.212 20.121 0.905 
P01009 Alpha-1-antitrypsin SERPINA1 - 
[A1AT_HUMAN] 
16.6 1 
  
2 1713 33.01 418 46.7 5.59 14 14 75 0.438 1.878 1.144 4.483 0.202 
O00264 Membrane-associated progesterone 
receptor component 1 PGRMC1 - 
[PGRC1_HUMAN] 
16.4 
  
1 1 191 15.90 195 21.7 4.70 4 4 8 1.013 1.035 1.561 0.609 1.228 
P24821 Tenascin TNC - [TENA_HUMAN] 16.4 
  
1 1 83 3.13 2201 240.7 4.89 5 5 5 1.817 1.682 1.502 1.151 1.022 
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Q14978 Nucleolar and coiled-body phosphoprotein 1 
NOLC1 - [NOLC1_HUMAN] 
16.4 
   
1 120 2.15 699 73.6 9.47 1 1 3 1.122 0.908 2.007 0.337 1.219 
P67936 Tropomyosin alpha-4 chain TPM4 - 
[TPM4_HUMAN] 
16.4 
   
2 4288 77.02 248 28.5 4.69 12 30 201 1.014 1.023 1.230 7.301 0.918 
Q6NZI2 Polymerase I and transcript release factor 
PTRF - [PTRF_HUMAN] 
16.4 
   
1 334 17.95 390 43.4 5.60 7 8 14 1.313 0.690 1.210 10.697 1.467 
P08729 Keratin, type II cytoskeletal 7 KRT7 - 
[K2C7_HUMAN] 
16.4 
   
6 1531 41.36 469 51.4 5.48 14 20 105 0.887 1.008 1.113 2.509 1.000 
P21796 Voltage-dependent anion-selective channel 
protein 1 VDAC1 - [VDAC1_HUMAN] 
16.4 
   
2 514 36.75 283 30.8 8.54 8 8 14 1.155 1.067 0.719 0.384 1.031 
P36542 ATP synthase subunit gamma, mitochondrial 
ATP5C1 - [ATPG_HUMAN] 
16.2 
   
1 175 15.10 298 33.0 9.22 4 4 9 0.917 1.791 1.261 0.611 0.521 
P08133 Annexin A6 ANXA6 - [ANXA6_HUMAN] 16.2 
   
1 2095 38.63 673 75.8 5.60 22 23 75 1.057 0.852 1.191 2.891 1.105 
P10809 60 kDa heat shock protein, mitochondrial 
HSPD1 - [CH60_HUMAN] 
16.2 
   
1 2447 56.20 573 61.0 5.87 30 30 93 1.161 0.993 1.104 0.657 0.999 
Q14697 Neutral alpha-glucosidase AB GANAB - 
[GANAB_HUMAN] 
16.2 
   
1 512 16.31 944 106.8 6.14 13 13 23 0.685 1.131 1.018 0.603 0.597 
P51991 Heterogeneous nuclear ribonucleoprotein 
A3 HNRNPA3 - [ROA3_HUMAN] 
16.2 
   
1 899 27.25 378 39.6 9.01 8 11 30 0.410 1.027 1.018 0.531 0.452 
P53999 Activated RNA polymerase II transcriptional 
coactivator p15 SUB1 - [TCP4_HUMAN] 
16.2 
   
1 245 15.75 127 14.4 9.60 2 2 7 0.385 1.386 0.910 0.319 0.256 
P52907 F-actin-capping protein subunit alpha-1 
CAPZA1 - [CAZA1_HUMAN] 
16.2 
   
1 145 18.53 286 32.9 5.69 4 4 7 3.031 1.078 0.885 1.459 1.280 
Q02818 Nucleobindin-1 NUCB1 - [NUCB1_HUMAN] 16.2 
   
1 483 25.38 461 53.8 5.25 9 9 18 0.793 0.943 0.861 0.530 0.711 
Q02252 Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial 
ALDH6A1 - [MMSA_HUMAN] 
16.2 
   
1 239 8.22 535 57.8 8.50 5 5 11 0.664 0.840 0.548 0.382 0.741 
Q6PF15 Kelch-like protein 35 KLHL35 - 
[KLH35_HUMAN] 
16 
   
1 44 2.57 583 62.9 7.83 1 2 4 29.628 4.085 3.745 0.823 7.155 
P21333 Filamin-A FLNA - [FLNA_HUMAN] 16 
   
1 2103 23.31 2647 280.6 6.06 41 44 77 1.227 0.967 1.509 2.216 1.357 
P51888 Prolargin PRELP - [PRELP_HUMAN] 16 
   
1 84 6.81 382 43.8 9.38 3 3 5 0.504 0.471 1.466 33.466 1.145 
P22105 Tenascin-X TNXB - [TENX_HUMAN] 16 
   
2 85 2.12 4289 464.0 5.34 3 3 3 1.548 1.570 1.155 2.143 0.973 
P30043 Flavin reductase (NADPH) BLVRB - 
[BLVRB_HUMAN] 
16 
   
1 897 50.00 206 22.1 7.65 7 7 34 1.620 2.564 1.051 1.372 0.710 
P07738 Bisphosphoglycerate mutase BPGM - 
[PMGE_HUMAN] 
16 
   
1 54 4.63 259 30.0 6.54 1 1 2 3.572 3.046 0.925 0.847 1.157 
P62195 26S protease regulatory subunit 8 PSMC5 - 
[PRS8_HUMAN] 
16 
   
1 240 10.34 406 45.6 7.55 2 3 7 2.260 1.612 0.921 1.436 1.382 
P49748 Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial ACADVL - 
[ACADV_HUMAN] 
16 
   
1 100 5.80 655 70.3 8.75 3 3 4 2.260 1.612 0.921 1.436 1.382 
Q05707 Collagen alpha-1(XIV) chain COL14A1 - 
[COEA1_HUMAN] 
16 
   
1 1210 13.36 1796 193.4 5.30 18 18 49 1.294 0.834 0.898 10.120 1.426 
P78527 DNA-dependent protein kinase catalytic 
subunit PRKDC - [PRKDC_HUMAN] 
16 
   
1 30 0.19 4128 468.8 7.12 1 1 1 0.313 0.510 0.733 0.279 0.605 
P10412 Histone H1.4 HIST1H1E - [H14_HUMAN] 16 
   
3 431 32.88 219 21.9 11.03 2 10 24 2.349 1.835 0.509 1.323 1.559 
P16401 Histone H1.5 HIST1H1B - [H15_HUMAN] 16 
   
1 172 11.06 226 22.6 10.92 2 4 11 2.625 1.714 0.508 0.986 1.506 
P0C0S5 Histone H2A.Z H2AFZ - [H2AZ_HUMAN] 15.8 
   
2 237 31.25 128 13.5 10.58 2 4 14 0.642 1.584 1.217 0.744 1.025 
P02647 Apolipoprotein A-I APOA1 - 
[APOA1_HUMAN] 
15.8 1 
  
1 1131 46.44 267 30.8 5.76 15 16 57 0.349 2.125 1.169 3.265 0.150 
Q9Y490 Talin-1 TLN1 - [TLN1_HUMAN] 15.8 
   
1 2009 14.25 2541 269.6 6.07 23 30 64 1.351 1.474 1.142 1.038 0.949 
P04792 Heat shock protein beta-1 HSPB1 - 
[HSPB1_HUMAN] 
15.8 
   
1 1495 43.41 205 22.8 6.40 8 8 69 1.298 0.775 1.077 4.369 1.586 
P49419 Alpha-aminoadipic semialdehyde 
dehydrogenase ALDH7A1 - [AL7A1_HUMAN] 
15.8 
   
1 98 8.35 539 58.5 7.99 2 2 3 2.197 1.568 1.042 1.436 1.382 
Q13838 Spliceosome RNA helicase DDX39B - 
[DX39B_HUMAN] 
15.8 
   
2 543 36.68 428 49.0 5.67 11 11 24 0.717 0.884 1.023 0.611 0.647 
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Q13151 Heterogeneous nuclear ribonucleoprotein 
A0 HNRNPA0 - [ROA0_HUMAN] 
15.8 
   
1 158 16.39 305 30.8 9.29 3 5 7 0.731 1.743 0.960 0.136 0.413 
P01859 Ig gamma-2 chain C region IGHG2 - 
[IGHG2_HUMAN] 
15.8 1 
  
1 976 31.60 326 35.9 7.59 5 10 77 1.195 1.620 0.777 2.720 0.729 
P07355 Annexin A2 ANXA2 - [ANXA2_HUMAN] 15.8 
   
2 6078 69.62 339 38.6 7.75 26 26 208 0.754 0.731 0.655 2.435 1.127 
P62191 26S protease regulatory subunit 4 PSMC1 - 
[PRS4_HUMAN] 
15.8 
   
1 98 9.77 440 49.2 6.21 2 3 3 2.369 1.891 0.425 0.728 1.236 
Q9UNM6 26S proteasome non-ATPase regulatory 
subunit 13 PSMD13 - [PSD13_HUMAN] 
15.8 
   
1 127 9.04 376 42.9 5.81 2 2 2 1.164 4.359 0.342 0.216 0.263 
Q8N684 Cleavage and polyadenylation specificity 
factor subunit 7 CPSF7 - [CPSF7_HUMAN] 
15.6 
   
1 41 5.31 471 52.0 8.00 1 1 2 0.488 2.108 3.279 0.777 0.228 
Q01081 Splicing factor U2AF 35 kDa subunit U2AF1 - 
[U2AF1_HUMAN] 
15.6 
   
2 64 12.50 240 27.9 8.81 3 3 3 0.645 0.768 2.660 0.939 0.828 
Q32P28 Prolyl 3-hydroxylase 1 LEPRE1 - 
[P3H1_HUMAN] 
15.6 
   
1 139 4.62 736 83.3 5.14 3 3 4 1.399 1.023 1.415 0.547 1.260 
P16104 Histone H2AX H2AFX - [H2AX_HUMAN] 15.6 
   
2 345 27.27 143 15.1 10.74 2 5 27 0.671 1.935 1.277 0.661 0.830 
P31939 Bifunctional purine biosynthesis protein 
PURH ATIC - [PUR9_HUMAN] 
15.6 
   
1 304 18.41 592 64.6 6.71 7 7 9 1.134 1.012 1.144 0.914 1.006 
P01042 Kininogen-1 KNG1 - [KNG1_HUMAN] 15.6 
   
1 246 9.78 644 71.9 6.81 8 8 9 0.700 1.596 1.134 2.627 0.498 
P50395 Rab GDP dissociation inhibitor beta GDI2 - 
[GDIB_HUMAN] 
15.6 
   
1 870 43.82 445 50.6 6.47 17 17 35 0.887 1.064 1.132 0.860 0.806 
Q13595 Transformer-2 protein homolog alpha TRA2A 
- [TRA2A_HUMAN] 
15.6 
   
1 191 10.28 282 32.7 11.27 2 3 7 0.734 1.031 1.108 0.195 0.740 
Q12805 EGF-containing fibulin-like extracellular 
matrix protein 1 EFEMP1 - [FBLN3_HUMAN] 
15.6 
   
1 62 6.69 493 54.6 5.07 2 2 3 2.222 1.596 0.921 1.974 1.373 
P13804 Electron transfer flavoprotein subunit alpha, 
mitochondrial ETFA - [ETFA_HUMAN] 
15.6 
   
1 148 12.01 333 35.1 8.38 3 3 10 0.657 1.011 0.864 0.526 0.729 
P23526 Adenosylhomocysteinase AHCY - 
[SAHH_HUMAN] 
15.6 
   
1 104 7.18 432 47.7 6.34 2 3 5 0.682 0.976 0.658 0.358 0.689 
Q9ULC5 Long-chain-fatty-acid--CoA ligase 5 ACSL5 - 
[ACSL5_HUMAN] 
15.6 
   
1 318 13.03 683 75.9 6.92 7 7 11 0.605 0.802 0.413 0.712 0.772 
P06454 Prothymosin alpha PTMA - [PTMA_HUMAN] 15.4 
   
1 6865 35.14 111 12.2 3.78 5 5 310 0.900 1.008 1.270 0.485 1.109 
P13010 X-ray repair cross-complementing protein 5 
XRCC5 - [XRCC5_HUMAN] 
15.4 
   
1 617 21.58 732 82.7 5.81 11 11 26 0.522 1.231 1.134 0.508 0.487 
P18206 Vinculin VCL - [VINC_HUMAN] 15.4 
   
1 1911 31.48 1134 123.7 5.66 29 30 73 1.404 0.904 1.131 2.429 1.425 
Q14498 RNA-binding protein 39 RBM39 - 
[RBM39_HUMAN] 
15.4 
   
1 374 8.11 530 59.3 10.10 3 3 9 1.032 0.849 1.111 0.459 1.068 
P21291 Cysteine and glycine-rich protein 1 CSRP1 - 
[CSRP1_HUMAN] 
15.4 
   
1 489 44.56 193 20.6 8.57 6 6 17 0.912 1.039 1.080 21.887 0.735 
P22626 Heterogeneous nuclear ribonucleoproteins 
A2/B1 HNRNPA2B1 - [ROA2_HUMAN] 
15.4 
   
1 3204 58.36 353 37.4 8.95 17 20 127 0.681 1.069 1.023 0.608 0.531 
P02452 Collagen alpha-1(I) chain COL1A1 - 
[CO1A1_HUMAN] 
15.4 
   
1 830 9.02 1464 138.9 5.80 11 11 45 1.124 0.428 0.904 5.938 2.536 
P04083 Annexin A1 ANXA1 - [ANXA1_HUMAN] 15.4 
   
1 2360 53.47 346 38.7 7.02 17 17 73 1.096 1.213 0.658 1.887 0.898 
O75874 Isocitrate dehydrogenase [NADP] 
cytoplasmic IDH1 - [IDHC_HUMAN] 
15.4 
   
1 1237 52.17 414 46.6 7.01 16 18 42 0.828 0.761 0.235 0.423 1.048 
P12004 Proliferating cell nuclear antigen PCNA - 
[PCNA_HUMAN] 
15.2 
   
1 107 16.09 261 28.8 4.69 4 4 7 0.954 0.709 1.790 0.414 1.326 
P09382 Galectin-1 LGALS1 - [LEG1_HUMAN] 15.2 
   
1 1621 65.93 135 14.7 5.50 9 9 66 0.664 0.862 1.398 1.653 0.928 
Q9BVK6 Transmembrane emp24 domain-containing 
protein 9 TMED9 - [TMED9_HUMAN] 
15.2 
   
1 88 17.02 235 27.3 8.02 1 3 5 0.409 2.208 1.238 0.226 0.201 
Q9NYF8 Bcl-2-associated transcription factor 1 
BCLAF1 - [BCLF1_HUMAN] 
15.2 
   
1 75 3.80 920 106.1 9.98 4 4 5 0.816 1.105 1.232 0.343 0.807 
P35749 Myosin-11 MYH11 - [MYH11_HUMAN] 15.2 
   
1 1059 13.13 1972 227.2 5.50 14 20 40 0.986 1.006 1.228 3.765 1.372 
P05455 Lupus La protein SSB - [LA_HUMAN] 15.2 
   
1 266 10.29 408 46.8 7.12 4 4 8 0.591 1.193 0.989 0.412 0.522 
P17858 ATP-dependent 6-phosphofructokinase, liver 
type PFKL - [PFKAL_HUMAN] 
15.2 
   
1 154 5.90 780 85.0 7.50 3 4 5 0.609 1.716 0.842 0.422 0.462 
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Table 5.4 Summary of top-scoring proteins displaying differential expression between clinical groups. Data was generated using Proteome Discoverer 
v2.4. Protein changes are shown as peptide reporter ion ratios for peptides matching that protein. Differential expression for each comparison is represented 
on a continuous colour scale from red (high) to blue (low). A ‘biomarker score’ combining scores for ratio, count, variability, unique peptide matches and 
expression pattern is presented for each protein, along with an indication of whether it is a classical serum or red blood cell protein. Yellow accession 
numbers represent proteins of interest that were considered for verification. The full list is provided as additional information
P67809 Nuclease-sensitive element-binding protein 
1 YBX1 - [YBOX1_HUMAN] 
15.2 
   
3 261 11.42 324 35.9 9.88 2 2 3 0.622 0.771 0.738 0.367 0.729 
P06396 Gelsolin GSN - [GELS_HUMAN] 15.2 
   
1 1356 37.98 782 85.6 6.28 22 23 45 0.882 0.836 0.582 1.793 1.099 
P16402 Histone H1.3 HIST1H1D - [H13_HUMAN] 15.2 
   
3 415 32.58 221 22.3 11.02 2 10 22 2.365 1.851 0.547 1.035 1.506 
Q27J81 Inverted formin-2 INF2 - [INF2_HUMAN] 15 
  
1 1 34 1.20 1249 135.5 5.38 1 1 1 1.720 1.565 1.893 1.464 1.084 
O95810 Serum deprivation-response protein SDPR - 
[SDPR_HUMAN] 
15 
  
1 1 195 2.12 425 47.1 5.21 1 1 9 1.557 1.373 1.007 6.635 0.872 
O60888 Protein CutA CUTA - [CUTA_HUMAN] 15 
   
1 115 15.08 179 19.1 5.50 1 1 1 1.104 1.535 2.324 1.506 0.710 
O14773 Tripeptidyl-peptidase 1 TPP1 - 
[TPP1_HUMAN] 
15 
   
1 59 3.73 563 61.2 6.48 2 2 3 0.725 0.888 1.614 0.660 0.789 
P09497 Clathrin light chain B CLTB - [CLCB_HUMAN] 15 
   
1 49 9.61 229 25.2 4.64 3 3 3 0.821 1.557 1.234 0.292 0.520 
P62318 Small nuclear ribonucleoprotein Sm D3 
SNRPD3 - [SMD3_HUMAN] 
15 
   
1 69 7.14 126 13.9 10.32 1 1 2 1.189 1.325 1.187 0.268 0.885 
P68032 Actin, alpha cardiac muscle 1 ACTC1 - 
[ACTC_HUMAN] 
15 
   
4 12184 61.54 377 42.0 5.39 7 20 431 1.000 0.746 1.154 2.721 1.382 
Q9NZN4 EH domain-containing protein 2 EHD2 - 
[EHD2_HUMAN] 
15 
   
1 184 6.08 543 61.1 6.46 3 3 7 0.847 0.699 1.047 7.219 1.154 
Q8N2N9 Ankyrin repeat domain-containing protein 
36B ANKRD36B - [AN36B_HUMAN] 
15 
   
3 28 0.96 1353 153.5 8.85 1 1 2 2.181 3.061 0.979 0.542 0.703 
Q9Y6C9 Mitochondrial carrier homolog 2 MTCH2 - 
[MTCH2_HUMAN] 
15 
   
1 163 7.92 303 33.3 7.97 1 1 5 2.260 1.612 0.921 1.436 1.382 
Q6XQN6 Nicotinate phosphoribosyltransferase 
NAPRT1 - [PNCB_HUMAN] 
15 
   
1 62 6.88 538 57.5 5.68 2 2 3 3.682 2.629 0.908 0.866 1.381 
Q09666 Neuroblast differentiation-associated 
protein AHNAK - [AHNK_HUMAN] 
15 
   
1 1937 26.60 5890 628.7 6.15 50 54 75 0.825 0.717 0.795 2.339 1.109 
P61019 Ras-related protein Rab-2A RAB2A - 
[RAB2A_HUMAN] 
15 
   
2 46 9.91 212 23.5 6.54 2 2 2 5.393 2.011 0.783 0.292 2.645 
Q9Y6Q1 Calpain-6 CAPN6 - [CAN6_HUMAN] 15 
   
1 29 1.56 641 74.5 7.05 1 1 1 2.162 3.493 0.620 0.661 0.611 
A6NDG6 Phosphoglycolate phosphatase PGP - 
[PGP_HUMAN] 
15 
   
1 38 5.92 321 34.0 6.14 1 1 1 3.560 2.633 0.520 0.900 1.334 
O43252 Bifunctional 3'-phosphoadenosine 5'-
phosphosulfate synthase 1 PAPSS1 - 
[PAPS1_HUMAN] 
15 
   
1 152 9.94 624 70.8 6.86 5 5 6 0.595 1.194 0.460 0.372 0.529 
Q15746 Myosin light chain kinase, smooth muscle 
MYLK - [MYLK_HUMAN] 
15 
  
1 1 263 2.04 1914 210.6 6.15 4 4 9 0.795 0.688 1.454 7.900 1.297 
153 
 
Protein groups were also annotated as possible blood contaminants that would not be 
considered for verification; 77 proteins were identified as classical serum proteins and 
14 as red blood cell-specific proteins with several of these scoring highly. 
Identification of serum proteins that had been targeted for depletion suggested 
incomplete immunodepletion. The presence of these blood proteins may have arisen 
as a result of contamination during sampling and/or due to vascularisation of the 
tissue, especially the eutopic tissues. The presence of abundant structural cellular 
proteins was also noticeable and may reduce coverage of less-abundant proteins. For 
selection of proteins of interest, weight was given to candidates whose expressions 
differed significantly between endometriosis and both control groups and in both cycle 
phases. Selection was also weighted based on prior knowledge of the function of these 
gene products, those known to be secreted proteins and those for which commercial 
detection reagents were available for verification. 
5.2.2 Proteins of interest 
Twenty two proteins were identified as proteins of interest. Carboxypeptidase M 
(CPM) was the highest scoring non-blood contaminant protein. It was increased in the 
comparison between endometriosis and controls in both the proliferative and secretory 
phases (ratio=2.45 and 1.62, respectively). CPM expression was also increased in the 
endometriosis versus pain group in the secretory phase (ratio=2.53), although was 
lower in ectopic compared to eutopic tissue (ratio=0.32). CPM is an extracellular 
peptidase attached to the outer membrane by a glycosyl-phosphoinositol anchor. Its 
function is to cleave C-terminal lysines and arginines from peptides and proteins as 
part of their processing into mature forms. A role in inflammmation is supported by 
its regulated expression on macrophages and by the ability of CPM to inactivate 
anaphylatoxins and alter the receptor specificity for bradykinin. CPM also modulates 
the activity of chemokines CXCL12 and CCL1 providing further evidence for CPMs 
involvement in the inflammatory response, but also stem cell mobilisation, monocyte 
recruitment and cancer. Its increased expression in endometriosis supports a role in 
inflammation, although its lowered expression in ectopic lesions is somewhat at odds 
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with this. Lumican was also identified as a candidate biomarker from the profiling. Its 
expression was highest in ectopic tissue compared to eutopic endometrium in the 
secretory phase (ratio=14.89) and similar to that seen by 2D-DIGE profiling (Chapter 
4), Tropomyosin beta chain (TPM2) expression was also elevated in ectopic tissue 
compared to eutopic tissue (ratio=9.16) as seen by the 2D-DIGE profiling, although 
its expression changed little in the other comparisons. 
Progesterone receptor (PGR) was identified from this profiling. It was over-expressed 
in endometriosis compared to controls and the pain group in the secretory phase 
(ratio=1.45 and 1.76, respectively) and also between endometriosis and controls in the 
proliferative phase (ratio=2.42). However, PGR expression was lower in ectopic 
tissue compared to eutopic tissue in the secretory phase (ratio=0.32). The effects of 
progesterone are mediated via intracellular progesterone receptors that are expressed 
from a single gene as two protein isoforms, PGRA and PGRB. From the MS data it 
was not clear which isoform had been identified. 
Impaired gene expression in the endometrium of patients with endometriosis was 
reported to occur throughout the menstrual cycle(Burney et al., 2007) (Burney et al 
2007). Some of the dysregulated genes that were reported (FOXO1A, MIG6 and 
CYP26A1) are known targets of progesterone and their overall pattern of abberrant 
expression suggested a prolongation of the proliferative phenotype even after 
ovulation. An incomplete transition of the endometrium from the proliferative phase 
to the secretory phase is a common characteristic in endometriosis attributed to 
progesterone resistance. The mechanisms underlying this resistance are poorly 
understood and may be caused by altered PGR expression, reduced release of 
progesterone by the corpus luteum or the action of endometrium-specific 
transcriptional repressors of the PGR. Whether the higher expression of PGR observed 
herein in eutopic endometrium from endometriosis patients is involved in or a 
response to progesterone resistance is not clear. However, its lowered expression in 
ectopic versus eutopic tissue does suggest a direct involvement in progesterone 
resistance that may promote the progression of endometriosis.  
155 
 
Membrane-associated progesterone receptor component 1 (PGRMC1) was also 
identified as a protein of interest from this data set. Similar to PGR, the protein was 
over-expressed in proliferative eutopic tissue in endometiosis versus control 
(ratio=1.56) and under-expressed in ectopic tissue (ratio=0.61). PGRMC1 and 2 are 
porrly characterised but may mediate non-genomic progesterone signalling and act as 
regulators of steroid hormone synthesis. PGRMC1 is expressed and regulated in the 
human endometrium in a cycle-dependent manner, but also in endometriotic lesions 
with the lowest expression reported in the secretory phase (Kao et al 2002, Chen et al 
2009, Bunch et al 2014).  This may also contribute to the progesterone resistance seen 
in endometriosis. PGRMC1 is also over-expressed in some cancers (Neubauer et al 
2008), suggesting that these receptors are active during rapid growth and proliferation. 
The results presented herein are in partial agreement with the literature in that it was 
down-regulated in endometriotic lesions, however this down-regulation was not 
observed in secretory phase eutopic endometrium. Its up-regulation in the proliferative 
phase eutopic tissue from endometriosis patients matched that of PGR, suggesting that 
it supports progesterone-dependent proliferation. 
Glycodelin (PAEP) was another protein found to be under-expressed in secretory 
phase ectopic tissue compared to eutopic tissue (ratio=0.21). This lowered expression 
may be explained by the fact that PAEP is a progesterone-regulated gene and thus 
matches the down-regulation of PGR in ectopic tissue. In the normal endometrium, 
PAEP is down-regulated in the proliferative phase and then highly expressed during 
the mid-secretory, peaking during the implantation window (Meola et al.,2009). 
Depending on its glycosylation state, PAEP has roles in contraception, 
immunosuppression, angiogenesis and apoptosis. 
Tenascin C (TNC) was up-regulated in endometriosis compared to controls in both 
the proliferative and secretory phases (ratios=1.82 and 1.50 respectively). It was also 
up-regulated in endometriosis compared to pain in the secretory phase (ratio=1.68). 
Tenascin C is an extracellular matrix glycoprotein that plays a role in cell 
differentiation, proliferation, invasion and axonal guidance. The role of TNC in the 
endometrium and endometriosis is not well understood, although its expression has 
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been demonstrated in human endometrium and is reported to be regulated across the 
menstrual cycle, with highest expression during the proliferative phase (Sasano et al., 
1993, Harrington et al., 1999). The data presented here suggests that this regulated 
expression may be lost in endometriosis. Expression of TNC has been reported to be 
upregulated in ectopic lesions compared to eutopic endometrium throughout the cycle 
(Tan, 2008 #324). Whilst an increased expression of TNC in ectopic tissue was not 
observed here, its increased expression in the endometrium of cases may drive the 
disease process by promoting the proliferation and invasion of endometrial cells at 
ectopic sites.  
Transgelin was moderately increased in endometriosis compared to pain in the 
secretory phase (ratio=1.32) and versus controls in the proliferative phase 
(ratio=2.17), with a high fold-change observed in ectopic versus eutopic tissue 
(ratio=18.83). Transgelin is a smooth muscle actin-binding protein that has been 
reported to play a potential role in the early invasion of endometrial cells into the 
mesothelium after initial attachment to the peritoneal wall. One study showed a 
significant upregulation of transgelin gene expression in ectopic tissue compared to 
eutopic endometrium (Dos Santos Hidalgo et al., 2011), in agreement with the present 
findings. Regulation of transgelin expression is thought to be controlled by 
transforming growth factor beta (TGF-β) in smooth muscle, and thus links transgelin 
function to cellular proliferation, motility, apoptosis, differentiation, immunologic 
response and tumourigenesis. 
5.2.3 Gene ontology (GO) and enrichment analysis 
To try and gain insight into the functional consequences of the altered protein 
expression, a functional enrichment analysis was undertaken. GO term enrichment for 
all differentially expressed proteins (>1.5-fold) proved rather ambigous since all terms 
relating to each gene product are automatically included in the analysis. Several 
general parent terms for the same processes and containing the same matched genes 
were therefore recorded as enriched and may have masked more specific annotations. 
Splitting the genes lists into up-regulated and down-regulated gene products generated 
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slightly more specific terms with slightly less multiplicity, but the results were still 
somewhat ambigous. GO enrichment analysis of up-regulated proteins mostly 
revealed enrichment of the biological processes RNA metabolism, mRNA splicing, 
translation and gene expression (Table 5.5). This included the over-representation of 
ribosomal proteins involved in these processes. This may suggest an up-regulation of 
protein translation in proliferating endometrial cells in endometriosis. Notably 
however, proteins involved in translational termination were also up-regulated in 
endometriosis. 
KEGG pathway mapping revealed enrichment of genes involved in metabolic 
pathways, the proteosome and focal adhesion/extra-cellular matrix interactions, 
although both up- and down-regulated gene products were enriched and pathways 
were not common to all comparisons. Genes enriched in the proteosome pathway were 
proteosome components PSMB5, PSMD2, PSMD1, PSMD12, PSMD13, PSMA2, 
PSMC3, PSMB7, PSMC5, PSMC1 and PSMA4. The proteosome regulates protein 
turnover in proccesses such as regulation of the cell cycle, cell differentiation, signal 
transduction, antigen processing, stress signalling, inflammatory responses and 
apoptosis. The proteosome has not been studied extensively in endometriosis. 
However the few studies that have examined proteosomal degradation have been 
aimed at understanding the pathophysiology of the disease (Gonzalez-Ramos et al., 
2010) and identifying the proteosome as a potential drug target to block the action of 
NF-κB (Celik et al., 2008, Gonzalez-Ramos et al., 2008). NF-κB binds to target DNA 
in the nucleus and upregulates the transcription of genes involved in inflammation, 
cell growth and apoptosis (Celik et al., 2008). Dysregulation of protein proteosomal 
expression may potentially contribute to the development of ectopic endometrial 
lesions due to reduced sensitivity to apoptosis. Furthermore dysregulation of 
proteosomal function in implants may induce inflammation due to the consequent 
activation of NF-κB. Thus, the activation of NF-κB via altered proteosome function 
could play a potential role in the pathophysiology of endometriosis by inducing an 
inflammatory response and the growth of endometriotic lesions.
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Table 5.5 GO enrichment analysis for altered (≥1.5 fold-change) proteins. Enrichment analyis was performed using WebGestalt. Each clinical group was 
analysed separately for enrichment of biological process, molecular function, cellular component, GO slim, protein interaction networks, KEGG pathways 
and disease association. Significantly enriched terms were identified using a hypergeometric test with a Benjamini-Hochberg (BH) correction. The corrected  
P values are shown.
 ES vs CS EP vs CP ES v PS EcS v ES 
Biological Process Upregulated Downregulated Upregulated Downregulated Upregulated Downregulated Upregulated Downregulated 
Cellular macromolecular complex subunit organization 5.34E-13 3.16E-05       
mRNA metabolic process 5.34E-13 2.20E-05 0.0099  4.85E-06   1.10E-25 
Cellular protein complex disassembly 3.46E-10 3.34E-05       
Protein complex disassembly 4.90E-10        
Translational termination 6.69E-09  0.0044      
Cellular aromatic/cyclic compound metabolic process   0.0092      
Cellular nitrogen compound metabolic process   0.0139    1.92E-10  
Nucleic acid metabolic process     4.85E-06    
Cellular catabolic process     3.42E-05   5.02E-10 
Response to wounding       8.51E-14  
Actin filament-based process/cytoskeleton organisation       8.51E-14  
Acute inflammatory response   0.0197 2.58E-06 2.63E-09  1.57E-12  
KEGG Pathways         
Metabolic pathways 7.26E-11 4.41E-07    1.40E-05  2.75E-20 
Ribosome 4.72E-15       3.29E-16 
Focal adhesion 2.21E-05    3.74E-05  1.48E-18 6.72E-32 
Regulation of actin cytoskeleton  3.77E-06 4.82E-07    2.48E-11  
ECM-receptor interaction     0.0001 1.40E-05 2.92E-09  
Spliceosome 9.27E-06 9.31E-09   0.0005    
Proteasome 3.55E-05 4.29E-05   1.36E-10    
Oxidative phosphorylation 5.93E-05       4.13E-07 
Disease associations         
Carcinoma  9.60E-07  2.33E-07  8.97E-05   
Neoplasm Invasiveness  7.87E-06     3.61E-08 5.76E-10 
Cancer or viral infections  6.40E-06    0.0007   
Anemia, Hemolytic 2.15E-13    3.69E-12  1.50E-09  
Adhesion  5.10E-08    1.38E-06 1.39E-18  
Hematologic Diseases 1.30E-10        
Protein Deficiency 5.19E-08    2.13E-11   2.18E-10 
Cardiovascular Diseases     5.04E-11  5.54E-10  
Huntington's disease  1.10E-06   3.87E-15   2.11E-12 
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Biological processes and pathways involved in cell-matrix interactions and focal 
adhesions were also enriched in the up-regulated proteins groups. Several genes 
involved in focal adhesion formation and regulation (CRKL, VTN, ITGA2, RAP1B, 
TNXB, PRKCA, TNC, LAMA5, MAPK3) and the extracellular matrix (HSPG2, FN1, 
VTN, LAMA5, TNC, ITGA2, TNXB, COL6A1) were enriched. Focal adhesions are 
specialised structures formed between cells and the extracellular matrix (ECM) 
through transmembrane integrin complexes that link to the actin cytoskeleton and 
signalling proteins (Figures 5.6 and 5.7). Cell-matrix adhesions play essential roles in 
involving cell motility, proliferation, differentiation, survival and regulation of gene 
expression, serving a significant role in tissue and organ morphogenesis and structure.  
 
Figure 5.6 Differentially expressed genes within the focal adhesion pathway. 
Red colour indicates some of the significantly enriched genes from this dataset. Green 
colour indicates other genes involved in this pathway. 
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Figure 5.7 differentially expressed genes within the ECM. Red colour indicates 
significantly enriched genes from the dataset. Green colour indicates other genes involved in 
cell-ECM interactions. 
Integrin signalling is dependent upon the non-receptor tyrosine kinase activities of the 
FAK (focal adhesion kinase) and SRC proteins as well as adaptor protein functions 
that initiate downstream signalling events. These signalling events culminate in re-
organisation of the actin cytoskeleton, a pre-requisite for changes in cell shape, 
motility and invasion. Similar morphological alterations and modulations of gene 
expression are initiated by the binding of growth factors to their respective receptors 
emphasising the significant cross-talk between adhesion and growth factor-mediated 
signalling. The adhesion of retrograde shed endometrial cells to the ECM is one of the 
vital stages in the implantation of ectopic endometrial cells. The data presented here 
suggest some of the adhesion and ECM proteins that may be involved in the 
implantation process and establishement of endometriotic lesions. Studies have 
suggested that FAK signalling plays an important role in mediating increased cell 
migration in endometriosis induced by ovarian steroid hormones (Mu and Ma, 2015).  
Despite such reports, the mechanisms involved in ectopic cell attachment to the 
peritoneum and other ectopic areas remains poorly defined and further studies are 
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required to establish the molecular determinants involved and whether these proteins 
would be good markers of disease development and progression.  
Functional analysis also revealed genes involved in cancer and neoplastic 
invasiveness. Endometriosis is a benign condition which shares some features with 
cancer such as local and distant invasion, attachment and damage to affected tissues. 
Women with the disease are known to be at an increased risk of developing epithelial 
ovarian cancer, although the molecular mechanisms involved are not clear (Worley et 
al., 2013). Further work should be carried out to ascertain the relevance of these genes 
in the pathogenesis of endometriosis and their potential role as therapeutic targets.  
 
5.3 Conclusions 
For the protein-based profiling there was a significant difference in coverage between 
the optimisation and main experiments. This was attributed to considerable loss of 
protein during the processing steps. A significant number of proteins identified 
comprised of cytokeratins, serum proteins and muscle proteins. This may be attributed 
to differential contamination due to sampling and may also be due to poor 
immunodepletion. However, protein labelling has some advantages over peptide 
labelling. Separation methods based on molecular weight e.g. SDS-PAGE can be 
applied to intact proteins as a fractionation step and differentially labelled samples can 
be mixed earlier in the workflow reducing technical variation. TMT labelling of 
lysines at the protein level would also compromise tryptic cleavage, and although 
sequential digestion with Glu-C and trypsin would alleviate this issue to generate 
shorter peptides more amenable to MS analysis, the number of labelled peptides 
identified was consequently reduced, thus compromising quantitative coverage.  
Due to time constraints and the lack of material remaining, this experiment could not 
be repeated. It is therefore difficult to conclude whether this protein-based profiling 
approach is complementary to peptide-based approaches or offers improved 
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proteomic coverage. Because of the protein loss, possible contamination and poor 
labelling efficiency in the protein labelling experiment, selection of meaningful 
candidates for verification was not possible. 
There was better coverage afforded by the peptide-based profiling approach with 
1,431 proteins quantified across the six clinical groups. Blood protein contamination 
was still a serious issue and will exacerbate sample heterogeneity leading to a high 
false discovery rate. The present data suggested dysregulation of progesterone 
signalling that may contribute to the progesterone resistance associated with 
endometriosis. PGR and PGRMC1 were found to be dysregulated, as was the 
downstream target PAEP. The role of these changes in promoting progesterone 
resistance in endometriosis warrant further investigation. Differentially expressed 
proteins involved in regulating translation and cell-matrix interactions were also 
enriched and their roles in promoting endometriosis also warrant further investigation.   
Proteins of interest identified from this data that warrant verification include; TNC, 
CPM, TPM2, LUM, PAEP, PGR and PGRMC1.  
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CHAPTER 6: CANDIDATE VERIFICATION IN SERUM 
6.1 Introduction 
Proteins of interest identified from the discovery profiling were selected for 
verification as potential biomarkers of endometriosis. The present work also aimed to 
validate several candidate markers reported in the literature. These literature 
candidates were sICAM1, MCP1, MIF, IL1R2, VEGF and FST, whilst LUM, TPM2, 
CPM, PAEP and TNC were selected from the discovery profiling work. One of the 
original aims was to verify the expression of candidates in the individual tissue lysates 
by western blotting. However, this was not possible as there was insufficient sample 
remaining for some cases and controls. Additionally, verification by western blotting 
in over 50 samples would have been laborious and only semi-quantitative at best. 
Also, since the overall aim of the project was to develop a non-invasive diagnostic 
test, it was decided that the candidates should be further tested in serum samples 
collected from the same and additional patients using commercial ELISA kits. Assays 
were first tested for reproducibility and sensitivity using a test pool of all samples. 
Candidate serum measurements were correlated with measurements of progesterone, 
oestradiol, CRP and CA125, clinico-pathological features and epidemiological data, 
particularly phase of the menstrual cycle. The data was incorporated into multi-marker 
models to assess if the candidates could complement one another and improve 
classification performance. A commercial multiplex platform was also employed to 
potentially identify additional candidates, this using a subset of the serum samples. 
6.2 Single marker analysis  
In total, 13 candidates (sICAM1, MCP1, MIF, IL1R2, VEGF, FST, PAEP, LUM, 
TPM2, CPM, TNC, CA125 and CRP) were measured in a set of 109 discovery set 
serum samples (Control=23, Pain=24 and Endometriosis=62) from the same patients 
from which tissue samples had been analysed and additional case controls that had 
been excluded from the tissue analysis. Oestrogen and progesterone measurements 
were also analysed. The differences in concentrations of single markers was first 
164 
 
assessed to determine any differences between the clinical groups (Table 6.1). As 
previously reported, there was a significant difference in the levels of CA125 between 
healthy controls and endometriosis (P=0.001) and pain and endometriosis (P=0.022) 
(Figure 6.1). The concentration of sICAM1 in serum also displayed a significant 
difference between endometriosis and healthy controls (P=0.022) and between 
endometriosis and pain controls (P=0.004) with no difference between the two control 
groups (P=0.541). Oestrogen and progesterone levels were also significantly changing 
between the pain and endometriosis groups (P=0.025 and P=0.025, respectively), but 
not between the endometriosis and healthy controls. VEGF, IL1R2, MIF, MCP, CPM, 
TNC, LUM, PAEP, CRP and FST failed to show any significant differences between 
the clinical groups, whilst the TPM2 assay failed to give a signal on the standard curve 
for even undiluted serum. 
Table 6.1 Median concentrations and ranges of individual marker candidates 
in serum and P values for comparison of different clinical groups. 
The student t-test or Mann-Whitney test was used. P values <0.05 were considered 
significant and are shown in yellow. 
 
      E v C E v P C v P 
Candidate biomarker Units Control Pain Endometriosis Phase P value P value P value 
sICAM1 ng/mL 
301.4 
(162.2-391.3) 
265.7 
(162.8-347.9) 
339.7 
(290.3-423.5) 
All 0.023 0.004 0.541 
IL1R2 ng/mL 
12.71 
(10.51-14) 
11.37 
(9.66-16.88) 
12.69 
(10.14-15.06) 
All 0.738 0.598 0.477 
MCP1 ng/mL 
0.32 
(0.22-0.41) 
0.25 
(0.17-0.43) 
0.26 
(0.21-0.37) 
All 0.238 0.608 0.481 
MIF ng/mL 
24.81 
(15.99-41.88) 
30.87 
(13.31-56.62) 
23.09 
(14.74-36.81) 
All 0.654 0.362 0.442 
VEGF ng/mL 
301.4 
(162.2-391.3) 
265.7 
(162.8-347.9) 
339.7 
(290-423.5) 
All 0.105 0.968 0.279 
FST ng/mL 
0.82 
(0.59-1.25) 
0.73 
(0.56-1.24) 
0.67 
(0.5-0.9) 
All 0.185 0.295 0.919 
PAEP ng/mL 
7.22 
(4.10-20.61) 
11.23 
(8.04-22.73) 
10.35 
(4.57-25.26) 
All 0.367 0.631 0.196 
LUM ng/mL 
47.05 
(31.64-62.06) 
39.47 
(13.53-63.7) 
46.1 
(34.86-61.1) 
All 0.862 0.498 0.461 
CA125 U/mL 
7.9 
(4.1-15.9) 
10.85 
(3.85-21.7) 
20.4 
(7.45-45.95) 
All 0.001 0.022 0.5301 
Oestrogen pmol/L 
245 
(78-673) 
379 
(142-716) 
148.5 
(18-478.8) 
All 0.238 0.027 0.424 
Progesterone nmol/L 
1.9 
(1.2-21.55) 
6.1 
(2-31.4) 
2.1 
(1.35-5.15) 
All 0.966 0.026 0.115 
CRP mg/L 
0.75 
(0.6-1.88) 
0.6 
(0.6-2.27) 
0.7 
(0.6-2.7) 
All 0.914 0.544 0.665 
CPM ng/mL 
4.31 
(0.92-25.30) 
3.83 
(1.16-9.69) 
5.0 
(2.0-121.0) 
All 0.629 0.968 0.663 
TNC ng/mL 
73.24 
(26.54-88.33) 
40.31 
(21.83-63.35) 
45.24 
(34.86-65.13) 
All 0.369 0.359 0.279 
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Figure 6.1 Graphical representation of single marker analysis in the three clinical 
groups. (C= healthy controls (n=24), P= Pain (n=23) and E=endometriosis (n=62)). All 
graphs were generated using GraphPad Prism Version 5.01. A student t-test was applied 
where data was normally distributed and a Mann Whitney test where data was not normally 
distributed. A P value of <0.05 was considered significant. 
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The data was also analysed to determine whether these candidate markers differed 
across the menstrual cycle. CA125 was significantly differentially expressed between 
both healthy and pain control groups and endometriosis in the secretory phase 
(P=0.006 and 0.03) but not the proliferative phase (Figure 6.3).  
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Figure 6.2 Graphical representation of single marker analysis by cycle phase. 
Graphs were generated using GraphPad Prism Version 5.0.1. A student t-test was applied 
where data was normally distributed and Mann Whitney where data was not normally 
distributed. A P value of <0.05 was considered statistically significant. 
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sICAM1 was also significantly elevated in the secretory phase endometriosis versus 
pain groups (P=0.023), whilst VEGF was elevated in secretory phase endometriosis 
versus healthy controls (P=0.023). As expected progesterone was significantly higher 
in the secretory phase than proliferative phase, but showed a non-significant down-
regulation in the endometriosis group. No differences were found for any of the other 
candidates suggesting that they would not make useful diagnostic markers. 
  
6.3 Receiver operator characteristic (ROC) curve analysis  
ROC curve analysis was performed to determine the diagnostic performance of each 
biomarker separately. The area under the curves (AUCs) and sensitivities at 90% 
specificity were generated using GraphPad Prism software (Tables 6.2 and 6.3). 
 Table 6.2 Area under the ROC curve (AUC) analysis for single candidates. 
Candidate Phase E v C (AUC) P value E v P (AUC) P value 
sICAM1 All 0.628 0.080 0.703 0.004 
IL1R2 All 0.528 0.717 0.501 0.988 
MCP1 All 0.593 0.230 0.537 0.664 
MIF All 0.566 0.397 0.677 0.039 
VEGF All 0.619 0.105 0.503 0.965 
FST All 0.598 0.183 0.577 0.293 
PAEP All 0.566 0.365 0.534 0.628 
LUM All 0.513 0.859 0.594 0.238 
CA125 All 0.724 0.002 0.660 0.064 
Oestrogen All 0.586 0.239 0.657 0.026 
Progesterone All 0.504 0.962 0.659 0.025 
CRP All 0.508 0.914 0.541 0.566 
CPM All 0.537 0.625 0.504 0.963 
TNC All 0.568 0.366 0.574 0.356 
AUCs with significant P values (<0.05) are highlighted in yellow. 
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Table 6.3 Sensitivities of individual candidates at 90% specificity. 
   
 
 
 
 
 
 
 
 
 
 
 
The highest AUC was observed for CA125 (AUC=0.724; P=0.002) for discriminating 
between endometriosis and controls (Table 6.2). At a cut-off of >23 IU/mL the 
sensitivity of CA125 was 47% at 90% specificity for discriminating between 
endometriosis and healthy controls and 31% sensitivity at a cut off of >38 IU/mL for 
discriminating between endometriosis and pain controls (Table 6.3). CA125 has been 
investigated extensively as a potential peripheral biomarker of endometriosis, 
although is reported to lack diagnostic accuracy as a single biomarker. The data 
presented here supports this notion, with studies rarely reporting sensitivities above 
50% at high specificity (80-95%). The diagnostic performance of CA125 in 
endometriosis is confounded by the fact that endometriosis has varying degrees of 
chronicity and is mostly elevated in advanced disease (see Chapter 1). CA125 is also 
not specific for endometriosis and does not efficiently differentiate endometriosis 
from other diseases e.g. fibroids, PID and ovarian cancer.  
In discriminating between endometriosis and controls, the sensitivity of sICAM1 was 
18% (>450 ng/mL), and in discriminating between endometriosis and pain was 34% 
(>373 ng/mL) at 90% specificity. sICAM1 is secreted from the endometrium and 
endometrioitic implants. Studies have been conflicting about the usefulness of 
Candidate E v C E v P 
sICAM1 18% 34% 
IL1R2 21% 10% 
MCP1 5% 12% 
MIF 15% 5% 
VEGF 10% 3% 
FST 23% 10% 
PAEP 10% 27% 
LUM 11% 13% 
CA125 47% 31% 
Oestrogen 26% 34% 
Progesterone 8% 18% 
CRP 11% 12% 
CPM 12% 8% 
TNC 12% 5% 
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sICAM1 in diagnosing endometriosis. The data presented here does not support its 
use as a single marker for the diagnosis of endometriosis. MIF was able to discriminate 
between endometriosis and pain (AUC=0.677; P=0.039). MIF is a pro-inflammatory 
cytokine involved in T cell activation, cell growth, apoptosis and angiogenesis. It has 
been reported to have higher expression in advanced stage endometriosis (Morin et al 
2005). However inflammatory cytokines are unlikely to make useful markers for 
differential diagnosis of endometriosis and non-endometriotic pathologies presenting 
with similar symptoms e.g. pelvic pain and infertility where inflammatory pathways 
are activated.  
Combining markers could afford higher diagnostic accuracy by complementing one 
another to overcome the variable aetiology and disease manifestations of 
endometriosis. With this in mind, the diagnostic potential of combinations of the 
candidate markers was tested. Due to the relatively small sample size of this study, 
only combinations of two or three markers per comparison could be assessed to avoid 
overfitting. Logistic regression was used to combine marker candidates and their 
diagnostic performances tested using R software. The AUC values of these models 
were also cross-validated using R software. Table 6.4 and 6.5 displays the 
performance and cross-validation of the best models for discriminating between 
endometriosis and both control groups, reporting sensitivity at >90% and >80% 
specificity. 
A model combining CA125 and sICAM1 was able to discriminate between 
endometriosis and controls with 55% sensitivity at 91% specificity (AUC=0.781); an 
improvement of 8% over using CA125 alone. By reducing the specificity to 83%, the 
CA125 sICAM1 model gave a sensitivity of 66% with no benefit of adding a third 
candidate. In discriminating between endometriosis and pain, the best combination 
was CA125 LUM TNC (AUC=0.739; sensitivity=63%, specificity=83%), although 
increasing the specificity to 92% reduced the sensitivity to 47%. At 63% sensitivity 
and 81% specificity, the best model that discriminated between endometriosis and 
both control groups (healthy and pain groups) was CA125 ICAM FST LUM. 
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Table 6.4 Combined marker model performances at different specificities 
 
Cross-validation of the AUC values of the above models showed that there was some 
loss in performance in the models especially in discriminating between endometriosis 
and pain. There was 5% and 16% loss in sensitivity at 92% and 83% specificity 
respectively in the ICAM TNC model (AUC=0.66) and 10% and 19% loss in 
sensitivity of the ICAM LUM TNC model (AUC= 0.667) in discriminating between 
endometriosis and pain. There was also loss in performance in the CA125 ICAM FST 
LUM model (AUC= 0.691) for discriminating between endometriosis and both 
healthy and pain controls with 4% and 15% loss in sensitivity at 91% and 81% 
specificity. Performance of models CA125 ICAM (AUC=0.744) and CA125 ICAM 
FST (AUC=0.75) for discriminating between endometriosis and healthy controls did 
E vs C AUC Sensitivity Specificity 
Marker combination at ≥90% specificity    
CA125 ICAM 0.781 55 91 
CA125 ICAM FST 0.796 53 91 
Marker combination at ≥80% specificity    
CA125 ICAM 0.781 66 83 
CA125 ICAM FST 0.796 66 83 
E vs P AUC Sensitivity Specificity 
Marker combination at ≥90% specificity    
ICAM TNC 0.718 31 92 
ICAM LUM TNC 0.739 47 92 
Marker combination at ≥80% specificity    
ICAM TNC 0.718 55 83 
ICAM LUM TNC 0.739 63 83 
Endometriosis vs All Controls (C and P) AUC Sensitivity Specificity 
Marker combination at ≥90% specificity    
CA125 ICAM FST LUM 0.756 30 92 
CA125 ICAM FST 0.750 30 92 
CA125 ICAM 0.736 37 92 
Marker combination at ≥80% specificity    
CA125 ICAM FST LUM 0.756 63 81 
CA125 ICAM FST 0.750 55 83 
CA125 ICAM 0.736 53 83 
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not change much. However, there was a 5% decrease in sensitivity at 91 and 83% 
specificity.  
Table 6.5. Cross validated results of combined marker models 
  
E vs C AUC Sensitivity Specificity 
Marker combination at ≥90% specificity    
CA125 ICAM 0.744 52 91 
CA125 ICAM FST 0.75 52 91 
Marker combination at ≥80% specificity       
CA125 ICAM 0.744 61 83 
CA125 ICAM FST 0.75 60 83 
E vs P AUC Sensitivity Specificity 
Marker combination at ≥90% specificity       
ICAM TNC 0.66 26 92 
ICAM LUM TNC 0.667 37 92 
Marker combination at ≥80% specificity    
ICAM TNC 0.66 39 83 
ICAM LUM TNC 0.667 44 83 
Endometriosis vs All Controls (C and P) AUC Sensitivity Specificity 
Marker combination at ≥90% specificity    
CA125 ICAM FST LUM 0.691 26 91 
CA125 ICAM FST 0.703 21 91 
Marker combination at ≥80% specificity    
CA125 ICAM FST LUM 0.691 48 81 
CA125 ICAM FST 0.75 47 85 
. 
6.4 Proseek analysis 
30 serum samples (15 endometriosis and 15 pain group) were randomly selected and 
analysed on the Proseek Oncology II platform (Olink Bioscience) which uses a 
sensitive qPCR proximity extension assay. The protein analysis was reported as 
normalised protein expression values (NPX). All assay characteristics including 
detection limits and measurements of assay performance and validations are available 
from the manufacturer’s web page (http://www.olink.com/proseekmultiplex/ 
oncology). Table 6.5 displays the univariate analysis of the 17 analytes (of 92) that 
displayed significant difference between the endometriosis and pain groups. 16 of the 
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candidates were down-regulated in the endometriosis compared to pain group, with 
only MUC16/CA125 showing an elevation. This perhaps suggested some bias in the 
sample set. Significant changes were only apparent in the secretory phase. Data for 
the most significantly changing proteins are shown in Figure 6.3. 
 
Table 6.6. List of significant proteins from the Proseek Oncology II analysis. 
 
Yellow shading shows the most significantly altered proteins. 
 
 
 
Marker 
Candidate 
Endo vs. Pain 
(all stages) 
ES vs. 
PS 
EP vs. 
PP 
Regulation 
(E vs P) Expression Biological function 
DKN1A 0.044 0.014 ns down   
GPNMB 0.025 0.021 ns down   
CA9 0.030 0.027 ns down   
CD27 0.004 0.012 ns down T-cell specific 
apoptosis, immune 
function 
ESM1 0.004 0.005 ns down endothelial cells angiogenesis 
LYN 0.006 0.011 ns down widely expressed 
immune response, 
signalling 
MUC16 0.047   up   
WFDC2 0.010 0.028 ns down   
ANXA1 0.016   down   
MSLN 0.042 0.038 ns down   
TFP1-2 0.042 ns ns down   
S1004 0.030 0.050 ns down   
TGFa 0.008 0.010 ns down 
keratinocytes, tumour 
cell lines 
EGFR ligand, 
proliferation 
FADD 0.034 0.040 ns down   
METAP2 0.047 0.008 ns down   
S100A11 0.031 0.050 ns down   
EPHA2 0.032 0.029 ns down   
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Figure 6.3 Graphical representation of most significant candidates from the Proseek®. 
Oncology II panel analysis. A student t-test was applied where data was normally 
distributed and a Mann Whitney test where data was not normally distributed. A P value of 
<0.05 was considered to be significant. 
 
6.5 Conclusions 
Selected markers from the discovery profiling and those reported in the literature were 
verified using ELISA in serum samples collected from all study participants. ROC 
curve analyses were performed to assess their diagnostic performance either as single 
markers or as combinations of markers for discriminating between endometriosis and 
controls. From this data, CA125 displayed the highest performance as a single marker, 
but lacked sensitivity to be considered for clinical use. The best marker combination 
in discriminating between endometriosis and healthy controls was CA125, ICAM at 
61% sensitivity and 83% specificity. Adding FST to this combination did not improve 
174 
 
sensitivity. Combination of ICAM, LUM, and TNC gave the best performance in 
discriminating endometriosis and pain controls at 63% sensitivity and 83% specificity. 
CA125, ICAM, FST, LUM displayed the best performance in discriminating 
endometriosis and both pain and healthy controls. However, there was a loss in 
sensitivity of these models after cross-validation of these models. Whilst the use of a 
panel of markers improved on the sensitivity, this may still be too low for clinical use. 
Future work should involve validation of these models in independent samples with a 
more detailed analysis by cycle phase. Several candidates from the Proseek analysis 
also warrant verification. Notably however, none of the markers would be significant 
if adjusted for multiple testing.  
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CHAPTER 7: DISCUSSION AND FUTURE WORK 
7.1 Discussion 
Diagnosis of endometriosis using a non-invasive method is a major priority in 
endometriosis research (Rogers et al., 2013). The current gold standard is surgery 
together with histological confirmation. The symptoms of endometriosis are neither 
sensitive nor specific for the condition, therefore diagnosis based on symptoms alone 
is unreliable. Thus, there is a 5-11 year delay in diagnosis from the onset of symptoms 
to definitive diagnosis. Laparoscopic diagnosis also carries the potential risks of 
bladder, bowel and major blood vessel damage, infection and adhesion formation. The 
procedure is also expensive and adds significant economic burden to the health service 
as well as to the patient. A clinically reliable test would have significant impact on 
reducing health care and individual costs by reducing the latency period of time to 
diagnosis. Early diagnosis could also mean early treatment and improved outcomes. 
The main aim of this study was to identify potential biomarkers for the non-invasive 
diagnosis of endometriosis by proteomic profiling of a set of well-characterised tissue 
samples obtained from women with endometriosis and relevant control groups 
without endometriosis. Patient and control selection criteria and conditions for 
sampling are of particular importance in biomarker studies and account for the 
majority of biological and technical variability. Endometriosis is an oestrogen-
dependent disease therefore only pre-menopausal women were used in this study. 
Selection of appropriate controls is of critical importance. On one hand it is important 
to ascertain molecular diffferences between women with endometriosis and those 
without, but it is also important to establish differences in women with endometriosis 
and those presenting with similar symptoms, especially pelvic pain and/or infertility. 
For this group of patients, a non-invasive test would be useful to rule out 
endometriosis. To address this, two groups of control patients were therefore selected 
for this study; a healthy control group and a pain control group. The healthy control 
group were women with no known disease at laparoscopy, while the pain group 
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comprised of women with chronic PID and chronic pelvic pain of unknown cause who 
would benefit from a non-invasive test to rule out endometriosis. 
Endometriosis is phenotypically heterogeneous with each form having a different 
presentation and possibly aetiology. This heterogeneity results in sample variability 
due to differences in tissue composition of the samples, especially ectopic tissue, as 
was apparent from the profiling in this study. The changing cellular composition of 
the endometrium, especially in response to a changing hormonal environment is a 
major challenge that has to be considered while designing endometriosis biomarker 
studies. An ideal biomarker for endometriosis would maintain a high sensitivity and 
specificity regardless of when during the menstrual cycle a sample was obtained. 
However, influence of the menstrual cycle poses a significant challenge in 
endometrial-based biomarker development especially for proteins whose expression 
are regulated by oestrogen or progesterone. Samples were matched according to the 
stage of the menstrual cycle using a triple approach (documented chronologically, 
confirmed histologically and by serum measurement of sex hormones), that would 
allow determination of cycle stage-specific changes and isolating those due to disease. 
This was important in maintaining biological homogeneity across the clinical groups. 
However, this meant that sample numbers in some clinical groups were compromised 
e.g. healthy controls in the secretory phase (n=4) and no representation of pain 
controls in the proliferative phase.  
Oestrogen-dependent diseases such as fibroids, endometrial polyps and cancer that 
have been observed to exist with endometriosis in affected women may also confound 
the interpretation of molecular profiles derived from endometrial tissue. These 
conditions pose a challenge for biomarker discovery, especially from endometrial 
tissue, by making it difficult to delineate a biomarker that is unique to endometriosis. 
To address this issue, patients who were diagnosed with benign or malignant 
conditions affecting the endometrium were excluded from the study. Exposure to 
medications used to treat endometriosis causes down-regulation of the endometrium, 
therefore these patients were also excluded from the study, thus reducing the sample 
numbers in the endometriosis groups. 
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Proteomics is increasingly being applied to the human endometrium. Despite the 
challenges that come with analysis of the proteome, advances in MS instrumentation 
has enhanced it as a powerful tool in biomarker discovery research. Proteomics studies 
on endometriosis have mostly focused on identifying differences between eutopic 
endometrium in women with and without endometriosis, mostly for the purpose of 
gaining a better understanding of the pathophysiology of the disease. However, efforts 
have been made to search for biomarkers for non-invasive diagnosis of the disease, 
but despite this, no biomarkers have yet been validated for clinical use. 
This study was divided into a discovery phase using untargeted proteomic strategies 
to identify candidate biomarkers from endometrial and endometriosis tissues collected 
in the course of this study, and a candidate selection and verification phase using 
serum samples from the same women. The aim was to identify secreted proteins that 
could be validated as potential markers for non-invasive differential diagnosis. In the 
discovery phase, two main proteomic strategies were employed namely 2D-DIGE and 
protein and peptide TMT labelling coupled to multi-dimensional fractionation and 
LC-MS/MS. These profiling methods provided the largest protein coverage of all 
techniques employed to date on a phenotypically well-characterised cohort.  
Due to the heterogeneous nature of endometrial tissues there were some challenges 
experienced in proteomic profiling of these tissue samples. Presence of high 
abundance cellular structural proteins was observed, possibly masking proteins of low 
abundance. Blood contamination was a challenge as evidenced by the identification 
of red blood cell proteins from the profiling. This contamination may have arisen as a 
result of contamination during sampling or due to vascularisation of the tissue, 
especially the eutopic tissues samples. Additionally, there was also presence of high 
abundance serum proteins that would lower proteomic coverage. To address this issue, 
an immunodepletion step for the tissue lysates was incorporated. Whilst this 
undoubtedly improved the protein load and coverage, several proteins targeted during 
this step were identified by MS as differentially expressed, suggesting incomplete 
depletion. Due to protein loss, there was poor coverage in the protein labelling 
experiment that was possibly confounded by contamination, incomplete 
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immunodepletion and sub-stoichiometric TMT labelling. This experiment could not 
be repeated and therefore it was difficult to conclude whether this approach would 
offer improved and complementary coverage of the endometrial proteome. These 
challenges made selection of potential candidates from this profiling somewhat 
redundant, although some candidates common to the 2D-DIGE profiling were 
observed. The peptide profiling method was much more successful, providing 
quantitative coverage of over 1,400 proteins. Whilst the issues of sample 
heterogeneity and blood contamination were still an issue and would raise the number 
of false discoveries, the strategy did provide a list of potential biomarker candidates 
that warranted verification. The profiling also provided some insight into the biology 
of endometriosis most notably progesterone resistance that is associated with 
endometriosis.   
Proteins identified from the discovery profiling that had potential as biomarkers were 
PAEP, LUM, CPM, TPM2 and TNC, and were selected for testing in serum using 
ELISA. These proteins have been previously identified in some studies ((Hood et al., 
2015, Tan et al., 2008, Harrington et al., 1999, Meola et al., 2009) whose aim was to 
gain molecular understanding on the human endometrium during the menstrual cycle 
and to understand aetiology, however their usefulness as diagnostic biomarkers has 
yet to be assessed. Promising markers identified from the literature were CA125, MIF, 
VEGF, sICAM1, IL1R2, MCP1 and FST and these were also tested alongside the 
other candidates in the discovery set serum. Candidate measurements were also 
incorporated into multi-marker models to assess whether this would improve 
diagnostic performance. The most studied serum marker for endometriosis is CA125. 
However, its widespread presence in tissues derived from the coloemic epithelium 
impairs its usefulness as a stand-alone diagnostic test. Of the marker candidates tested 
herein, CA125 was the best performing single marker, however its sensitivity in 
discriminating endometriosis from healthy and pain controls was rather modest. The 
other candidate markers were essentially ruled out as single markers, failing to provide 
accurate discrimination of the endometriosis and control groups. This failure could 
also be attributed to lack of secretion of these markers from tissue to serum. Another 
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reason could be that the pooling of tissue samples presents an average level of 
expression across the groups to mask the effects of individual outliers and increase the 
FDR 
Combining several markers improved the sensitivity, with a logistic regression model 
combining CA125, sICAM1, FST and LUM giving the highest performance with a 
sensitivity of 63% and specificity of 81%. This indicates that adding these other 
markers complements CA125 in detecting cases. To avoid over-fitting and reporting 
overly optimistic diagnostic performance of this model, this model was cross-
validated resulting in decrease in sensitivity; 26% and 48% at 91% and 81% 
specificity. It is difficult to conclude whether this model warrants future independent 
validation in a further prospective study to assess if it will be suitable for translation 
into clinical practice. Biomarker data could also be tested against outcome measures 
to establish if any of the candidate markers have prognostic potential. 
 
7.2 Future work 
Challenges arising due to the heterogeneous nature of endometrial tissue and its 
sampling should be addressed in any future discovery work. The cell types within a 
single tissue sample are often highly variable e.g. ectopic endometrial lesions may 
contain few endometrial cells alongside other structural components. One approach to 
address this problem would be the microdissection of tissue samples, although this 
would require considerable input from a trained pathologist. Laser capture 
microdissection could be used to obtain purer and relevant endometrial cell 
populations prior to proteomic analyses. Future research could also look into 
menstrual tissue and material obtained from the peritoneal cavity at laparoscopy 
performed at the time of menstruation. Differences in retrograde-shed menstrual 
material between women with and without endometriosis might reveal unique proteins 
with diagnostic potential. One could also use the serum samples for profiling to 
potentially identify blood-borne biomarkers directly. However, this is also likely to be 
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challenging. The dynamic range of protein expression in serum may be as high as ten 
orders of magnitude, with 99% of the protein content represented by the 22 most 
abundant proteins. Immunodepletion would be applied as used herein, although deep 
coverage (sub-ng/mL) would still be difficult to achieve and multi-dimensional 
fractionation would need to be applied. Since MS instrument time is a limiting factor, 
the running of multiple fractions from single samples would not be possible, even with 
multiplex mass tagging. Thus, a pooling approach would need to be employed with 
the caveat that individual protein expression information is lost, outliers cannot be 
identified and the false discovery rate is increased. In turn, this would necessitate more 
verification testing.    
Future work should involve the validation of the derived multi-marker model (CA125, 
sICAM1, FST and LUM) in a larger independent cohort of sera collected 
prospectively from women presenting with pelvic pain and no laparoscopic evidence 
of endometriosis and those diagnosed with endometriosis. The profiling work 
presented herein also identified numerous other proteins of interest that may have 
biomarker potential and hence warrant further verification. In future work, these 
would be tested as serum markers alone and in combination. ELISA is the ideal 
method for quantitative analysis of proteins in serum and is the gold standard in 
clinical diagnostics. However, a proportion of the candidates lack reliable ELISA tests 
for verification. Indeed, the availability of such reagents was applied here as a filtering 
criteria when selecting putative markers for testing. Due to the costs involved and time 
required in developing ELISAs, the majority of candidates identified from discovery 
profiling are left untested and potentially useful biomarkers may be missed. Priority 
should therefore be given to the development of low-cost, high-throughput, multiplex 
assays for protein quantification that do not rely on antibodies. Multiple reaction 
monitoring (MRM) assays based on MS are a favourable alternative to immunoassays. 
Such assays are highly-specific, cost-effective and can be more rapidly developed in 
comparison to ELISA assays. MRM also offers better multiplexing capabilities, 
allowing simultaneous quantification of numerous proteins within a single run. Future 
work would thus involve the development of MRM. This would first involve detection 
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of unique proteotypic peptides for each candidate (n≥3; ideally already observed in 
the discovery phase profiling) by high-accuracy mass monitoring of trypsinised crude 
or immunodepleted serum. Peptides would be subjected to optimised fragmentation 
on a triple quad instrument to confirm identification and predominant fragment ions 
chosen as transitions. Absolute quantification would be achieved by comparing parent 
ion intensities with spiked standards using 13C isotopically-labelled synthetic peptides. 
Assays would be optimised for minimal sample processing and multiplexed where 
possible. 
The work also identified putative tissue markers and some of these warrant 
verification by immunohistochemical staining. These may have applications as semi-
invasive biomarkers for the staging of endometriosis and/or for its prognosis. One 
protein of particular interest was the progesterone receptor (PGR). Endometriosis is 
associated with progesterone resistance. PGR expression possibly suggests perturbed 
progesterone signalling may be at play. Further studies are required to establish the 
role of altered PGR (and PGRMC1) expression in endometriosis, whether this affects 
downstream progesterone-regulated genes such as PAEP, as suggested from the 
present data and how this might be involved in progesterone resistance. Future work 
should also involve a re-analysis of the profiling data, specifically to identify 
menstrual cycle stage-specific differences in the healthy controls (CS versus CP), and 
thus the effect of endometriosis and pain on these changes. This would add to the 
functional analysis and could potentially identify novel sex-steroid hormone-
dependent protein changes. The functional enrichment analysis of the profiling data 
suggested differences in the focal adhesion, ECM and actin re-arrangement pathways 
in endometriosis. Future research using cell-based and animal models should explore 
the role of the altered proteins in promoting the proliferation, invasion and 
establishment of endometriotic lesion.  
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